Tubulysins and protein-tubulysin conjugates

Tubulysin-based protein conjugates address the challenge of multidrug resistance in cancer treatment by targeting and disrupting the cytoskeleton of dividing cells, offering a potent solution for treating resistant tumors.

JP2024167209APending Publication Date: 2024-12-03REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024125601
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-12-21
Filing Date
2024-08-01
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing antibody-drug conjugates (ADCs) face challenges with treatment-emergent resistance mechanisms such as multidrug resistance (MDR) in cancer treatment, including up-regulation of transporters and loss of cognate antigen expression, which compromise their clinical benefit.

Method used

Development of tubulysin-based protein conjugates, which are potent tubulin polymerization inhibitors that disrupt the cytoskeleton of dividing cells, offering a novel approach to overcome resistance by targeting multidrug-resistant cancer cells.

Benefits of technology

Tubulysin-based conjugates demonstrate high potency against multidrug-resistant cancer cells, providing a potential solution to extend the utility of ADCs by enhancing their efficacy in treating resistant tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167209000001_ABST
    Figure 2024167209000001_ABST
Patent Text Reader

Abstract

To provide compounds useful for anti-cancer and antiangiogenesis treatments.SOLUTION: The present invention provides a compound with a structure of formula I or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: Figure 14
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] (Field) Provided herein are novel tubulysins and their protein conjugates, as well as and various diseases, including administering said tubulysin and its protein conjugates. and methods for treating disorders and conditions. [Background technology]

[0002] (background) Antibody-drug conjugates (ADCs) are increasingly being applied in cancer treatment regimens. However, de novo or treatment-emergent resistance mechanisms may compromise clinical benefit. Two resistance mechanisms that arise under continuous ADC exposure in vitro are multidrug resistance (MDR) and These resistance mechanisms include upregulation of transporters that confer resistance to HIV-1, and loss of cognate antigen expression. New techniques to circumvent this will help extend the usefulness of next-generation ADCs.

[0003] Tubulysins, which were first isolated from the culture medium of myxobacteria, rapidly organize the cytoskeleton of dividing cells. This is a group of extremely powerful tubulin polymerization inhibitors that disrupt tubulin and induce apoptosis. Lysine is a cytosine that is a cytosine of N-methyl-D-pipecolic acid (Mep), L-isoleucine (Ile), and tubuvaline (tubu valine (Tuv), which is composed of rare N,O-acetals and secondary alcohols or acetones. Tubulysins A, B, C, G, and I contain a C-terminal tubutyrosine (Tu t) contains a γ-amino acid, whereas tubulysins D, E, F, and H instead contain a tubufurin at that position. tubuphenylalanine (Tup) (Angew. Chem. Int. Ed. Engl. 43 , 4888-4892).

[0004] Tubulysin demonstrates its potent activity in drug-resistant cells through a validated mechanism of action. It has emerged as a promising anti-cancer lead compound due to its activity against multidrug-resistant cancers. The average cell growth inhibitory activity is comparable to that of the well-known epothilones, vinblastine, and taxol. It exceeds 10 to 1000 times (Biochem. J. 2006, 396, 235-242; Nat. Prod. Rep. 2015, 32, 654-662). Tubulysin has been shown to be highly effective against cancer cells, including multidrug-resistant KB-V1 cervical cancer cells. and has potent antiproliferative activity (Angew. Chem. Int. Ed. 2004, 43, 4888-4892; and Biochem ical Journal 2006, 396, 235-242). Summary of the Invention

[0005] (overview) Provided herein are compounds useful, for example, in anti-cancer and anti-angiogenic therapy. .

[0006] In one embodiment, provided are compounds having the structure of Formula I, or their pharmaceutical equivalents. and acceptable salts: [ka] (In the formula, R 1 is C1-C 10 is alkyl; R 3 is -C(O)C1-C5 alkyl, -C(O)N(H)C1-C 10 Alkyl, or -(C1-C10 (Alkylene)-NR 3 a R 3b and where R 3a and R 3b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl, Alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally has been replaced by will; R 4 and R 5 is, independently in each occurrence, hydrogen or C-C alkyl; R 6 is -OH or -NHNH; R 7 is, independently in each occurrence, hydrogen, —OH, halogen, or —NR 7a R 7b and where R 7a and R 7b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, acyl, and amino acid residues, , alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and and acyl are optionally substituted; R 8 is, independently in each case, hydrogen, deuterium, -NHR 9 or halogen, where R 9 is hydrogen, —C1-C5 alkyl, or —C(O)C1-C5 alkyl; and m is 1 or 2; Q is —CH— or —O—, where When Q is -O-, R 2 is C1-C 10 Alkyl, C1-C 10 Alkynyl, -C1-C 10Archi ylene-(5-membered heteroaryl), -C1-C3 alkylene-Q 1 -(CH2) n Aryl or C1-C3 aryl or When Q is -CH2-, R 2 is C5-C 10 Alkyl, C1-C 10 Alkynyl, -C1-C 10 Al alkylene-(5-membered heteroaryl), -C1-C3 alkylene-Q 1 -(CH2) n Aryl or C1-C3 is hydroxyalkyl; and Q 1 is —CH— or —O—; The heteroaryl may be unsubstituted or may be substituted with an alkyl, aminoalkyl, hydroxyl substituted with alkyl, carboxyalkyl, benzyl, or phenyl; the aryl is unsubstituted or substituted with nitro or amino; and and n is an integer from 1 to 5.

[0007] In one embodiment, provided are compounds having the structure of Formula I, or their pharmaceutical equivalents. and acceptable salts: [ka] (In the formula, R 1 is C1-C 10 is alkyl; R 3 is -C(O)C1-C5 alkyl, -C(O)N(H)C1-C 10 Alkyl, or -(C1-C 10 (Alkylene)-NR 3 a R 3b and where R 3a and R3b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl, Alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally has been replaced by will; R 4 and R 5 is, independently in each occurrence, hydrogen or C1-C5 alkyl; or in certain embodiments, Te, R 4 and R 5 together with the carbon to which they are attached form a 3- to 8-membered cycloalkyl, substituted cycloalkyl, forming a heterocycloalkyl, heterocycloalkyl, or substituted heterocycloalkyl; R 6 is —OH or —NHNH; or, in certain embodiments, R 6 is -NHSO2R 60 and where R 60 is an alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclo alkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl; R 7 is, independently in each occurrence, hydrogen, —OH, halogen, or —NR 7a R 7b and where R 7a and R 7b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl, Alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally has been replaced by will; R 8 is, independently in each case, hydrogen, deuterium, -NHR 9 or halogen, where R 9is hydrogen, —C1-C5 alkyl, or —C(O)C1-C5 alkyl; and m is 1 or 2; Q is —CH— or —O—, where When Q is -O-, R 2 is C1-C 10 Alkyl, C1-C 10 Alkynyl, -C1-C 10 Archi ylene-(5-membered heteroaryl), -C1-C3 alkylene-Q 1 -(CH2) n Aryl or C1-C3 aryl or When Q is -CH2-, R 2 is C5-C 10 Alkyl, C1-C 10 Alkynyl, -C1-C 10 Al alkylene-(5-membered heteroaryl), -C1-C3 alkylene-Q 1 -(CH2) n Aryl or C1-C3 is hydroxyalkyl; and Q 1 is —CH— or —O—; The heteroaryl may be unsubstituted or may be substituted with an alkyl, aminoalkyl, hydroxyl substituted with alkyl, carboxyalkyl, benzyl, or phenyl; the aryl is unsubstituted or substituted with nitro or amino; and and n is an integer from 1 to 5.

[0008] In another embodiment, provided is a compound of Formula A, Formula B, Formula C, or Formula D, or and pharmaceutically acceptable salts thereof: [ka] (In the formula, L is a linker; BA is a binder; k is an integer from 1 to 30; R 1 is C1-C 10 is alkyl; R 3 is -C(O)C1-C5 alkyl, -C(O)N(H)C1-C 10 Alkyl, or -(C1-C 10 (Alkylene)-NR 3 a R 3b and where R 3a and R 3b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl, Alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally has been replaced by will; R 4 and R 5 is, independently in each occurrence, hydrogen or C-C alkyl; R 6 is -OH, -O-, -NHNH2, or -NHNH-; R 7 is, independently in each occurrence, hydrogen, —OH, —O—, halogen, or —NR 7a R 7b and where R 7a and R 7b is, independently in each occurrence, a bond, hydrogen, alkyl, alkenyl, alkyl aryl, cycloalkyl, aryl, heteroaryl, acyl, and amino acid residues; Here, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl acyl, and acyl are optionally substituted; R 8 is, independently in each case, hydrogen, deuterium, -NHR 9 or halogen, where R 9is hydrogen, —C1-C5 alkyl, or —C(O)C1-C5 alkyl; and m is 1 or 2; Q is —CH— or —O—, where When Q is -O-, R 2 is C1-C 10 Alkyl, C1-C 10 Alkynyl, positional isomeric C1 -C 10 Triazolylene, -C1-C 10 Alkylene-(5-membered heteroaryl), positional isomers of -C1-C 10 Alkylene-(5-membered heteroarylene), -C1-C3 alkylene-Q 1 -(CH2) n Aryl, C1-C3 Hydroxyalkyl or C1-C 10 is an alkyl ether; or When Q is -CH2-, R 2 is C5-C 10 Alkyl, C1-C 10 Alkynyl, positional isomers C1-C 10 Triazolylene, -C1-C 10 Alkylene-(5-membered heteroaryl), positional isomers of -C1-C 10 Alkylene-(5-membered heteroarylene), -C1-C3 alkylene-Q 1 -(CH2) n Aryl, C1-C3 Hydroxyalkyl or C1-C 10 alkyl ether; and Q 1 is —CH— or —O—; The regioisomeric triazolylenes may be unsubstituted or may be substituted with alkyl, alkenyl, alkynyl, substituted with quinyl, cycloalkyl, aryl, heteroaryl, and acyl; The heteroaryl or positional isomeric heteroarylene may be unsubstituted or may be alkyl. alkyl, aminoalkyl, -alkylene-NH-, hydroxylalkyl, -alkylene-O-, chlorine substituted with carboxyalkyl, -alkylene-COO-, benzyl, or phenyl; The aryl is unsubstituted or substituted with nitro, amino, or -NH-. ;and and n is an integer from 1 to 5.

[0009] In another embodiment, provided is a compound of Formula A, Formula B, Formula C, or Formula D, or Pharmaceutically acceptable salts include: [ka] (In the formula, L is a linker; BA is a binder; k is an integer from 1 to 30; R 1 is C1-C 10 is alkyl; R 3 is -C(O)C1-C5 alkyl, -C(O)N(H)C1-C 10 Alkyl, or -(C1-C 10 (Alkylene)-NR 3 a R 3b and where R 3a and R 3b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl, Alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally has been replaced by will; R 4 and R 5 is, independently in each occurrence, hydrogen or C-C alkyl; R 6is —OH, —O—, —NHNH, or —NHNH—; or in certain embodiments, R 6 -NHSO 2nd Round 60 where R 60 is an alkyl, alkenyl, alkynyl, cycloalkyl, Heterocycloalkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl or when bonded to -L-, it is a divalent -alkylene-, -alkenylene-, -alkenylene-, Quinylene, -cycloalkylene, -heterocycloalkylene, -arylene, -heteroa arylene-, substituted arylene-, or substituted heteroarylene-; R 7 is, independently in each occurrence, hydrogen, —OH, —O—, halogen, or —NR 7a R 7b and where R 7a and R 7b is, independently in each occurrence, a bond, hydrogen, alkyl, alkenyl, alkyl aryl, cycloalkyl, aryl, heteroaryl, and acyl, where alkyl , alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are , optionally substituted, or when attached to -L-, a divalent -alkylene-, -alkene-, alkynylene, cycloalkylene, arylene, heteroarylene or -acylene-, where -alkylene-, -alkenylene-, -alkynylene-, - Cycloalkylene-, -arylene-, -heteroarylene-, and -acylene- are optionally It has been replaced; R 8 is, independently in each case, hydrogen, deuterium, -NHR 9 or halogen, where R 9is hydrogen, —C1-C5 alkyl, or —C(O)C1-C5 alkyl; and m is 1 or 2; Q is —CH— or —O—, where When Q is -O-, R 2 is C1-C 10 Alkyl, divalent -C1-C 10 Alkylene, C1-C 10 Alkynyl, divalent -C1-C 10 Alkynylene-, positional isomers of C1-C 10 alkyltriazolyl, Positional isomers of divalent -C1-C 10 Alkyltriazolylene-, -C1-C 10 Alkylene-(5-membered hetero aryl), positional isomeric divalent -C1-C 10 Alkylene-(5-membered heteroarylene)-, -C1-C3 Alkylene-Q 1 -(CH2) n Aryl, divalent -C1-C3 alkylene-Q 1 -(CH2) n Arylene, C1-C3 Hydroxyalkyl, divalent -C1-C3 hydroxyalkylene-, C1-C 10 alkyl ethers, or divalent -C1-C 10 alkyl ether; or When Q is -CH2-, R 2 is C5-C 10 Alkyl, divalent -C5-C 10 Alkylene, C1-C 10 Alkynyl, divalent -C1-C 10 Alkynylene-, positional isomers of C1-C 10 Alkyltriazolyl , positional isomers of divalent -C1-C 10 Alkyltriazolylene-, -C1-C 10 Alkylene-(5-membered heterocyclic (aryl), regioisomeric divalent -C1-C10 Alkylene-(5-membered heteroarylene)-, -C1-C 3Alkylene-Q 1 -(CH2) n Aryl, divalent -C1-C3 alkylene-Q 1 -(CH2) n Arylene, C1-C 3 Hydroxyalkyl, divalent -C1-C3 hydroxyalkylene-, C1-C 10 alkyl ethers, or divalent -C1-C 10 alkyl ether; and Q 1 is —CH— or —O—; The regioisomeric triazolylenes may be unsubstituted or may be substituted with alkyl, alkenyl, alkynyl, substituted with quinyl, cycloalkyl, aryl, heteroaryl, and acyl; The heteroaryl or positional isomeric heteroarylene may be unsubstituted or may be alkyl. alkyl, aminoalkyl, -alkylene-NH-, hydroxylalkyl, -alkylene-O-, chlorine substituted with carboxyalkyl, -alkylene-COO-, benzyl, or phenyl; The aryl is unsubstituted or substituted with nitro, amino, or -NH-. ;and and n is an integer from 1 to 5.

[0010] In one embodiment, provided is a linker of formula LPa, formula LPb, formula LPc, or formula LPd. -payload, or a pharmaceutically acceptable salt thereof: [ka] (In the formula, L is a linker; R 1 is C1-C 10 is alkyl; R 3is -C(O)C1-C5 alkyl, -C(O)N(H)C1-C 10 Alkyl, or -(C1-C 10 (Alkylene)-NR 3 a R 3b and where R 3a and R 3b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl, Alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally has been replaced by will; R 4 and R 5 is, independently in each occurrence, hydrogen or C-C alkyl; R 6 is -OH, -O-, -NHNH2, or -NHNH-; R 7 is, independently in each occurrence, hydrogen, —OH, —O—, halogen, or —NR 7a R 7b and where R 7a and R 7b is, independently in each occurrence, a bond, hydrogen, alkyl, alkenyl, alkyl aryl, cycloalkyl, aryl, heteroaryl, acyl, and amino acid residues; Here, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl acyl, and acyl are optionally substituted; R 8 is, independently in each case, hydrogen, deuterium, -NHR 9 or halogen, where R 9 is hydrogen, —C1-C5 alkyl, or —C(O)C1-C5 alkyl; and m is 1 or 2; Q is —CH— or —O—, where When Q is -O-, R2 is C1-C 10 Alkyl, C1-C 10 Alkynyl, positional isomeric C1 -C 10 Triazolylene, -C1-C 10 Alkylene-(5-membered heteroaryl), positional isomers of -C1-C 10 Alkylene-(5-membered heteroarylene), -C1-C3 alkylene-Q 1 -(CH2) n Aryl, C1-C3 Hydroxyalkyl or C1-C 10 is an alkyl ether; or When Q is -CH2-, R 2 is C5-C 10 Alkyl, C1-C 10 Alkynyl, positional isomers C1-C 10 Triazolylene, -C1-C 10 Alkylene-(5-membered heteroaryl), positional isomers of -C1-C 10 Alkylene-(5-membered heteroarylene), -C1-C3 alkylene-Q 1 -(CH2) n Aryl, C1-C3 Hydroxyalkyl, or C1-C 10 alkyl ether; and Q 1 is —CH— or —O—; The regioisomeric triazolylenes may be unsubstituted or may be substituted with alkyl, alkenyl, alkynyl, substituted with quinyl, cycloalkyl, aryl, heteroaryl, and acyl; The heteroaryl or positional isomeric heteroarylene may be unsubstituted or may be alkyl. alkyl, aminoalkyl, -alkylene-NH-, hydroxylalkyl, -alkylene-O-, chlorine substituted with carboxyalkyl, -alkylene-COO-, benzyl, or phenyl; The aryl is unsubstituted or substituted with nitro, amino, or -NH-. ;and and n is an integer from 1 to 5.

[0011] In one embodiment, provided is a linker of formula LPa, formula LPb, formula LPc, or formula LPd. -payload, or a pharmaceutically acceptable salt thereof: [ka] (In the formula, L is a linker; R 1 is C1-C 10 is alkyl; R 3 is -C(O)C1-C5 alkyl, -C(O)N(H)C1-C 10 Alkyl, or -(C1-C 10 (Alkylene)-NR 3 a R 3b and where R 3a and R 3b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl, Alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally has been replaced by will; R 4 and R 5 is, independently in each occurrence, hydrogen or C-C alkyl; R 6 is —OH, —O—, —NHNH, or —NHNH—; or in certain embodiments, R 6 -NHSO 2nd Round 60 where R 60 is an alkyl, alkenyl, alkynyl, cycloalkyl, Heterocycloalkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl or when bonded to -L-, it is a divalent -alkylene-, -alkenylene-, -alkenylene-, Quinylene, -cycloalkylene, -heterocycloalkylene, -arylene, -heteroa arylene-, substituted arylene-, or substituted heteroarylene-; R 7 is, independently in each occurrence, hydrogen, —OH, —O—, halogen, or —NR 7a R 7b and where R 7a and R 7b is, independently in each occurrence, a bond, hydrogen, alkyl, alkenyl, alkyl aryl, cycloalkyl, aryl, heteroaryl, and acyl, where alkyl , alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are , optionally substituted, or when attached to -L-, a divalent -alkylene-, -alkene-, alkynylene, cycloalkylene, arylene, heteroarylene or -acylene-, where -alkylene-, -alkenylene-, -alkynylene- , -cycloalkylene-, -arylene-, -heteroarylene-, and -acylene- are optionally It has been replaced; R 8 is, independently in each case, hydrogen, deuterium, -NHR 9 or halogen, where R 9 is hydrogen, —C1-C5 alkyl, or —C(O)C1-C5 alkyl; and m is 1 or 2; Q is —CH— or —O—, where When Q is -O-, R 2 is C1-C 10 Alkyl, divalent -C1-C10 Alkylene, C1-C 10 Alkynyl, divalent -C1-C 10 Alkynylene-, positional isomers of C1-C 10 alkyltriazolyl, Positional isomers of divalent -C1-C 10 Alkyltriazolylene-, -C1-C 10 Alkylene-(5-membered hetero aryl), positional isomeric divalent -C1-C 10 Alkylene-(5-membered heteroarylene)-, -C1-C3 Alkylene-Q 1 -(CH2) n Aryl, divalent -C1-C3 alkylene-Q 1 -(CH2) n Arylene, C1-C3 Hydroxyalkyl, divalent -C1-C3 hydroxyalkylene-, C1-C 10 alkyl ethers, or divalent -C1-C 10 alkyl ether; or When Q is -CH2-, R 2 is C5-C 10 Alkyl, divalent -C5-C 10 Alkylene, C1-C 10 Alkynyl, divalent -C1-C 10 Alkynylene-, positional isomers of C1-C 10 Alkyltriazolyl , positional isomers of divalent -C1-C 10 Alkyltriazolylene-, -C1-C 10 Alkylene-(5-membered heterocyclic (aryl), regioisomeric divalent -C1-C 10 Alkylene-(5-membered heteroarylene)-, -C1-C 3Alkylene-Q 1 -(CH2) n Aryl, divalent -C1-C3 alkylene-Q 1 -(CH2) n Arylene, C1-C 3 Hydroxyalkyl, divalent -C1-C3 hydroxyalkylene-, C1-C 10 alkyl ethers, or divalent -C1-C 10 alkyl ether; and Q 1 is —CH— or —O—; The regioisomeric triazolylenes may be unsubstituted or may be substituted with alkyl, alkenyl, alkynyl, substituted with quinyl, cycloalkyl, aryl, heteroaryl, and acyl; The heteroaryl or positional isomeric heteroarylene may be unsubstituted or may be alkyl. alkyl, aminoalkyl, -alkylene-NH-, hydroxylalkyl, -alkylene-O-, chlorine substituted with carboxyalkyl, -alkylene-COO-, benzyl, or phenyl; The aryl is unsubstituted or substituted with nitro, amino, or -NH-. ;and and n is an integer from 1 to 5.

[0012] In another embodiment, the antibodies described herein include antibodies or antigen-binding fragments thereof. An antibody-drug conjugate, wherein the antibody or antigen-binding fragment thereof is a The antibody-drug conjugate is conjugated to a compound such as

[0013] In another embodiment, described herein are compounds, linker-payload, or antibody-drug conjugates and methods for making the compositions. [Brief explanation of the drawings]

[0014] BRIEF DESCRIPTION OF THE DRAWINGS [Figure 1]FIG. 1 shows the synthetic chemistry schemes for tubulysin payloads, tubulysin linker-payloads, and their protein conjugates. [Figure 2] FIG. 2 shows the synthetic chemistry schemes for tubulysin payloads, tubulysin linker-payloads, and their protein conjugates. [Figure 3] FIG. 3 shows the synthetic chemistry schemes for tubulysin payloads, tubulysin linker-payloads, and their protein conjugates. [Figure 4] FIG. 4 shows the synthetic chemistry schemes for tubulysin payload, tubulysin linker-payload, and their protein conjugates. [Figure 5] FIG. 5 shows the synthetic chemistry schemes for tubulysin payload, tubulysin linker-payload, and their protein conjugates. [Figure 6] FIG. 6 shows the synthetic chemistry schemes for tubulysin payload, tubulysin linker-payload, and their protein conjugates. [Figure 7] FIG. 7 shows the synthetic chemistry schemes for tubulysin payload, tubulysin linker-payload, and their protein conjugates. [Figure 8] FIG. 8 shows the synthetic chemistry schemes for tubulysin payloads, tubulysin linker-payloads, and their protein conjugates. [Figure 9] FIG. 9 shows the synthetic chemistry schemes for tubulysin payload, tubulysin linker-payload, and their protein conjugates. [Figure 10] FIG. 10 shows the synthetic chemistry schemes for tubulysin payload, tubulysin linker-payload, and their protein conjugates. [Figure 11]FIG. 11 shows the synthetic chemistry schemes for tubulysin payload, tubulysin linker-payload, and their protein conjugates. [Figure 12] FIG. 12 shows the synthetic chemistry schemes for tubulysin payload, tubulysin linker-payload, and their protein conjugates. [Figure 13] FIG. 13 shows the synthetic chemistry schemes for tubulysin payload, tubulysin linker-payload, and their protein conjugates. [Figure 14] FIG. 14 shows the synthetic chemistry schemes for tubulysin payloads, tubulysin linker-payloads, and their protein conjugates.

[0015] [Figure 15] FIG. 15 shows size-exclusion chromatography of anti-STEAP2 Ab-LP3, anti-STEAP2 Ab-LP4, control Ab-LP3, and control Ab-LP4.

[0016] [Figure 16] Figure 16 shows that anti-STEAP2 Tubulysin ADCs exhibit significant anti-tumor activity against NOG mice bearing CTG-2440 prostate cancer PDXs.

[0017] [Figure 17] Figure 17 shows that anti-STEAP2 Tubulysin ADCs exhibit significant anti-tumor activity against NOG mice bearing CTG-2441 prostate cancer PDXs. DETAILED DESCRIPTION OF THE INVENTION

[0018] DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS Provided herein are compounds, compositions, and methods for treating, for example, cancer in a subject. This is a useful method for

[0019] (definition) When referring to the compounds provided herein, the following terms are used as defined below unless otherwise indicated. Unless otherwise defined, technical and scientific terms used herein have the following meanings: All terms have the same meaning as commonly understood by one of ordinary skill in the art. In the event that there are a plurality of definitions for terms used herein, those definitions shall prevail unless otherwise stated. will be done.

[0020] As used herein, "alkyl" refers to a monovalent saturated hydrocarbon radical moiety. Alkyl is optionally substituted and may be linear, branched, or cyclic, i.e., cycloalkenyl. Alkyl may be a radical having 1 to 20 carbon atoms, i.e., C, C 1-20 Alkyl; a radical having 1 to 12 carbon atoms, i.e., C 1-12 Alkyl; 1~ Radicals with 8 carbon atoms, i.e., C 1-8 Alkyl; alkyl having 1 to 6 carbon atoms Dical, i.e., C 1-6 alkyl; and radicals having 1 to 3 carbon atoms, i.e., C 1-3 Examples of alkyl moieties include, but are not limited to, methyl ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, i-butyl, pentyl cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl moieties Pentyl moieties include, but are not limited to, n-pentyl and Hexyl moieties include, but are not limited to, n-hexyl and i-pentyl. Examples of suitable ion exchangers include, but are not limited to, ion exchangers.

[0021] As used herein, "alkylene" refers to a divalent alkyl group. Unless otherwise specified, alkylene includes, but is not limited to, 1 to 20 carbon atoms. The olefin group is optionally substituted as described herein for alkyl. In some embodiments, the alkylene is unsubstituted.

[0022] The designation of an amino acid or amino acid residue without specifying its stereochemistry refers to the L-form of that amino acid, the D-form or a racemic mixture thereof.

[0023] As used herein, "haloalkyl" refers to an alkyl group as defined above. wherein the alkyl is a halogen, such as fluorine (F), chlorine (Cl), bromine (Br), or iodine. haloalkyl refers to said alkyl containing at least one substituent selected from iodine(I). Examples of alkyl groups include, but are not limited to, -CF3, -CH2CF3, -CCl2F, and -CCl3. do not have.

[0024] As used herein, "alkenyl" refers to an alkyl group having at least two carbon atoms and one or more alkyl groups. Alkenyl refers to a monovalent hydrocarbon radical moiety containing a non-aromatic carbon-carbon double bond. is optionally substituted and can be linear, branched, or cyclic. The radicals are those with 2 to 20 carbon atoms, i.e., C 2-20 Alkenyl; 2 to 12 carbon atoms Radicals with elementary atoms, i.e., C 2-12 Alkenyl; Radicals containing 2 to 8 carbon atoms le, i.e., C 2-8 Alkenyl; a radical having 2 to 6 carbon atoms, i.e., C 2-6 a alkenyl; and radicals having 2 to 4 carbon atoms, i.e., C 2-4 Alkenyl is an example. Examples of alkenyl moieties include, but are not limited to, vinyl, propenyl, butyl, and butyl. Examples include, but are not limited to, thenyl and cyclohexenyl.

[0025] As used herein, "alkynyl" refers to a group having at least two carbon atoms and one or more alkyl groups. Alkynyl refers to a monovalent hydrocarbon radical moiety containing a carbon-carbon triple bond of any Alkynyl is substituted with, and can be linear, branched, or cyclic. Radicals with 2 to 20 carbon atoms, i.e., C 2-20 Alkynyl; 2 to 12 carbon atoms radicals, i.e., C 2-12 Alkynyl; a radical having 2 to 8 carbon atoms, i.e. Wachi, C 2-8 Alkynyl; a radical having 2 to 6 carbon atoms, i.e., C 2-6 Alkynyl; and radicals having 2 to 4 carbon atoms, i.e., C 2-4 Alkynyl is an example of this. Examples of alkynyl moieties include, but are not limited to, ethynyl, propynyl, and butynyl. Examples include, but are not limited to:

[0026] As used herein, "alkoxy" refers to a monovalent saturated hydrocarbon radical moiety. wherein the hydrocarbon contains a single bond to an oxygen atom and the radical is positioned on the oxygen atom. For example, ethoxy is CH3CH2-O·. An alkoxy substituent is The alkoxy is optionally bonded to the compound through this oxygen atom of the alkoxy substituent. It can be substituted and linear, branched, or cyclic, i.e., cycloalkoxy. The alkoxy includes those having 1 to 20 carbon atoms, i.e., C 1-20 Alcoki C; those having 1 to 12 carbon atoms, i.e., C 1-12 Alkoxy; 1 to 8 carbon atoms That is, C 1-8 Alkoxy; having 1 to 6 carbon atoms, i.e., C 1-6 Alkoxy; and those having 1 to 3 carbon atoms, i.e., C 1-3 Alkoxy is an example. Examples of alkoxy moieties include, but are not limited to, methoxy, ethoxy, n-propyl, and propyl. propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, i-butoxy, pentoxy cyclopropoxy, cyclobutoxy, cyclopentoxy, and Including, but not limited to, cyclohexoxy.

[0027] As used herein, "haloalkoxy" refers to an alkoxy group as defined above. alkoxy, wherein the alkoxy is at least one selected from halogen, for example, F, Cl, Br, or I. "alkoxy" refers to any of the above alkoxy groups containing at least one substituent.

[0028] As used herein, "aryl" refers to an aromatic compound in which the ring atoms are carbon atoms. Aryl refers to a monovalent moiety that is a radical. Aryl is optionally substituted and may be monocyclic or polycyclic. The aryl moiety can be of the formula, for example, bicyclic or tricyclic. those with up to 20 ring carbon atoms, i.e., C 6-20 Aryl; having 6 to 15 ring carbon atoms That is, C 6-15 Aryl, and those having 6 to 10 ring carbon atoms, i.e. , C 6-10Examples of aryl moieties include, but are not limited to: Phenyl, naphthyl, fluorenyl, azulenyl, anthryl, phenanthryl, and pyridine Examples include, but are not limited to, lenyl.

[0029] As used herein, "arylalkyl" refers to the radical of an alkyl compound. where the alkyl compound is substituted with an aromatic substituent, i.e., That is, the aromatic compound contains a single bond to an alkyl group, and the radical is The arylalkyl group is attached to the illustrated chemical structure via the alkyl group. Arylalkyl has the structure, for example: [ka] where B is an aromatic moiety, e.g., aryl or phenyl. The arylalkyl may be optionally substituted, i.e., the aryl and / or alkyl groups may be substituted. The alkyl groups may be substituted as disclosed herein. Examples of arylalkyl include: Examples include, but are not limited to, benzyl.

[0030] As used herein, "alkylaryl" is a radical of an aryl compound. where the aryl compound is substituted with alkyl substituents, and That is, the aryl compound contains a single bond to an alkyl group, and the radical is The alkylaryl group is bonded to the exemplified chemical structure via the aryl group. Alkylaryl has the structure, for example: [ka] where B is an aromatic moiety, e.g., phenyl. The aryl is optionally substituted, i.e., the aryl and / or alkyl groups are Examples of alkylaryl include toluyl, methyl ... These include, but are not limited to:

[0031] As used herein, "aryloxy" refers to an aryl group in which the ring atoms are carbon atoms and the A monovalent moiety that is a radical of an aromatic compound in which the ring is substituted with an oxygen radical. That is, the aromatic compound contains a single bond to an oxygen atom and the radical is attached to the oxygen atom. For example, in the case of phenoxy, [ka] The aryloxy substituent is bonded to the compound it substitutes through this oxygen atom. The aryloxy is optionally substituted. The aryloxy is preferably a substituted aryl having 6 to 20 carbon atoms. Radicals with ring carbon atoms, i.e., C 6-20 Aryloxy; 6 to 15 ring carbon atoms What has, i.e., C 6-15 aryloxy and those having 6 to 10 ring carbon atoms; That is, C 6-10 Examples include, but are not limited to, aryloxy. Examples of aryl moieties include phenoxy, naphthoxy, and anthroxy. Not limited to:

[0032] As used herein, "arylene" refers to an aromatic ring in which the ring atoms are only carbon atoms. Arylene refers to a divalent moiety of an optionally substituted, monocyclic or polycyclic, e.g. For example, it can be a bicyclic or tricyclic ring. Examples of the arylene moiety include 6 to 20 having ring carbon atoms, i.e., C 6-20 Arylene; having 6 to 15 ring carbon atoms That is, C 6-15 arylene, and those having 6 to 10 ring carbon atoms, i.e. , C 6-10 Examples include, but are not limited to, arylene.

[0033] As used herein, "heteroalkyl" refers to an alkyl group in which one or more carbon atoms are replaced by a heteroatom. As used herein, "heteroalkenyl" refers to an alkyl substituted by "Alkenyl" refers to an alkenyl in which one or more carbon atoms are replaced by a heteroatom. As used herein, "heteroalkynyl" refers to an alkyl group in which one or more carbon atoms are bonded to a heteroatom. Suitable heteroatoms include nitrogen, oxygen, and Heteroalkyl, heteroalkenyl, heteroaryl, heteroaryls ... and heteroalkynyl are optionally substituted. Examples of heteroalkyl moieties include alkynyl, ... Examples of alkyl groups include aryl, arylaminoalkyl, arylsulfonylalkyl, and arylsulfinylalkyl. Examples of heteroalkyl moieties include, but are not limited to, methylamino, methylsulfonyl, and methylsulfinyl.

[0034] As used herein, "heteroaryl" refers to a group of ring atoms in which the ring atoms are carbon atoms and at least one heteroaryl. A monovalent radical of an aromatic compound containing one oxygen, sulfur, nitrogen, or phosphorus atom Examples of heteroaryl moieties include those having 5 to 20 ring atoms; 5 to 15 ring atoms; and Examples include, but are not limited to, those having 5 to 10 ring atoms. is optionally substituted.

[0035] As used herein, "heteroarylene" refers to a heteroaryl group in which one or more ring atoms of the aromatic ring are substituted or unsubstituted. Heteroaryl refers to a divalent heteroaryl substituted with a hydrogen, sulfur, nitrogen, or phosphorus atom. The aryl group is optionally substituted.

[0036] As used herein, "heterocycloalkyl" refers to a group in which one or more carbon atoms are heterocyclic. The preferred heteroatoms are nitrogen and cycloalkyl. Heterocycloalkyl includes, but is not limited to, , oxygen, and sulfur atoms. Examples of heterocycloalkyl moieties include morpholinyl, piperylene, and the like. Lysinyl, tetrahydropyranyl, pyrrolidinyl, imidazolidinyl, oxazolidinyl , thiazolidinyl, dioxolanyl, dithiolanyl, oxanyl, or thianyl. Examples include, but are not limited to:

[0037] As used herein, a "Lewis acid" is a molecule or ion that accepts a lone pair of electrons. The Lewis acids used in the methods described herein are other than protons. Lewis acids include non-metallic acids, metallic acids, hard Lewis acids, and soft Lewis acids. Lewis acids include, but are not limited to, aluminum, boron, iron, tin, and titanium. Tungsten, magnesium, copper, antimony, phosphorus, silver, ytterbium, scandium, nickel Exemplary Lewis acids include, but are not limited to, Lewis acids of zinc, zinc ions, and zinc. Examples include AlBr3, AlCl3, BCl3, boron trichloride methyl sulfide, BF3, boron trifluoride methyl Boron trifluoride methyl sulfide, Boron trifluoride tetrahydrofuran , dicyclohexylboron trifluoromethanesulfonate, iron(III) bromide, iron(III) chloride , tin(IV) chloride, titanium(IV) chloride, titanium(IV) isopropoxide, Cu(OTf)2, CuCl2, CuB r2, zinc chloride, alkylaluminum halide (R n AlX 3-n wherein R is a hydrocarbyl Zn(OTf)2, ZnCl2, Yb(OTf)3, Sc(OTf)3, MgBr2, NiCl2, Sn(OTf)2, Ni(OTf)2 and Mg(OTf)2.

[0038] As used herein, "N-containing heterocycloalkyl" refers to an N-containing heterocycloalkyl group in which one or more carbon atoms are heterocyclic. and at least one of the substituted heteroatoms is a nitrogen atom. Suitable heteroatoms other than nitrogen include oxygen and sulfur atoms. N-containing heterocycloalkyl may be optionally substituted. Examples of N-containing heterocycloalkyl moieties include morpholinyl, piperidinyl, and pyrrolyl. azolidinyl, imidazolidinyl, oxazolidinyl, or thiazolidinyl. Not limited to these.

[0039] As used herein, the term "optionally substituted" is used to describe a radical moiety. For example, optionally substituted alkyl means that such moiety is optionally substituted with one or more substituents. Examples of such substituents include halo, cyano, nitro, and the like. halo, amino, hydroxyl, optionally substituted haloalkyl, aminoalkyl, hydroxyl alkyl, azido, epoxy, optionally substituted heteroaryl, optionally substituted hydroxyl Tetracycloalkyl, [ka] (In the formula, R A , R B , and R C Each occurrence independently represents a hydrogen atom, an alkyl, an alkenyl, an alkyl Alkynyl, aryl, alkylaryl, arylalkyl, heteroalkyl, heteroa aryl, or heterocycloalkyl, or R A and R B is that they are combined together with the atoms forming a saturated or unsaturated carbocyclic ring, wherein the ring is optionally substituted and one or more ring atoms are optionally substituted with a heteroatom). In some embodiments, the radical moiety is an optionally substituted heterocyclic group. heteroaryl, optionally substituted heterocycloalkyl, or optionally substituted saturated or or an optionally substituted unsaturated carbocyclic ring, said optionally substituted heteroaryl; Optionally substituted heterocycloalkyl or optionally substituted saturated or unsaturated carbon The substituents on the ring, when substituted, are optionally further substituted with further substituents. In some embodiments, the aryl group is not substituted with any of the substituents described herein. When a described group is optionally substituted, the substituents attached to the group may be any group other than those otherwise defined. Unless otherwise specified, it is unsubstituted.

[0040] As used herein, a "binding agent" refers to a molecule that specifically binds to a given binding partner, e.g., an antigen. Any molecule capable of isomeric binding, such as a protein, antibody, or fragment thereof. Point to one side.

[0041] As used herein, a "linker" refers to a linker that connects a binder to one or more of the molecules described herein. The above compounds may be covalently linked to, for example, payload compounds and enhancers; or divalent, trivalent, or aryl groups that can be covalently linked (e.g., via reactive groups). Or refers to a multivalent moiety.

[0042] As used herein, "amide synthesis conditions" refers to, for example, carboxylic acids, activated carboxylic acids, to achieve amide formation by reaction of carboxylic acids or acyl halides with amines. In some instances, amide synthesis conditions refer to suitable reaction conditions for the reaction of a carboxylic acid with an amine. Some of these examples refer to reaction conditions suitable for achieving the formation of an amide bond between In this method, the carboxylic acid is first converted to an activated carboxylic acid, and then the activated carboxylic acid is reacted with the activated carboxylic acid. The carboxylic acid reacts with the amine to form an amide. Suitable conditions for achieving amide formation are: Examples include, but are not limited to, dicyclohexylcarbodiimide (DCC), diisopropyl Carbodiimide (DIC), (benzotriazol-1-yloxy)tris(dimethylamino)phos Benzonium hexafluorophosphate (BOP), (benzotriazol-1-yloxy) tripitrium Lolidinophosphonium hexafluorophosphate (PyBOP), (7-azabenzotriazole -1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyAOP), Mototripyrrolidinophosphonium hexafluorophosphate (PyBrOP), O-(benzotriazol-2-yl) (1-isopropyl-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU ), O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoride TBTU, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pi Lysinium 3-oxide hexafluorophosphate (HATU), N-ethoxycarbonyl-2- Ethoxy-1,2-dihydroquinoline (EEDQ), N-ethyl-N′-(3-dimethylaminopropyl) carbamazepine 2-chloro-1,3-dimethylimidazolidinium hexafluorophosphate (EDC) phosphate (CIP), 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT), and carbonyldiimide The present invention utilizes reagents to effect the reaction of carboxylic acids with amines, including tetrahydrofuran (CDI). In some examples, the carboxylic acid is first , converted to an activated carboxylic acid ester, and then reacted with an amine to form the activated carboxylic acid ester. In some embodiments, the carboxylic acid is treated with a reagent to form an amide bond. The reagent deprotonates the carboxylic acid, and then the deprotonated carboxylic acid is As a result of nucleophilic attack on the protonated reagent by The carboxylic acid is activated by forming a product complex with the acid. Activation of carboxylic acids The carboxylic acid ester is more soluble in amines than before the carboxylic acid is activated. This results in amide bond formation. Thus, the carboxylic acid is said to be activated. Exemplary reagents include DCC and DIC. Examples include:

[0043] As used herein, "positional isomer," "positional isomers," or "positional isomers" refers to a group of isomers that are heterocyclic or heterocyclic. A "mixture of isomers" can be obtained by treating an appropriate azide (e.g., -N3, or PE) with an appropriate alkyne. 1,3-cycloaddition or strain-promoted alkyne-azide cycloaddition (S-G-N3 derivatized antibody) derived from This refers to the product of a PAAC (Prodrug-Amplifiable Conjugate-Activated Carboxyacylcholinesterase) reaction, also known as a click reaction. For example, positional isomers and mixtures of positional isomers can be synthesized by the click reaction products shown below: Characterized by: [ka] In some embodiments, two or more suitable azides and two or more suitable alkynes are combined with an azide Each pair of alkynes participates in one or more independent click reactions to form regioisomeric click reactions. Utilized within a synthetic scheme en route to a product that can give rise to a mixture of reaction products For example, one skilled in the art can independently catalyze the first suitable azide on the way to the product. and a second suitable azide can react with a second suitable alkyne. can react with four possible click reaction positional isomers, or You will be aware that this will result in the production of a mixture of substances.

[0044] As used herein, the term "residue" refers to a chemical residue in a compound that remains after a chemical reaction. For example, the term "amino acid residue" or "N-alkyl amino acid residue" The amide coupling of an amino acid or N-alkyl amino acid to a suitable coupling partner is carried out. refers to the product of coupling or peptide coupling; After peptide coupling of the amino acid amide, for example, a water molecule is expelled to form the amide. This results in a product having an amino acid residue or an N-alkyl amino acid residue incorporated therein. The term "amino acid" refers to naturally occurring and synthetic α, β, γ, or δ amino acids, and is used in proteins. Amino acids found in the , methionine, phenylalanine, tryptophan, proline, serine, threonine, Stains, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine Examples of amino acids include, but are not limited to, arginine, histidine, and arginine. In the present invention, the amino acid is in the L-configuration. Alternatively, the amino acid may be alanyl, valinyl, or the like. , leucinyl, isoleucinyl, prolinyl, phenylalaninyl, tryptophanyl, Methioninyl, glycinyl, serinyl, threoninyl, cysteinyl, tyrosinyl, as Paraginyl, glutaminyl, aspartoyl, glutaroyl, lysinyl, argininyl, Histidinyl, β-alanyl, β-valinyl, β-leucinyl, β-isoleucinyl, β-propanol lorinyl, β-phenylalaninyl, β-tryptophanyl, β-methioninyl, β-glycinyl β-serinyl, β-threoninyl, β-cysteinyl, β-tyrosinyl, β-asparagine Glucosyl, β-glutaminyl, β-aspartoyl, β-glutaroyl, β-lysinyl, β-aspartoyl The amino acid derivatives may be β-histidinyl or β-histidinyl derivatives. The term "amino acid" refers to a group of amino acids that can be derived from natural or unnatural amino acids as described and exemplified herein. The amino acid derivatives are obvious to those skilled in the art and include natural and unnatural amino acids. Esters, amino alcohols, amino aldehydes, amino lactones, and N-methyl derivatives of In some embodiments, the amino acid residue is: [ka] is (In the formula, S c is a side chain of a natural or unnatural amino acid, or a bond (e.g., in the case of glycine, hydrogen in the case of serine; -CH2OH in the case of cysteine; -CH2CH2CH2CH2 in the case of lysine NH2; -CH2CH2COOH for glutamic acid; -CH2CH2C(O)NH2 for glutamine; or tyrosine (e.g., -CH2C6H5OH in the case of phenylalanine); and [ka] represents a bond to another chemical entity. c is hydrogen, alkyl, Selected from the group consisting of heteroalkyl, arylalkyl, and heteroarylalkyl. can be.

[0045] As used herein, a "therapeutically effective amount" refers to a dose or amount of a compound administered in the treatment or management of a disease or disorder. sufficient to provide a therapeutic benefit to the patient or to suppress one or more symptoms associated with the disease or disorder "Dysphagia" refers to an amount (e.g., of a compound) that is sufficient to delay or minimize the effects of steroids.

[0046] As used herein, "structural isomers" are isomers that have the same molecular formula but differ in the arrangement of atoms. Structural isomers refer to compounds that have different chemical structures due to the way they are synthesized. Exemplary structural isomers include: n-Propyl and isopropyl; n-butyl, sec-butyl, and tert-butyl; and n-butyl Examples include pentyl, isopentyl, and neopentyl.

[0047] Certain groups, moieties, substituents, and atoms are depicted with wavy lines intersecting the bond(s). and indicates the atom through which the group, moiety, substituent, or atom is bonded. For example: [ka] A phenyl group substituted with a propyl group, depicted as, has the following structure: [ka] As used herein, a cyclic group (e.g., aromatic, heterocyclic, etc.) is formed through a bond between the ring atoms. (aromatic, fused ring, and saturated or unsaturated cycloalkyl or heterocycloalkyl) Diagrams showing bonded substituents are not intended to be limiting unless otherwise specified, and are not intended to be limiting unless otherwise specified. According to techniques known in the art to which the disclosure pertains, the cyclic group may be selected from any of the cyclic groups or fused ring groups. is meant to indicate that the substituent may be substituted at any ring position on any ring. For example, the following group [ka] (wherein the subscript q is an integer from 0 to 4, and the substituent R 1 The location of , i.e., directly bonded to any vertex of the bond line structure, i.e., to a specific ring carbon atom. (not shown) is the substituent R 1 The following non-limiting examples of groups are attached to specific ring carbon atoms: include: [ka] .

[0048] As used herein, the phrase "reactive linker" or the abbreviation "RL" refers to, e.g., For example, [ka] where RG is a reactive group and SP is a spacer group. This refers to a monovalent group comprising a reactive group ("RG") and a spacer group ("SP"), depicted as: The reactive linkers described herein contain two or more reactive groups and two or more spacer groups. A spacer group may comprise any group that bridges the reactive group to another group, such as a payload. A reactive linker (RL) is a bivalent moiety that, together with the payload to which it is attached, intermediates useful as synthetic precursors for the preparation of the antibody conjugates described herein (" The reactive linker provides a linker-payload ("linker-payload" or LP). The reactive linker can be linked to another group, e.g., an antibody, capable of reacting with the reactive portion of the modified antibody, or antigen-binding fragment thereof, or the enhancing group It contains a reactive group that is a functional group or functional site. The moiety resulting from the reaction of the reactive group, together with the linking group, forms a conjugate as described herein. In some embodiments, the "reactive group" comprises an anti- functional groups or functional sites (e.g., functional groups or functional sites) that react with cysteine ​​or lysine residues of the antibody or its antigen-binding fragment For example, maleimide or N-hydroxysuccinimide (NHS) ester. In the formula (I), a "reactive group" refers to a functional group that can undergo a click chemistry reaction or Functionalized moieties (e.g., click chemistry, see Huisgen, Proc. Chem. Soc. 1961, Wang et al., J. Am. Chem. Soc. 2003, and Agard et al., J. Am. Ch (See em. Soc. 2004). In some embodiments of the click chemistry reaction, In this case, the reactive group is an alkyne capable of undergoing a 1,3-cycloaddition reaction with an azide. Suitable such reactive groups include strained alkynes, e.g., strain-promoting alkyne-azide rings. Suitable for SPAAC (Single-Polyaryl Alkyl Chain Addition), cycloalkynes such as cyclooctynes, aromatic cycloalkynes, Benzannulated alkynes undergo 1,3-cycloaddition with alkynes in the absence of copper catalysts. Suitable alkynes include, but are not limited to, alkynes that can be Dibenzoazacyclooctyne or [ka] Dibenzocyclooctyne or [ka] Biarylazacyclooctynone or [ka] Difluorinated cyclooctyne or [ka] Substituted alkynes, e.g., fluorinated alkynes, aza-cycloalkynes, bicycles [6. bicycle[6.1.0]nonyne or [ka] (BCN (wherein R is alkyl, alkoxy, or acyl) and derivatives thereof are also included. Particularly useful alkynes include, but are not limited to: [ka] The linker-payload containing such a reactive group is functionalized with an azide group. Such functionalized antibodies are useful for conjugating azido-poly(2-hydroxybenzoates) to antibodies. In some embodiments, such antibodies are functionalized with ethylene glycol groups. Such functionalized antibodies are synthesized by cleaving at least one glutamine in the presence of the enzyme transglutaminase. An antibody having a residue, for example, Gln295 in the heavy chain, is treated with a compound having an amino group and an azide group. It is induced by

[0049] In some instances, the reactive group is an alkyne, e.g., [ka] which can be converted by click chemistry to azides, e.g. [ka] to produce a click chemistry product, e.g., [ka] In some instances, the group can form a modified antibody or antigen-binding fragment thereof. In some instances, the reactive group is an alkyne, e.g., [ka] which can be converted by click chemistry to azides, e.g. [ka] to produce a click chemistry product, e.g., [ka] In some instances, the reactive group can be an alkyne, e.g., [ka] which can be converted by click chemistry to azides, e.g. [ka] to produce a click chemistry product, e.g., [ka] In some instances, the reactive group can be a functional group, such as [ka] which reacts with cysteine ​​residues on the antibody or antigen-binding fragment thereof to attach carbon atoms thereto. Sulfur-carbon bonds, e.g., [ka] (wherein Ab represents an antibody or an antigen-binding fragment thereof, and S represents the group through which the functional group binds to Ab.) (Indicates the S atom on the corresponding cysteine ​​residue) In some instances, the reactive group is a functional group, such as [ka] which reacts with a lysine residue on an antibody or antigen-binding fragment thereof to form an amide thereto Bonds, e.g. [ka] (wherein Ab represents an antibody or an antigen-binding fragment thereof, and NH represents the functional group via which the Ab binds.) (The NH atom on the corresponding lysine side chain residue is shown.) Form.

[0050] As used herein, the phrase "biodegradable moiety" refers to a moiety that degrades in vivo, typically non-toxic, biocompatible components that can be removed from the body by biological processes In some embodiments, the biodegradable portion is a portion that remains biodegradable for about 90 days or less, about 60 days or less, or completely or substantially degrades in vivo in less than 30 days or less, or in less than about 30 days, wherein the extent of degradation is , based on the percent mass loss of the biodegradable portion, and complete degradation is 100% Exemplary biodegradable moieties include, but are not limited to, poly( ε-caprolactone) (PCL), poly(3-hydroxybutyrate) (PHB), poly(glycolic acid) (PGA) , poly(lactic acid) (PLA), and its copolymer with glycolic acid (i.e., poly(D,L-lactide- Examples of such polyesters include aliphatic polyesters such as poly(propylene glycolide) (PLGA) (Vert M, Schwach G, Engel R and Coudane J (1998) J Control Release 53(1-3):85-92; Jain RA ( 2000) Biomaterials 21(23):2475-2490; Uhrich KE, Cannizzaro SM, Langer RS ​​and S Hakesheff KM (1999) Chemical Reviews 99(11):3181-3198; and Park TG , (1995) Biomaterials 16(15):1123-1130 (each of which is incorporated herein by reference in its entirety) incorporated herein by reference).

[0051] As used herein, the phrase "binder linker" or "BL" refers to a binder (e.g., For example, an antibody or antigen-binding fragment thereof) can be coupled to a payload compound (e.g., a globulin or a globulin-binding fragment thereof) described herein. lysine) and, optionally, any bivalent linking, connecting, or linking to one or more side chain compounds; Generally, the antibody conjugates described herein are A suitable binder linker for the antibody conjugate should be sufficiently long to take advantage of the circulating half-life of the antibody conjugate. and at the same time, the conjugate is stable to antigen-mediated internalization. The linker is capable of releasing its payload after internalization. The cleavable linker may be cleavable or non-cleavable. After local translocation, the protein is cleaved by intracellular metabolism, e.g., hydrolysis, reduction, or enzymatic cleavage. A non-cleavable linker is a linker that is cleaved after internalization and subsequently disrupts the lysosomal compartmentalization of the antibody. A linker that releases the attached payload upon dissolution. Examples include acid-labile linkers, hydrolytically unstable linkers, and enzymatically cleavable linkers. These include linkers, reduction-labile linkers, self-immolative linkers, and non-cleavable linkers. Suitable linkers include, but are not limited to, peptides, glucuronides, succinates, and the like. Acid imide-thioether, polyethylene glycol (PEG) unit, hydrazone, mar-cap mal-caproyl unit, dipeptide unit, valine-citrulline unit, and para- para-aminobenzyloxycarbonyl (PABC), para-aminobenzyl (PAB) units or In some embodiments, the binder may include, but is not limited to, The linker (BL) is a linker between the reactive group (RG) of the reactive linker (RL) and a binding agent, e.g., an antibody, a modified antibody, or an antigen-binding fragment thereof.

[0052] In some examples, the BL comprises the following site: [ka] (In the formula, [ka] is the bond to the binding agent). In some examples, the BL comprises the following moiety: [ka] (In the formula, [ka] is the bond to the binding agent). In some examples, the BL comprises the following moiety: [ka] (In the formula, [ka] is the bond to the binding agent). In some examples, the BL comprises the following moiety: [ka] (In the formula, [ka] In some examples, the cysteine ​​bond is a bond to a cysteine ​​of an antibody or antigen-binding fragment thereof. BL is the following part: [ka] (In the formula, [ka] is the attachment to a lysine of the antibody or antigen-binding fragment thereof).

[0053] When applied to polypeptides, the phrases "substantial similarity" or "substantially similar" is calculated using default gap weights, for example by the programs GAP or BESTFIT. At least 95% sequence identity when optimally aligned, even more preferred Alternatively, it refers to two peptide sequences that share at least 98% or 99% sequence identity. The sequence similarity was also calculated based on the results of Altschul et al., J. Mol. Biol. 215: 403-10 (published data). (use default settings) or enter at blast.ncbi.nlm.nih.gov / Blast.cgi This may be determined using the available BLAST algorithm. Preferably, non-identical residues The positions differ by conservative amino acid substitutions. may be substituted with another amino group having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, conservative amino acid substitutions are those that preserve the function of a protein. Conservative substitutions do not substantially alter the functional properties of two or more amino acid sequences. If different, the percent sequence identity or degree of similarity shall be calculated based on the conservative nature of the substitution. The concentration may be adjusted upward to correct for . Methods for making this adjustment are known to those skilled in the art. See, for example, Pearson (1994) Methods Mol. Biol. 24: 307-331. Examples of amino acid groups with side chains of similar chemical properties include: (1) fatty acids; Aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; (2) aliphatic-hydro (3) amide-containing side chains: asparagine and glutamine; (4) aromatic side chains: Aromatic side chains: phenylalanine, tyrosine, and tryptophan; (5) Basic side chains: lysine, alanine (6) acidic side chains: aspartic acid and glutamic acid; and (7) Sulfur side chains include: cysteine ​​and methionine. Preferred conservative amino acid substitutions are: phenylalanine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine -valine, glutamic acid-aspartic acid, and asparagine-glutamine; or Conservative substitutions are disclosed in Gonnet et al. (1992) Science 256: 1443-1445. have a positive value in the PAM250 log-likelihood matrix A "moderately conservative" substitution is a change in the PAM250 log-likelihood matrix. It is any change that has a non-negative value.

[0054] (Compound or Payload - Q is carbon) Provided herein are compounds or payloads. Without being limited to any particular compound, the compound may include tubulysin or a tubulysin derivative. In some embodiments, the compound can be delivered to the cell as part of a conjugate. In such a manner, the compound acts on a target, e.g., a tubulysin or tubulin, at or within a target cell. Certain compounds can exhibit any of the activities of ricin derivatives. In some embodiments, the compounds may have additional activities such as agonists of the folate receptor, somatostatin, and the like. The activity of the tocostatin receptor and / or the bombesin receptor can be modulated.

[0055] In certain embodiments, described herein are compounds having the structure of Formula I, or and pharmaceutically acceptable salts or prodrugs thereof: [ka] (wherein Q is —CH—; R 2 is C5-C 10 alkyl; R 3 is -C(O)C1-C5 alkyl R 4 is hydrogen; R 5 is C1-C5 alkyl; and R 7 is a halogen). In one embodiment, useful R 1 Examples of the radical include methyl and ethyl. In an embodiment, useful R 1 The groups include propyl, butyl, pentyl, hexyl, and heptyl. , octyl, nonyl, decyl, and structural isomers thereof. Te, R 1 is methyl. In one embodiment, R 1 is ethyl. Te, R 1 is propyl and its structural isomers. In one embodiment, R 1 is butyl and In one embodiment, R 1 is pentyl and its structural isomers In one embodiment, R 1 is hexyl and its structural isomers. , R 1 is heptyl and its structural isomers. In one embodiment, R 1 is octyl and In one embodiment, R 1 is nonyl and its structural isomers. In one embodiment, R 1 is decyl and its structural isomers. In certain embodiments, useful R 2 The groups include n-pentyl, n-hexyl, n-heptyl, and n-octyl. In one embodiment, R 2 is n-pentyl or a structural isomer thereof. In another embodiment, R 2 is n-hexyl or its structure In another embodiment, R 2 is n-heptyl, or a structural isomer thereof. In another embodiment, R 2 is n-octyl, or a structural isomer thereof. Hey, R 2 is n-nonyl, or a structural isomer thereof. 2 is n- decyl, or a structural isomer thereof. 2 is n-hexyl. In certain embodiments of formula I above, useful R 3 The groups include -C(O)Me, -C(O)Et, and -C(O)propion. In one embodiment, R 3 is -C(O)M In another embodiment, R 3 is —C(O)Et. In another embodiment, R 3 teeth, -C(O)propyl and its structural isomers. In another embodiment, R 3 -C(O)butyl and and structural isomers thereof. In another embodiment, R 3 -C(O)pentyl and its structural variants In certain embodiments of Formula I above, useful R 5 The groups include methyl, ethyl, propyl, butyl, and pentyl. In one embodiment, R 5 is methyl In another embodiment, R 5 is ethyl. In another embodiment, R 5 is a prop In another embodiment, R 5 is butyl and its structural isomers In another embodiment, R 5 is pentyl and its structural isomers. In some embodiments, R 6 In one embodiment, R 6 is -OH In another embodiment, R 6 is -NHNH2. In Formula I, in certain embodiments as described above, In each R 7 independently comprise fluorine, chlorine, bromine, and iodine. R 7 is fluorine. In another embodiment, R 7 is chlorine. Hey, R 7 is bromine. In another embodiment, R 7 is iodine. In some embodiments of the above, R 8 is hydrogen, deuterium, -NHR 9 , or halogen. In some embodiments of formula I above, R 9 is hydrogen, -C1-C5 alkyl, or -C(O)C1-C5 alkyl In certain embodiments of formula I above, m is 1 or 2. In one embodiment, R 8 is hydrogen. In one embodiment, R 8 is deuterium. In certain embodiments, R 8 independently include fluorine, chlorine, bromine, and iodine. 8 Ha, Fu In another embodiment, R 8is chlorine. In another embodiment, R 8 teeth, In another embodiment, R 8 is iodine. In one embodiment, —NHR 9 is -NH2. In one embodiment, -NHR 9 -NHMe, -NHEt, -NHCH2CH2CH3, -NHCH2C In one embodiment, -NHR 9 is -NHMe In one embodiment, -NHR 9 is -NHEt. In one embodiment, -NHR 9 is -NHCH2C H2CH3. In one embodiment, -NHR 9 is -NHCH2CH2CH2CH3. In one embodiment, -NHR 9 is -NHCH2CH2CH2CH2CH3. In one embodiment, -NHR 9 is -NHC(O)Me , -NHC(O)Et, -NHC(O)CH2CH2CH3, -NHC(O)CH2CH2CH2CH3, and -NHC(O)CH2CH2CH2CH2CH3 In one embodiment, -NHR 9 is -NHC(O)Me. In one embodiment, -NHR 9 teeth , -NHC(O)Et. In one embodiment, -NHR 9 is —NHC(O)CH CH CH. In such a case, -NHR 9 is -NHC(O)CH2CH2CH2CH3. In one embodiment, -NHR 9 is -NH C(O)CH2CH2CH2CH2CH3. In one embodiment, m is 1. In one embodiment , m is 2.

[0056] In certain embodiments, described herein is a compound having the structure of Formula II, or and pharmaceutically acceptable salts or prodrugs thereof: [ka] In some embodiments, R 2 , R 3 , R 6 , and R 7 is as described in the previous paragraph.

[0057] In certain embodiments, described herein, Q is —CH—; R 2 But C5-C 10 alkyl; R 3 is —C(O)C1-C5 alkyl; R 4 and R 5 is methyl; R 7 But -OH , halogen, or -NH; R 8 independently in each occurrence hydrogen, deuterium, -NHR 9 (In the ceremony , R 9 is hydrogen or -C1-C5 alkyl), or halogen; and m is 1 or 2 a compound having the structure of Formula I, or a pharmaceutically acceptable salt or prodrug thereof; In one embodiment, R 1 , R 2 , R 3 , and QR 2 is as described above in Formula I In certain embodiments of formula I above, R 7 includes fluorine, chlorine, bromine, and iodine. In an embodiment, R 7 is fluorine. In another embodiment, R 7 is chlorine. In an embodiment of the present invention, R 7 is bromine. In another embodiment, R 7is iodine. In one embodiment, R 7 is —OH. In one embodiment, R 7 is -NH2. In the embodiment, R 8 is hydrogen. In one embodiment, R 8 is deuterium. In the embodiment, R 8 independently comprise fluorine, chlorine, bromine, and iodine. Hey, R 8 is fluorine. In another embodiment, R 8 is chlorine. In R 8 is bromine. In another embodiment, R 8 is iodine. In R 8 -NHR 9 In one embodiment, -NHR 9 is —NH2. In -NHR 9 are -NHMe, -NHEt, -NHCH2CH2CH3, -NHCH2CH2CH2CH3, and -NHCH2CH2CH2 In one embodiment, -NHR 9 is -NHMe. In one embodiment, -NHR 9 is -NHEt. In one embodiment, -NHR 9 is —NHCH2CH2CH3. In one embodiment -NHR 9 is -NHCH2CH2CH2CH3. In one embodiment, -NHR 9 is -NHCH2CH2CH 2CH2CH3. In one embodiment, m is 1. In one embodiment, m is 2. do.

[0058] In certain embodiments, described herein are compounds having the structure of Formula III, is a pharmaceutically acceptable salt thereof: [ka] In some embodiments, Q, R 2 , R 3 , R 7 , R 8 , R 9 , and QR 2 is described in the previous paragraph. That is exactly what happened.

[0059] In certain embodiments, described herein, Q is —CH—; R 2 But C1-C 10 alkynyl; and R 6 is -OH, or a compound having the structure of formula I, In one embodiment, R 1 , R 3 , R 4 , R 5 , R 7 , and R 8 is as defined above. In one embodiment of Formula I, R 2 is -CH2CCH. In one embodiment of I, R 2 is —CH2CH2CCH. In one embodiment of Formula I, R 2 -C H2CH2CH2CCH. In one embodiment of Formula I, R 2 is -CH2CH2CH2CH2CCH. In one embodiment, R 2 is —CH2CH2CH2CH2CH2CCH. In one embodiment of Formula I, R 2 is —CH2CH2CH2CH2CH2CH2CCH. In one embodiment of Formula I, R 2 is -CH2CH2CH2CH2CH 2CH2CH2CCH. In one embodiment of Formula I, R2 is -CH2CH2CH2CH2CH2CH2CH2CH2CH2CCH In one embodiment of Formula I, R 2 is -CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CCH. Formula I In one embodiment, R 2 is -CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CCH.

[0060] In certain embodiments, described herein is a compound having the structure of Formula IV, or and pharmaceutically acceptable salts thereof: [ka] In some embodiments, R 2 , R 3 , R 4 , R 5 , R 7 , and R 8 As stated in the previous paragraph, is.

[0061] In certain embodiments, described herein, Q is —CH—; R 2 But the position is different Sexual -C1-C 10 alkylene-(5-membered heteroaryl), wherein the heteroaryl is unsubstituted or alkyl, aminoalkyl, hydroxylalkyl, carboxyalkyl , benzyl, or phenyl); R 3 is -C(O)C1-C5 alkyl R 4 and R5 is C1-C5 alkyl; R 6 is —OH; and R 7 is —NH2 or a pharmaceutically acceptable salt or prodrug thereof. In an embodiment, R 1 , R8 , and R 9 In certain embodiments of formula I above, and useful R 2 The group is a positional isomer of -C1-C 10 Alkylene-(1,2,3-triazole) Thus, the regioisomeric 1,2,3-triazoles may be unsubstituted or may be substituted with alkyl, amino, or alkyl, hydroxyl alkyl, carboxy alkyl, benzyl, or phenyl In the following embodiments, the 1,2,3-triazole is As explained elsewhere in this document, terminal alkynes and azidosulfates can be used to give regioisomeric products. In one embodiment, R 2 teeth, [ka] In one embodiment, R 2 teeth, [ka] In one embodiment, R 2 teeth, [ka] In one embodiment, R 2 teeth, [ka] In one embodiment, R 2 teeth, [ka] In one embodiment, R 2 teeth, [ka] In one embodiment, R 2teeth, [ka] In one embodiment, R 2 teeth, [ka] In one embodiment, R 2 teeth, [ka] In one embodiment, R 2 teeth, [ka] In any one or more of the embodiments in this paragraph, Y is hydrogen, a alkyl, aminoalkyl, hydroxylalkyl, carboxyalkyl, benzyl, or In one embodiment, Y is phenyl. In one embodiment, Y is hydrogen. In one embodiment, Y is aryl. In one embodiment, Y is aminoalkyl. and Y is hydroxylalkyl. In one embodiment, Y is carboxyalkyl. In one embodiment, Y is phenyl. In certain embodiments of formula I above, Useful R 3 Groups include -C(O)Me, -C(O)Et, -C(O)propyl, -C(O)butyl, and -C(O)pentyl. In one embodiment, R 3 is —C(O)Me. In another embodiment, R 3 is —C(O)Et. In another embodiment, R 3 is -C(O)propyl and its structural isomers In another embodiment, R 3 is -C(O)butyl and its structural isomers. In the embodiment, R3 is —C(O)pentyl and its structural isomers. In this way, R is useful 4 and R 5 The groups are independently methyl, ethyl, propyl, and the like. butyl and its structural isomers, and pentyl and its structural isomers, For example, in one embodiment, R 4 and R 5 is Me. As another example, in one embodiment, R 4 and R 5 is ethyl. Another example is R 4 teeth, Methyl and R 5 is ethyl. R as an embodiment within this paragraph 4 and R 5 of Other exemplary combinations or swings are contemplated herein.

[0062] In certain embodiments, described herein is a compound having the structure of Formula V, or and pharmaceutically acceptable salts thereof: [ka] In some embodiments, R 2 , R 3 , R 4 , and R 5 is as described in the previous paragraph.

[0063] In certain embodiments, described herein is a compound having the structure of Formula VI or Formula VII. Compounds that can be used: [ka] (In the formula, R 10 is hydrogen, methyl, -CH2CH2NH2, -CH2CH2OH, -CH2COOH, -CH2CH2CH2COOH, phenyl or a pharmaceutically acceptable salt thereof. R 10 is hydrogen. In one embodiment, R 10 is methyl. R 10 is —CH2CH2NH2. In one embodiment, R 10 is -CH2CH2OH. In the embodiment, R 10 is —CHCOOH. In one embodiment, R 10 is -CH2CH2CH2COOH In one embodiment, R 10 is benzyl. In one embodiment, R 10 Ha, Fu It is Venil.

[0064] In some embodiments, provided herein is a method for treating a psoriasis comprising administering to a subject a therapeutically effective amount of: [ka] TIFF2024167209000066.tif219170TIFF2024167209000067.tif218170TIFF2024167209000068.tif224170TIFF2024167209000069.tif164170TIFF2024167209000070.tif230170TIFF2024167209000071.tif58170 or a positional isomer thereof; or a pharmaceutically acceptable salt thereof.

[0065] In certain embodiments, described herein are compounds having the structure of Formula XIII, or is a pharmaceutically acceptable salt or prodrug thereof: [ka] (wherein Q is —CH—; R 2 is C5-C 10 alkyl; R 3 is -C(O)C1-C5 alkyl R 4 is hydrogen or C1-C5 alkyl; R 5 is C1-C5 alkyl; or R 4 and R 5 teeth , together with the carbon to which they are attached, form a 3- to 8-membered cycloalkyl, substituted cycloalkyl, form a heterocycloalkyl, or a substituted heterocycloalkyl; and R 7 is a halogen In Formula XIII, in one embodiment, useful R 1 Examples of the groups include methyl and ethyl. In some embodiments, useful R 1 The groups include propyl, butyl, pentyl, Examples of alkyl groups include xyl, heptyl, octyl, nonyl, decyl, and structural isomers thereof. In one embodiment, R 1 is methyl. In one embodiment, R 1 is ethyl. In one embodiment, R 1 is propyl and its structural isomers. R 1 is butyl and its structural isomers. In one embodiment, R 1 is pentyl and its In one embodiment, R 1 is hexyl and its structural isomers. In an embodiment, R 1 is heptyl and its structural isomers. In one embodiment, R 1 is octyl and its structural isomers. In one embodiment, R 1 Nonyl and its structure In one embodiment, R 1is decyl and its structural isomers. Formula XIII In the above embodiment, useful R 2 Examples of the group include n-pentyl, n-hexyl, and n-heptyl. Examples of aryl include n-octyl, n-nonyl, and n-decyl. 2 teeth, n-pentyl, or a structural isomer thereof. 2 is n-hexyl, or is a structural isomer thereof. In another embodiment, R 2 is n-heptyl or its structural isomer In another embodiment, R 2 is n-octyl or its structural isomer. In an embodiment, R 2 is n-nonyl, or a structural isomer thereof. , R 2 is n-decyl, or a structural isomer thereof. 2 is n-hexyl In some embodiments of formula XIII above, useful R 3 Groups include -C(O)Me and -C(O)Et , —C(O)propyl, —C(O)butyl, and —C(O)pentyl. , R 3 is —C(O)Me. In another embodiment, R 3 is —C(O)Et. Hey, R 3 is —C(O)propyl and its structural isomers. In another embodiment, R 3 teeth , —C(O)butyl and structural isomers thereof. In another embodiment, R 3 is -C(O)pentyl and structural isomers thereof. In one embodiment, R 4 is hydrogen. In an embodiment, useful R 4The groups include methyl, ethyl, propyl, butyl, and pentyl. In one embodiment, R 4 is methyl. In another embodiment, R 4 is ethyl. In another embodiment, R 4 is propyl and its structural isomers In another embodiment, R 4 is butyl and its structural isomers. Te, R 4 is pentyl and its structural isomers. In some embodiments of formula XIII above, Useful R 5 Groups include methyl, ethyl, propyl, butyl, and pentyl. In an embodiment, R 5 is methyl. In another embodiment, R 5 is ethyl. In another embodiment, R 5 is propyl and its structural isomers. Te, R 5 is butyl and its structural isomers. In another embodiment, R 5 Pentyl and and structural isomers thereof. In one embodiment, R 4 and R 5 is methyl. In R 4 and R 5 together with the carbon to which they are attached form a cyclopropyl or substituted cyclopropyl group. In one embodiment, R 4 and R 5 along with the carbon to which they are attached , cyclobutyl or substituted cyclobutyl. In one embodiment, R 4 and R 5 are those together with the carbon to which it is attached is cyclopentyl or substituted cyclopentyl. In R 4 and R5 together with the carbon to which they are attached form a cyclohexyl or substituted cyclohexyl group. In one embodiment, R 4 and R 5 along with the carbon to which they are attached , cycloheptyl or substituted cycloheptyl. In one embodiment, R 4 and R 5 Ha, so Together with the carbon to which they are attached, they are cyclooctyl or substituted cyclooctyl. In an embodiment, R 4 and R 5 together with the carbon to which they are attached are cyclopropyl One methylene carbon in the cyclopropyl is replaced with Z, and Z is oxygen, nitrogen, or sulfur. 4 and R 5 Is that a cyclobutyl, together with the carbon to which they are attached, and a methylene carbon in said cyclobutyl; wherein one of is replaced with Z, and Z is oxygen, nitrogen, or sulfur. In one embodiment, R 4 and R 5 together with the carbon to which they are attached form a cyclo pentyl, wherein one or more methylene carbons in the cyclopentyl are replaced with Z; and Z is oxygen, nitrogen, or sulfur. R 4 and R 5 together with the carbon to which they are attached, is cyclohexyl, One or more methylene carbons in the cyclohexyl group are replaced by Z, and Z is oxygen, nitrogen, or sulfur. 4 and R 5 are those together with the carbon to which it is attached, is a cycloheptyl, and one or more The cycloalkyl group, wherein a methylene carbon is replaced with Z, and Z is oxygen, nitrogen, or sulfur. In one embodiment, R 4 and R 5 along with the carbon to which they are attached , cyclooctyl, wherein one or more methylene carbons in the cyclooctyl are replaced with Z; and Z is oxygen, nitrogen, or sulfur. In some embodiments of III, R 60 is an alkyl, alkenyl, alkynyl, cycloalkynyl aryl, heterocycloalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl Aryl. 60 The alkyl group is R 1 The items described in this paragraph Examples of suitable R include methyl and ethyl. 60 Alkenyl, alkynyl, a Aryl and heteroaryl are described elsewhere herein. 60 Cycloa Alkyl and heterocycloalkyl include those described in this paragraph. R with the carbon to which they are attached 4 and R 5 Formula XIII In the above embodiment, each R 7 contains independently fluorine, chlorine, bromine, and iodine In one embodiment, R 7 is fluorine. In another embodiment, R 7 is chlorine In another embodiment, R 7 is bromine. In another embodiment, R 7 is iodine In the above embodiment of Formula XIII, R 8 is hydrogen, deuterium, -NHR 9 , or Haloge In certain embodiments of formula XIII above, R 9 is hydrogen, -C1-C5 alkyl, or -C(O ) C1-C5 alkyl. In certain embodiments of formula XIII above, m is 1 or 2. In the embodiment, R 8 is hydrogen. In one embodiment, R 8 is deuterium. In the embodiment, R 8 independently comprise fluorine, chlorine, bromine, and iodine. Hey, R 8 is fluorine. In another embodiment, R 8 is chlorine. In R 8 is bromine. In another embodiment, R 8 is iodine. In -NHR 9 is -NH2. In one embodiment, -NHR 9 -NHMe, -NHEt, -NHCH2 In one embodiment, -NHCH CH CH CH CH CH and -NHCH CH CH CH CH CH. 9 is -NHMe. In one embodiment, -NHR 9 is -NHEt. NHR 9 is -NHCH2CH2CH3. In one embodiment, -NHR 9 is -NHCH2CH2CH2CH3. In one embodiment, -NHR 9 is -NHCH2CH2CH2CH2CH3. In one embodiment, -NHR 9 -NHC(O)Me, -NHC(O)Et, -NHC(O)CH2CH2CH3, -NHC(O)CH2CH2CH2CH3, and -NHC(O)CH2C In one embodiment, —NHR 9 is -NHC(O)Me. -NHR 9 is -NHC(O)Et. In one embodiment, -NHR 9 is -NHC(O)CH2CH2CH3 In one embodiment, -NHR 9 is —NHC(O)CH 2 CH 2 CH 2 CH 3 . In one embodiment , -NHR 9 is -NHC(O)CH2CH2CH2CH2CH3. In one embodiment, m is 1. In an embodiment, m is 2.

[0066] In certain embodiments, described herein are compounds having the structure of Formula XIV, or is a pharmaceutically acceptable salt or prodrug thereof: [ka] In some embodiments, R 2 , R 3 , R 7 , and R 60 is as described in the previous paragraph .

[0067] In certain embodiments, described herein, Q is —CH—; R 2 But C5-C 10 alkyl; R 3 is —C(O)C1-C5 alkyl; R 4 and R 5 is methyl; R 7 But -OH , halogen, or -NH; R 8independently in each occurrence hydrogen, deuterium, -NHR 9 , or Halogen (wherein R 9 is hydrogen or -C1-C5 alkyl); and m is 1 or 2; A compound having the structure of Formula XIII, or a pharmaceutically acceptable salt or prodrug thereof. In one embodiment, R 1 , R 2 , R 3 , and QR 2 is as described in formula XIII above. In some embodiments of formula XIII above, R 7 are fluorine, chlorine, bromine, and iodine In one embodiment, R 7 is fluorine. In another embodiment, R 7 is chlorine In another embodiment, R 7 is bromine. In another embodiment, R 7 Yes, you In one embodiment, R 7 is —OH. In one embodiment, R 7 is -NH2 In one embodiment, R 8 is hydrogen. In one embodiment, R 8 is deuterium In some embodiments, R 8 independently include fluorine, chlorine, bromine, and iodine. In an embodiment, R 8 is fluorine. In another embodiment, R 8 is chlorine. In an embodiment of the present invention, R 8 is bromine. In another embodiment, R 8 is iodine. In one embodiment, R 8 -NHR 9 In one embodiment, -NHR 9 is -NH2. In one embodiment, -NHR 9 is -NHMe, -NHEt, -NHCH2CH2CH3, -NHCH2CH2CH2CH3, and -N In one embodiment, —NHR 9 is -NHMe. -NHR 9 is -NHEt. In one embodiment, -NHR 9 is -NHCH2CH2CH3. In one embodiment, -NHR 9 is -NHCH2CH2CH2CH3. In one embodiment, -NHR 9 teeth,- In some embodiments of formula XIII above, R 60 is alkyl, alkoxy alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl A suitable R is aryl, substituted aryl, or substituted heteroaryl. 60 The alkyl group may be a group represented by the formula X R in the context of III 1 For example, methyl, ethyl, etc. Suitable R 60 Alkenyl, alkynyl, aryl, and heteroaryl are defined elsewhere in this specification. The preferred R 60 Cycloalkyl and heterocycloalkyl include those of formula X R with the carbon to which they are attached as described in the context of III 4 and R 5 against In one embodiment, m is 1. In one embodiment, , m is 2.

[0068] In certain embodiments, described herein are compounds having the structure of Formula XV, or is a pharmaceutically acceptable salt of: [ka] In some embodiments, Q, R 2 , R 3 , R 7 , R 8 , R 9 , QR 2 , and R 60 is mentioned in the previous paragraph. It is as stated.

[0069] In certain embodiments, described herein, Q is —CH—; R 2 But C1-C 10 alkynyl; and R 60 alkyl, alkenyl, alkynyl, cycloalkyl, hexyl Heterocycloalkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl 1. A compound having the structure of Formula XIII, or a pharmaceutically acceptable salt or protease thereof, It is a drug. 60 As alkyl groups, in the context of formula XIII, R 1 It is stated against Suitable R groups include, for example, methyl and ethyl. 60 Alkenyl, alkynyl Aryl, aryl, and heteroaryl are described elsewhere herein. 60 S Cycloalkyl and heterocycloalkyl include those described in the context of formula XIII. , R along with the carbon to which they are attached 4 and R 5 Examples include those described for In an embodiment, R 1 , R 3 , R 4 , R 5 , R 7 , and R 8 is as described above. In an embodiment, R 2is —CHCCH. In one embodiment of Formula XIII, R 2 is -CH2CH2CCH In one embodiment of Formula XIII, R 2 is —CH2CH2CH2CCH. One embodiment of Formula XIII In the same way, R 2 is —CH2CH2CH2CH2CCH. In one embodiment of Formula XIII, R 2 is -CH2 In one embodiment of Formula XIII, R 2 is -CH2CH2CH2CH2CH2CH2CH2CCH In one embodiment of Formula XIII, R 2 is -CH2CH2CH2CH2CH2CH2CH2CH2CCH. Formula XII In one embodiment of I, R 2 is -CH2CH2CH2CH2CH2CH2CH2CH2CH2CCH. One embodiment of Formula XIII In an embodiment, R 2 is -CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CCH. In one embodiment of Formula XIII Hey, R 2 is -CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CCH.

[0070] In certain embodiments, described herein are compounds having the structure of Formula XVI, or is a pharmaceutically acceptable salt thereof: [ka] In some embodiments, R 2 , R 3 , R 4 , R 5 , R 7 , R 8 , and R 60 is described in the previous paragraph. That is exactly what happened.

[0071] In certain embodiments, described herein, Q is —CH—; R 2 But the position is different Sexual -C1-C 10 alkylene-(5-membered heteroaryl), wherein the heteroaryl is unsubstituted or alkyl, aminoalkyl, hydroxylalkyl, carboxyalkyl , benzyl, or phenyl); R 3 is -C(O)C1-C5 alkyl R 4 and R5 is C1-C5 alkyl; R 7 is -NH; and R 60 However, alkyl, alkene Nyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl , substituted aryl, or substituted heteroaryl; or A suitable R is a pharmaceutically acceptable salt or prodrug of 60 As an alkyl group , R in the context of Formula XIII 1 For example, methyl, ethyl, etc. Suitable R 60 Alkenyl, alkynyl, aryl, and heteroaryl are defined herein. The preferred R 60 As the cycloalkyl and heterocycloalkyl, , R together with the carbon to which they are attached as described in the context of formula XIII 4 and R 5 Against In one embodiment, R 1 , R 8 , and R 9 As mentioned above, In certain embodiments of formula XIII above, useful R 2 As a group, the positional isomer -C1- C 10Alkylene-(1,2,3-triazoles), wherein the regioisomeric 1,2,3-triazoles are It may be unsubstituted or may be substituted with alkyl, aminoalkyl, hydroxylalkyl, carboxya The following embodiments are also included: wherein 1,2,3-triazoles may be present in the form of positional isomers, as described elsewhere herein. The product is derived from a click chemistry reaction between a terminal alkyne and an azide. In an embodiment, R 2 teeth, [ka] In one embodiment, R 2 teeth, [ka] In one embodiment, R 2 teeth, [ka] In one embodiment, R 2 teeth, [ka] In one embodiment, R 2 teeth, [ka] In one embodiment, R 2 teeth, [ka] In one embodiment, R 2 teeth, [ka] In one embodiment, R 2 teeth, [ka] In one embodiment, R 2 teeth, [ka] In one embodiment, R 2 teeth, [ka] In any one or more of the embodiments in this paragraph, Y is hydrogen, a alkyl, aminoalkyl, hydroxylalkyl, carboxyalkyl, benzyl, or In one embodiment, Y is phenyl. In one embodiment, Y is hydrogen. In one embodiment, Y is aryl. In one embodiment, Y is aminoalkyl. and Y is hydroxylalkyl. In one embodiment, Y is carboxyalkyl. In one embodiment, Y is phenyl. In one embodiment of formula XIII above, , useful R 3 Groups include -C(O)Me, -C(O)Et, -C(O)propyl, -C(O)butyl, and -C(O)pentyl. In one embodiment, R 3 is —C(O)Me. Te, R 3 is —C(O)Et. In another embodiment, R 3 -C(O)propyl and its structural variants In another embodiment, R 3 is -C(O)butyl and its structural isomers. In an embodiment of the present invention, R 3 is -C(O)pentyl and its structural isomers. In certain embodiments, useful R 4 and R 5The groups are independently methyl, ethyl, propyl and the like. Structural isomers, butyl and its structural isomers, and pentyl and its structural isomers, and For example, in one embodiment, R 4 and R 5 is methyl. Another example In one embodiment, R 4 and R 5 is ethyl. Another example is R 4 is methyl and R 5 is ethyl. R as an embodiment within this paragraph 4 and R 5 Other examples of Any combination or swing is contemplated herein.

[0072] In certain embodiments, described herein are compounds having the structure of Formula XVII, or is a pharmaceutically acceptable salt thereof: [ka] In some embodiments, R 2 , R 3 , R 4 , R 5 , and R 60 is described in the above paragraph. That is exactly what is happening.

[0073] In certain embodiments, described herein are compounds having the structure of Formula XVIII or Formula XIX. The compound is: [ka] (In the formula, R 60 is an alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl alkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl). Suitable R 60As alkyl groups, in the context of formula XIII, R 1 For example, Suitable R groups include methyl, ethyl, etc. 60 Alkenyl, alkynyl, aryl, and Heteroaryl is described elsewhere herein. 60 Cycloalkyl and hexamethyl Tetracycloalkyls include those to which they are attached, as described in the context of formula XIII. R with carbon 4 and R 5 In one embodiment, R 10 is hydrogen, methyl, -CH2CH2NH2, -CH2CH2OH, -CH2COOH, -CH2CH2CH2COOH, benzyl, or phenyl; or a pharmaceutically acceptable salt thereof. In one embodiment, R 10 teeth , hydrogen. In one embodiment, R 10 is methyl. In one embodiment, R 10 teeth , -CH2CH2NH2. In one embodiment, R 10 is —CH2CH2OH. In one embodiment Te, R 10 is —CHCOOH. In one embodiment, R 10 is -CH2CH2CH2COOH. In the embodiment, R 10 is benzyl. In one embodiment, R 10 is phenyl .

[0074] In any of the foregoing embodiments of this section, R 7 is -NR 7a R 7b where R 7 a and R 7bis independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl alkyl, aryl, heteroaryl, acyl, and amino acid residues, Alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are In some embodiments, R 7a is hydrogen and R 7b is Amino It is an acid residue.

[0075] (Compound or Payload - Q is oxygen) In certain embodiments, described herein are compounds having the structure of Formula I, or A pharmaceutically acceptable salt or prodrug of: [ka] (wherein Q is —O—; R 2 is C1-C 10 alkyl; and R 7 is -OH or -NH2). In Formula I, in certain embodiments, useful R 1 Groups include methyl and ethyl In some embodiments, useful R 1 The groups include propyl, butyl, pentyl, and hexyl. , heptyl, octyl, nonyl, decyl, and their structural isomers. In an embodiment, R 1 is methyl. In one embodiment, R 1 is ethyl. In an embodiment, R 1 is propyl and its structural isomers. In one embodiment, R 1 teeth, butyl and its structural isomers. In one embodiment, R 1 is pentyl and its structural variants. In one embodiment, R 1is hexyl and its structural isomers. In the same way, R 1 is heptyl and its structural isomers. In one embodiment, R 1 Ha, O octyl and its structural isomers. In one embodiment, R 1 is nonyl and its structural isomers In one embodiment, R 1 is decyl and its structural isomers. In certain embodiments described above, useful R 2 The groups include methyl, ethyl, n-propyl, n- Butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, and n-decyl In one embodiment, R 2 is methyl. In one embodiment, R 2 Is, E In one embodiment, R 2 is n-propyl or its structural isomer. In the embodiment, R 2 is n-butyl, or a structural isomer thereof. 2 is n-pentyl, or a structural isomer thereof. 2 is n-hexyl or a structural isomer thereof. In another embodiment, R 2 is n-heptyl, or its structure In another embodiment, R 2 is n-octyl or its structural isomer. In another embodiment, R 2 is n-nonyl, or a structural isomer thereof. R 2 is n-decyl, or a structural isomer thereof. 3 is -C(O )C1-C5 alkyl, -C(O)N(H)C1-C 10 Alkyl, or -(C1-C10 (Alkylene)-NR 3a R 3b (In the formula, R 3a and R 3b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkane, alkyl, aryl, heteroaryl, and acyl, where alkyl, alkenyl, Alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally substituted. In certain embodiments of formula I above, useful R 3 The groups include -C(O)Me, -C( -C(O)Et, -C(O)propyl, -C(O)butyl, and -C(O)pentyl, and their structural isomers In one embodiment, R 3 is —C(O)Me. In another embodiment, R 3 teeth , -C(O)Et. In another embodiment, R 3 is -C(O)propyl and its structural isomers In another embodiment, R 3 is —C(O)butyl and its structural isomers. In the same way, R 3 is —C(O)pentyl and its structural isomers. In certain embodiments of Formula I above, In this case, useful R 3 Groups include -C(O)N(H)Me, -C(O)N(H)Et, -C(O)N(H)propyl and the like. Structural isomers, -C(O)N(H)butyl and its structural isomers, -C(O)N(H)pentyl and its structural isomers -C(O)N(H)hexyl and its structural isomers, -C(O)N(H)heptyl and its structural isomers, -C (O)N(H) octyl and its structural isomers, -C(O)N(H) nonyl and its structural isomers, -C(O)N(H) In one embodiment of formula I above, R 3 is -C(O)N( H) Me. In one embodiment of formula I above, R 3 is —C(O)N(H)Et. In the embodiment, R 3 is —C(O)N(H)propyl and its structural isomers. In an embodiment, R 3 is —C(O)N(H)butyl and its structural isomers. In R 3 is —C(O)N(H)pentyl and its structural isomers. Hey, R 3 is —C(O)N(H)hexyl and its structural isomers. In one embodiment of Formula I above, R 3 is —C(O)N(H)heptyl and its structural isomers. In one embodiment of Formula I above, Te, R 3 is —C(O)N(H)octyl and its structural isomers. In one embodiment of Formula I above, , R 3 is —C(O)N(H)nonyl and its structural isomers. In one embodiment of formula I above, R 3 is —C(O)N(H)decyl and its structural isomers. In certain embodiments of Formula I above, useful NaR 3 The group is -CH2-NR 3a R 3b , -CH2CH2-NR 3a R 3b , -CH2CH2CH2-NR 3a R 3b , -CH2CH2CH2CH2 -NR 3a R 3b , -CH2CH2CH2CH2CH2CH2-NR 3a R 3b , -CH2CH2CH2CH2CH2CH2CH2-NR 3a R 3b , -CH2CH2CH2CH2CH 2CH2CH2-NR 3a R3b ,-CH2CH2CH2CH2CH2CH2CH2CH2-NR 3a R 3b , -CH2CH2CH2CH2CH2CH2CH2CH2CH2 -NR 3a R 3b , and -CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2-NR 3a R 3b (In the formula, R 3a and R 3b In each case independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, hetero alkyl, alkenyl, alkynyl, cycloalkenyl, and acyl; alkyl, aryl, heteroaryl, and acyl are optionally substituted. In one embodiment of formula I above, R 3 is -CH2-NR 3a R 3b (wherein R 3a and R 3b is, each independently in each case hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl, where alkyl, alkenyl, alkynyl, cyclohexyl, (The alkyl, aryl, heteroaryl, and acyl are optionally substituted.) In one embodiment of Formula I, R 3 is -CH2CH2-NR 3a R 3b (wherein R 3a and R 3b In each case independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, hetero alkyl, alkenyl, alkynyl, cycloalkenyl, and acyl; The alkyl, aryl, heteroaryl, and acyl groups of formula I above are optionally substituted. In one embodiment, R 3is -CH2CH2CH2-NR 3a R 3b (wherein R 3a and R 3b In each case Independently, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, hetero aryl, and acyl, where alkyl, alkenyl, alkynyl, cycloalkane The alkyl, aryl, heteroaryl, and acyl are optionally substituted. In an embodiment, R 3 is -CH2CH2CH2CH2-NR 3a R 3b (wherein R 3a and R 3b In each case Independently, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, hetero aryl, and acyl, where alkyl, alkenyl, alkynyl, cycloalkane The alkyl, aryl, heteroaryl, and acyl are optionally substituted. In an embodiment, R 3 is -CH2CH2CH2CH2CH2-NR 3a R 3b (wherein R 3a and R 3b is at each venue In each case, independently, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, hydroxyl, aryl, and acyl, where alkyl, alkenyl, alkynyl, cyclo The alkyl, aryl, heteroaryl, and acyl are optionally substituted. In one embodiment, R 3 is -CH2CH2CH2CH2CH2CH2CH2-NR 3a R 3b (wherein R 3a and R 3b teeth , independently in each occurrence, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl aryl, heteroaryl, and acyl, where alkyl, alkenyl, alkynyl, The cycloalkyl, aryl, heteroaryl, and acyl are optionally substituted. In one embodiment of formula I above, R 3 is -CH2CH2CH2CH2CH2CH2CH2-NR 3a R 3b (wherein R 3 a and R 3b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl aryl, aryl, heteroaryl, and acyl, where alkyl, alkenyl, aryl Alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally substituted. In one embodiment of formula I above, R 3 is -CH2CH2CH2CH2CH2CH2CH2CH2-NR 3a R 3b in (wherein R 3a and R 3b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl , cycloalkyl, aryl, heteroaryl, and acyl, where alkyl, Alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are In one embodiment of formula I above, R 3 is -CH2CH2CH2CH2CH2CH2CH2 CH2CH2-NR 3a R 3b (wherein R 3a and R 3b is independently in each occurrence hydrogen, alkyl, alkene, aryl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl, Here, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and acyl is optionally substituted). In one embodiment of formula I above, R 3 is -CHCH 2CH2CH2CH2CH2CH2CH2CH2CH2CH2-NR 3a R 3b (wherein R 3a and R 3b is, independently in each case, hydrogen , alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and and acyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, aryl, In certain embodiments of Formula I above, the aryl, heteroaryl, and acyl are optionally substituted. In this case, useful R 4 Groups include hydrogen, methyl, ethyl, propyl, butyl, and pentyl. and structural isomers thereof. In one embodiment, R 4 is hydrogen. In the embodiment Hey, R 4 is methyl. In another embodiment, R 4 is ethyl. In the same way, R 4 is propyl and its structural isomers. In another embodiment, R 4 teeth, butyl and its structural isomers. In another embodiment, R 4 is pentyl and its structure In certain embodiments of Formula I above, useful R 5 The groups include hydrogen, methyl, Examples include ethyl, propyl, butyl, and pentyl, and their structural isomers. In an embodiment, R 5 is hydrogen. In one embodiment, R 5 is methyl. In an embodiment, R 5 is ethyl. In another embodiment, R 5 Propyl and its In another embodiment, R 5 is butyl and its structural isomers. In another embodiment, R 5 is pentyl and its structural isomers. Te, R 4 and R 5 together with the carbon to which they are attached form a 3- to 8-membered cycloalkyl, substituted cycloalkyl, This para forms a heterocycloalkyl, heterocycloalkyl, or substituted heterocycloalkyl. R as an embodiment in a graph 4 and R 5 Other exemplary combinations or perturbations of In certain embodiments of formula I above, R 6 includes —OH or —NHNH. In the same way, R 6 is —OH. In another embodiment, R 6 is -NHNH2. In an embodiment, R 6 is -NHSO2R 60 (wherein R 60 is an alkyl, alkenyl, or alkynyl group. aryl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, substituted aryl or substituted heteroaryl). In formula I above, in one embodiment, R 7 is -OH In the above formula I, in one embodiment, R 7 is -NH2. In Formula I, certain embodiments as described above In the embodiment, R 8 is hydrogen, deuterium, -NHR 9 or halogen. In the embodiment, R 9 is hydrogen, —C1-C5 alkyl, or —C(O)C1-C5 alkyl. In certain embodiments of I, m is 1 or 2. In one embodiment, R 8 is hydrogen In one embodiment, R 8 is deuterium. In certain embodiments, R 8 is independently In one embodiment, R 8 is fluorine. In an embodiment, R 8 is chlorine. In another embodiment, R 8 is bromine. In an embodiment, R 8 is iodine. In one embodiment, —NHR 9 is -NH2. In one embodiment, -NHR 9 is -NHMe, -NHEt, -NHCH2CH2CH3, -NHCH2CH2CH2CH3, and -N In one embodiment, —NHR 9 is -NHMe. -NHR 9 is -NHEt. In one embodiment, -NHR 9 is -NHCH2CH2CH3. In one embodiment, -NHR 9 is -NHCH2CH2CH2CH3. In one embodiment, -NHR 9 teeth,- NHCH2CH2CH2CH2CH3. In one embodiment, -NHR 9 is -NHC(O)Me, -NHC(O)Et, -NHC (O)CH2CH2CH3, -NHC(O)CH2CH2CH2CH3, and -NHC(O)CH2CH2CH2CH2CH2CH3. In -NHR 9 is -NHC(O)Me. In one embodiment, -NHR 9 is -NHC(O)Et In one embodiment, -NHR 9 is -NHC(O)CH2CH2CH3. In one embodiment, -NHR 9 is -NHC(O)CH2CH2CH2CH3. In one embodiment, -NHR 9 is -NHC(O)CH2CH2CH2CH2C In one embodiment, m is 1. In one embodiment, m is 2.

[0076] In certain embodiments, described herein are compounds having the structure of Formula VIII, or is a pharmaceutically acceptable salt thereof: [ka] In some embodiments, R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 is described in the above paragraph. In one embodiment of Formula VIII, R 3 is -C(O)Me and R 2 , R 4 , R 5 , R 6 , and R 7 is as described in the preceding paragraph. In one embodiment of Formula VIII , R3 is -C(O)N(H)C1-C 10 alkyl, and R 2 , R 4 , R 5 , R 6 , and R 7 is the parameter mentioned above. As shown in the graph.

[0077] In some embodiments, described herein are compounds having R 3 But -C(O)N(H)C1-C 10 Alkyl and;R 4 is hydrogen; R 5 is C1-C5 alkyl; and R 6 and R 7is —OH, or a pharmaceutically acceptable salt or prodrug thereof. In some embodiments, R 2 is as described above in Formula I. In some embodiments of Formula I above, In embodiments, useful R 3 Groups include -C(O)N(H)Me, -C(O)N(H)Et, -C(O)N(H)propyl and and its structural isomers, -C(O)N(H)butyl and its structural isomers, -C(O)N(H)pentyl and its structural isomers -C(O)N(H)hexyl and its structural isomers, -C(O)N(H)heptyl and its structural isomers -C(O)N(H) octyl and its structural isomers, -C(O)N(H) nonyl and its structural isomers, -C(O )N(H)decyl and its structural isomers. In one embodiment of formula I above, R 3 -C (O)N(H)Me. In one embodiment of formula I above, R 3 is —C(O)N(H)Et. In one embodiment, R 3 is -C(O)N(H)propyl and its structural isomers. In an embodiment, R 3 is —C(O)N(H)butyl and its structural isomers. In an embodiment, R 3 is —C(O)N(H)pentyl and its structural isomers. In the same way, R 3 is -C(O)N(H)hexyl and its structural isomers. In R 3 is —C(O)N(H)heptyl and its structural isomers. Hey, R 3 is —C(O)N(H)octyl and its structural isomers. In one embodiment of Formula I above, R 3is -C(O)N(H)nonyl and its structural isomers. In one embodiment of formula I above, , R 3 is —C(O)N(H)decyl and its structural isomers. In one embodiment, R 5 Is Methi In another embodiment, R 5 is ethyl. In another embodiment, R 5 teeth, propyl and its structural isomers. In another embodiment, R 5 is butyl and its structure In another embodiment, R 5 is pentyl and its structural isomers.

[0078] In certain embodiments, described herein are compounds having the structure of Formula IX: [ka] (In the formula, R 11 is C1-C 10 alkyl); or a pharmaceutically acceptable salt thereof. In an embodiment, R 11 is methyl. In one embodiment, R 11 is ethyl. In the embodiment, R 11 is propyl and its structural isomers. In one embodiment, R 11 is butyl and its structural isomers. In one embodiment, R 11 is pentyl and its In one embodiment, R 11 is hexyl and its structural isomers. In one embodiment, R 11 is heptyl and its structural isomers. , R 11 is octyl and its structural isomers. In one embodiment, R 11 Nonyl and In one embodiment, R 11 is decyl and its structural isomers .

[0079] In certain embodiments, described herein are compounds wherein Q is -O-; R 2 But C1-C 10 a R is alkynyl; 3 is —C(O)C1-C5 alkyl; and R 6 is —OH, or a pharmaceutically acceptable salt or prodrug thereof. In the same way, R 1 , R 4 , R 5 , R 7 , and R 8 is as described above in Formula I. In an embodiment, R 2 is —CHCCH. In one embodiment of Formula I, R 2 is -CH2CH2CCH In one embodiment of Formula I, R 2 is —CH2CH2CH2CCH. In one embodiment of Formula I, R 2 is —CH2CH2CH2CH2CCH. In one embodiment of Formula I, R 2 is -CH2CH2CH2CH2 In one embodiment of Formula I, R 2 is -CH2CH2CH2CH2CH2CH2CCH. In one embodiment, R 2 is —CH2CH2CH2CH2CH2CH2CH2CCH. In one embodiment of Formula I Te, R 2 is —CH2CH2CH2CH2CH2CH2CH2CH2CH2CCH. In one embodiment of Formula I, R 2 is -CH 2CH2CH2CH2CH2CH2CH2CH2CH2CCH. In one embodiment of Formula I, R2 is -CH2CH2CH2CH2 In one embodiment, R 3 is —C(O)Me. In the same way, R 3 is —C(O)Et. In another embodiment, R 3 -C(O)propyl and its In another embodiment, R 3 is -C(O)butyl and its structural isomers In another embodiment, R 3 is -C(O)pentyl and its structural isomers.

[0080] In certain embodiments, described herein is a compound having the structure of Formula X, or and pharmaceutically acceptable salts thereof: [ka] In some embodiments, R 2 , R 3 , R 4 , R 5 , and R 7 is as described in the previous paragraph. do.

[0081] In certain embodiments, described herein are compounds wherein Q is -O-; R 2 But C1-C 10 a R is alkynyl; 3 But -C(O)N(H)C1-C 10 alkyl; and R 6 is —OH or a pharmaceutically acceptable salt or prodrug thereof. In an embodiment, R 1 , R 4 , R 5 , R 7 , and R 8 is as described in Formula I above. In one embodiment of Formula I, R 2 is —CHCCH. In one embodiment of Formula I, R 2 is -CH 2CH2CCH. In one embodiment of Formula I, R 2 is —CH2CH2CH2CCH. One embodiment of Formula I In the same way, R 2 is —CH2CH2CH2CH2CCH. In one embodiment of Formula I, R 2 is -CH2CH2 In one embodiment of Formula I, R 2 is -CH2CH2CH2CH2CH2CH2CH2CCH In one embodiment of Formula I, R 2 is -CH2CH2CH2CH2CH2CH2CH2CH2CCH. One embodiment of Formula I In the same way, R 2 is —CH2CH2CH2CH2CH2CH2CH2CH2CH2CCH. In one embodiment of Formula I, R 2 is -CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2CCH. In one embodiment of Formula I, R 2 is -CH2C In one embodiment of formula I above, R 3 is -C(O)N(H In one embodiment of formula I above, R 3 is —C(O)N(H)Et. In an embodiment, R 3 is —C(O)N(H)propyl and its structural isomers. In the same way, R 3 is —C(O)N(H)butyl and its structural isomers. Hey, R 3 is —C(O)N(H)pentyl and its structural isomers. In one embodiment of Formula I above, R 3is —C(O)N(H)hexyl and its structural isomers. In one embodiment of Formula I above, Te, R 3 is —C(O)N(H)heptyl and its structural isomers. In one embodiment of formula I above, , R 3 is —C(O)N(H)octyl and its structural isomers. In one embodiment of formula I above, R 3 is —C(O)N(H)nonyl and its structural isomers. In one embodiment of formula I above, R 3 teeth , -C(O)N(H)decyl and its structural isomers.

[0082] In certain embodiments, described herein is a compound having the structure of Formula XI, or and pharmaceutically acceptable salts thereof: [ka] In some embodiments, R 2 , R 4 , R 5 , and R 8 is as described in the previous paragraph.

[0083] In certain embodiments, described herein are compounds wherein Q is -O-; R 2 But C1-C3 Al Kiren-Q 1 -(CH2) n aryl; or C1-C3 hydroxyalkyl; R 3 But -C(O)C1-C5 ar Kill;R 4 is hydrogen; R 5 is C1-C5 alkyl; and R 6 and R 7 is -OH a compound having the structure of Formula I, or a pharmaceutically acceptable salt or prodrug thereof; In one embodiment, R 1 and R 8is as described in Formula I above. In an embodiment, R 2 is C1-C3 alkylene-Q 1 -(CH2) n aryl, and Q 1 is -CH2- Thus, in one embodiment, R 2 is -CH2CH2(CH2) n aryl (wherein n is an integer from 1 to 5; In one embodiment, R 2 is -CH2CH2(CH2) n phenyl, and n is 1, 2 , 3, 4, or 5. In one embodiment, R 2 is -CH2CH2(CH2) n p-nitrophenyl and n is 1, 2, 3, 4, or 5. In one embodiment, R 2 is -CH2CH2(CH2) n p- aminophenyl, and n is 1, 2, 3, 4, or 5. In one embodiment, R 2 teeth , -CH2CH2CH2(CH2) n aryl, where aryl is unsubstituted or substituted with nitro or is substituted with amino, and n is an integer from 1 to 5. In one embodiment, R 2 teeth, -CH2CH2CH2(CH2) n phenyl and n is 1, 2, 3, 4, or 5. R 2 is -CH2CH2CH2(CH2) n p-nitrophenyl, and n is 1, 2, 3, 4, or 5. In one embodiment, R 2 is -CH2CH2CH2(CH2) n p-aminophenyl, and n is , 1, 2, 3, 4, or 5. In one embodiment, R 2 is -CH2CH2CH2CH2(CH2) n Aryl wherein aryl is unsubstituted or substituted with nitro or amino; and n is an integer from 1 to 5. In one embodiment, R 2 is -CH2CH2CH2CH2(CH2) n Feni and n is 1, 2, 3, 4, or 5. In one embodiment, R 2 is -CH2CH2CH2 CH2(CH2) n p-nitrophenyl, and n is 1, 2, 3, 4, or 5. In one embodiment, Hey, R 2 is -CH2CH2CH2CH2(CH2) n p-aminophenyl, and n is 1, 2, 3, 4, or is 5. In some embodiments, R 2 is C1-C3 alkylene-Q 1 -(CH2) n is aryl, Katsu Q 1 is —O—. Thus, in one embodiment, R 2 is -CH2O-(CH2) n Aryl wherein aryl is unsubstituted or substituted with nitro or amino, and n is an integer from 1 to 5. In one embodiment, R 2 is -CH2O-(CH2) n It is phenyl, n is 1, 2, 3, 4, or 5. In one embodiment, R 2 is -CH2O-(CH2) n p-nitrof and n is 1, 2, 3, 4, or 5. In one embodiment, R 2 is -CH2O- (CH2) np-aminophenyl, and n is 1, 2, 3, 4, or 5. Te, R 2 is -CH2CH2O-(CH2) n aryl, wherein aryl is unsubstituted or and n is an integer from 1 to 5. R 2 is -CH2CH2O-(CH2) n phenyl, and n is 1, 2, 3, 4, or 5. In the same way, R 2 is -CH2CH2O-(CH2) n p-nitrophenyl, and n is 1, 2, 3, 4, or is 5. In one embodiment, R 2 is -CH2CH2O-(CH2) n p-aminophenyl, and n is 1, 2, 3, 4, or 5. In one embodiment, R 2 is -CH2CH2CH2O-(CH2) n Ally wherein aryl is unsubstituted or substituted with nitro or amino. and n is an integer from 1 to 5. In one embodiment, R 2 is -CH2CH2CH2O-(CH2) n Feni and n is 1, 2, 3, 4, or 5. In one embodiment, R 2 is -CH2CH2CH2 O-(CH2) n p-nitrophenyl, and n is 1, 2, 3, 4, or 5. R 2 is -CH2CH2CH2O-(CH2) n p-aminophenyl, and n is 1, 2, 3, 4, or 5 In one embodiment, R 2 is —CHOH. In one embodiment, R 2 is -CHCH 2OH. In one embodiment, R 2 is —CH2CH2CH2OH. In certain embodiments of Formula I above, In this case, useful R 3 Groups include -C(O)Me, -C(O)Et, -C(O)propyl, -C(O)butyl, and -C (O) pentyl, as well as structural isomers thereof. In one embodiment, R 3 is -C( O) Me. In another embodiment, R 3 is —C(O)Et. In another embodiment, R 3 is —C(O)propyl and its structural isomers. In another embodiment, R 3 is -C(O)butyl In another embodiment, R 3 -C(O)pentyl and its structures In certain embodiments of Formula I above, useful R 5 The groups include methyl, ethyl, Examples include butyl, propyl, butyl, and pentyl, and their structural isomers. In an embodiment, R 5 is methyl. In another embodiment, R 5 is ethyl. In an embodiment, R 5 is propyl and its structural isomers. R 5 is butyl and its structural isomers. In another embodiment, R 5 is pentyl and It is a structural isomer of

[0084] In certain embodiments, described herein are compounds having the structure of Formula XII, or is a pharmaceutically acceptable salt thereof: [ka] In some embodiments, R2 and R 3 is as described in the previous paragraph. In an embodiment, R 2 is a C1-C3 alkylene-O- as described in the preceding paragraph. (CH2) n In one embodiment of Formula XII, R 2 is described in the above paragraph. It is a C1-C3 hydroxyalkyl such as

[0085] In some embodiments, provided herein is a method for treating a psoriasis comprising administering to a subject a therapeutically effective amount of: [ka] any of Formula I, Formula VIII, Formula IX, Formula X, Formula XI, or Formula XII, which may be selected from the group consisting of TIFF2024167209000095.tif233170TIFF2024167209000096.tif228170TIFF2024167209000097.tif220170TIFF2024167209000098.tif128170TIFF2024167209000099.tif170170 or a pharmaceutically acceptable salt thereof.

[0086] In certain embodiments, described herein are compounds having the structure of Formula XIII, or is a pharmaceutically acceptable salt or prodrug thereof: [ka] (wherein Q is —O—; R 2 is C1-C 10 alkyl; and R 7 is -OH or -NH2). In Formula XIII, in certain embodiments, useful R 1 Groups include methyl and ethyl. In some embodiments, useful R 1The groups include propyl, butyl, pentyl, hexyl, Examples of alkyl groups include aryl, heptyl, octyl, nonyl, decyl, and structural isomers thereof. In the embodiment, R 1 is methyl. In one embodiment, R 1 is ethyl. In the embodiment, R 1 is propyl and its structural isomers. In one embodiment, R 1 teeth butyl and its structural isomers. In one embodiment, R 1 is pentyl and its structure In one embodiment, R 1 is hexyl and its structural isomers. In an embodiment, R 1 is heptyl and its structural isomers. In one embodiment, R 1 teeth, octyl and its structural isomers. In one embodiment, R 1 Nonyl and its structural variants In one embodiment, R 1 is decyl and its structural isomers. In the above embodiment, useful R 2 The groups include methyl, ethyl, n-propyl, and n-butyl. Examples include n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, and n-decyl. In one embodiment, R 2 is methyl. In one embodiment, R 2 is ethyl In one embodiment, R 2 is n-propyl, or a structural isomer thereof. In the same way, R 2 is n-butyl, or a structural isomer thereof. 2 teeth, n-pentyl, or a structural isomer thereof. 2 is n-hexyl, or is a structural isomer thereof. In another embodiment, R 2 is n-heptyl or its structural isomer In another embodiment, R 2 is n-octyl or its structural isomer. In an embodiment, R 2 is n-nonyl, or a structural isomer thereof. , R 2 is n-decyl, or a structural isomer thereof. 3 is -C(O)C1- C5 alkyl, -C(O)N(H)C1-C 10 Alkyl, or -(C1-C 10 (Alkylene)-NR 3a R 3b (where , R 3a and R 3b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, alkyl, aryl, heteroaryl, and acyl, where alkyl, alkenyl , alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally substituted. In certain embodiments of formula XIII above, useful R 3 The groups include -C(O)Me, -C(O )Et, -C(O)propyl, -C(O)butyl, and -C(O)pentyl, and their structural isomers. In one embodiment, R 3 is —C(O)Me. In another embodiment, R 3 teeth,- C(O)Et. In another embodiment, R 3 is -C(O)propyl and its structural isomers In another embodiment, R 3 is —C(O)butyl and its structural isomers. In R 3is —C(O)pentyl and its structural isomers. In certain embodiments of Formula I above, and useful R 3 Examples of the group include -C(O)N(H)Me, -C(O)N(H)Et, -C(O)N(H)propyl, and the structures thereof. -C(O)N(H)butyl and its structural isomers, -C(O)N(H)pentyl and its structural isomers , -C(O)N(H)hexyl and its structural isomers, -C(O)N(H)heptyl and its structural isomers, -C(O )N(H) octyl and its structural isomers, -C(O)N(H) nonyl and its structural isomers, -C(O)N(H) de In one embodiment of formula XIII above, R 3 is -C(O)N (H)Me. In one embodiment of formula XIII above, R 3 is —C(O)N(H)Et. In one embodiment, R 3 is —C(O)N(H)propyl and its structural isomers. In one embodiment of I, R 3 is —C(O)N(H)butyl and its structural isomers. In one embodiment, R 3 is —C(O)N(H)pentyl and its structural isomers. In one embodiment of I, R 3 is —C(O)N(H)hexyl and its structural isomers. In one embodiment of II, R 3 is —C(O)N(H)heptyl and its structural isomers. In one embodiment of III, R 3 is -C(O)N(H) octyl and its structural isomers. In one embodiment of XIII, R 3 is -C(O)N(H)nonyl and its structural isomers. In one embodiment of III, R3 is -C(O)N(H)decyl and its structural isomers. In certain embodiments of II, useful R 3 The group is -CH2-NR 3a R 3b , -CH2CH2-NR 3a R 3b , -CH 2CH2CH2-NR 3a R 3b , -CH2CH2CH2CH2-NR 3a R 3b , -CH2CH2CH2CH2CH2CH2-NR 3a R 3b , -CH2CH2CH2CH2C H2CH2-NR 3a R 3b , -CH2CH2CH2CH2CH2CH2CH2CH2-NR 3a R 3b ,-CH2CH2CH2CH2CH2CH2CH2CH2-NR 3a R 3b ,-CH2CH2CH2CH2CH2CH2CH2CH2CH2-NR 3a R 3b , and -CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2-NR 3a R 3b (In the formula, R 3a and R 3b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl, Alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally In one embodiment of formula XIII above, R 3 is -CH2-NR 3a R 3b (wherein R 3a and R 3b is independently in each occurrence hydrogen, alkyl, alkenyl, alkyl aryl, cycloalkyl, aryl, heteroaryl, and acyl, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl is optionally substituted). In one embodiment of formula XIII above, R 3 is -CH2CH2-NR 3a R 3b (wherein R 3a and R 3b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl aryl, cycloalkyl, aryl, heteroaryl, and acyl, where alkyl , alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are , optionally substituted). In one embodiment of formula XIII above, R 3 is -CH2CH2CH2-NR 3a R 3 b (wherein R 3a and R 3b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl aryl, cycloalkyl, aryl, heteroaryl, and acyl, where alkyl , alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are , optionally substituted). In one embodiment of formula XIII above, R 3 is -CH2CH2CH2CH2-NR 3 a R 3b wherein R3a and R3b each independently represent hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, aryl, heteroaryl, and acyl, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and aryl groups In one embodiment of formula XIII above, R3 is -CH2CH2CH2CH2 CH2-NR 3a R 3b (wherein R 3a and R 3b is independently in each occurrence hydrogen, alkyl, alkenyl , alkynyl, cycloalkyl, aryl, heteroaryl, and acyl, , alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and In one embodiment of formula XIII above, R 3 is -CH2CH2 CH2CH2CH2CH2-NR 3a R 3b (wherein R 3a and R 3b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl. where alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, In one embodiment of Formula XIII above, R 3 is -CH2CH2CH2CH2CH2CH2CH2-NR 3a R 3b (wherein R 3a and R 3b is, in each case independently, water alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl, wherein alkyl, alkenyl, alkynyl, cycloalkyl, aryl, (aryl, heteroaryl, and acyl are optionally substituted). In the same way, R 3 is -CH2CH2CH2CH2CH2CH2CH2CH2-NR 3a R 3b (wherein R 3a and R 3b is, each independently in each case hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl, where alkyl, alkenyl, alkynyl, cyclohexyl, (The alkyl, aryl, heteroaryl, and acyl are optionally substituted.) In one embodiment of Formula XIII, R 3 is -CH2CH2CH2CH2CH2CH2CH2CH2CH2-NR 3a R 3b (Eq. Medium, R 3a and R 3b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cyclo alkyl, aryl, heteroaryl, and acyl, The alkyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally substituted. In one embodiment of formula XIII above, R 3 is -CH2CH2CH2CH2CH2CH2CH2CH2CH2CH 2CH2-NR 3a R 3b (wherein R 3a and R 3b is independently in each occurrence hydrogen, alkyl, alkenyl, aryl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally substituted). In certain embodiments of Formula XIII above, useful R 4 Groups include hydrogen, methyl, ethyl, propyl, butyl, and pentyl, as well as their derivatives. In one embodiment, structural isomers are included. Te, R 4 is hydrogen. In one embodiment, R 4 is methyl. Te, R4 is ethyl. In another embodiment, R 4 is propyl and its structural isomers In another embodiment, R 4 is butyl and its structural isomers. Hey, R 4 is pentyl and its structural isomers. In some embodiments of formula XIII above, , useful R 5 Groups include hydrogen, methyl, ethyl, propyl, butyl, and pentyl, and In one embodiment, R 5 is hydrogen. In the same way, R 5 is methyl. In another embodiment, R 5 is ethyl. In the embodiment, R 5 is propyl and its structural isomers. In another embodiment, R 5 is butyl and its structural isomers. In another embodiment, R 5 is pentyl and its In one embodiment, R 4 and R 5 is methyl. R 4 and R 5 together with the carbon to which they are attached form a 3- to 8-membered cycloalkyl, substituted cycloalkyl, This forms a cycloalkyl, heterocycloalkyl, or substituted heterocycloalkyl. R as an embodiment within a graph 4 and R 5 Other exemplary combinations or perturbations of In one embodiment, R 4 and R 5 along with the carbons to which they are attached, In one embodiment, R 4 and R 5 Is that together with the carbon to which they are attached is cyclobutyl or substituted cyclobutyl. Hey, R 4 and R 5 together with the carbon to which they are attached form cyclopentyl or substituted cyclopentyl. pentyl. In one embodiment, R 4 and R 5 along with the carbons to which they are attached, cyclohexyl or substituted cyclohexyl. In one embodiment, R 4 and R 5 Is that together with the carbon to which they are attached is cycloheptyl or substituted cycloheptyl. In the same way, R 4 and R 5 together with the carbon to which they are attached, form a cyclooctyl or substituted cyclohexyl group. In one embodiment, R 4 and R 5 along with the carbon to which they are attached. cyclopropyl in which one methylene carbon is replaced with Z; and Z is oxygen, nitrogen, or sulfur. In R 4 and R 5 together with the carbon to which they are attached are cyclobutyl, One methylene carbon in cyclobutyl is replaced by Z, and Z is not an oxygen, nitrogen, or sulfur atom. In one embodiment, R 4 and R 5 are combined cyclopentyl, together with the carbon atom in which one or more methylene groups are present; The cyclopentyl group, wherein carbon is replaced with Z, and Z is oxygen, nitrogen, or sulfur. In one embodiment, R 4 and R 5together with the carbon to which they are attached form a cyclo cyclohexyl, wherein one or more methylene carbons in said cyclohexyl are replaced with Z; and Z is oxygen, nitrogen, or sulfur. R 4 and R 5 together with the carbon to which they are attached are cycloheptyl, One or more methylene carbons in the cycloheptyl are replaced with Z, and Z is oxygen, nitrogen, or sulfur). 4 and R 5 are those together with the carbon to which it is attached, is a cyclooctyl, wherein one or more The cycloalkyl group, wherein a methylene carbon is replaced with Z, and Z is oxygen, nitrogen, or sulfur. In some embodiments of formula XIII above, R 60 is alkyl, alkenyl , alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, A suitable R is substituted aryl or substituted heteroaryl. 60 The alkyl group is R 1 whereas Examples of suitable alkyl groups include those described in this paragraph, for example, methyl, ethyl, etc. NaR 60 Alkenyl, alkynyl, aryl, and heteroaryl are used as defined elsewhere in this specification. The preferred R 60 Cycloalkyl and heterocycloalkyl are defined in this paragraph. As roughly stated, R with the carbon to which they are attached 4 and R 5 Described against In the above formula XIII, in one embodiment, R 7 is -OH. In Formula XIII, in one embodiment, R 7 is —NH2. In Formula XIII, the above embodiment So, R 8 is hydrogen, deuterium, -NHR 9 or halogen. In certain embodiments of formula XIII above, Hey, R 9 is hydrogen, —C1-C5 alkyl, or —C(O)C1-C5 alkyl. In one embodiment, m is 1 or 2. In one embodiment, R 8 is hydrogen. In an embodiment, R 8 is deuterium. In certain embodiments, R 8 are independently fluorine , chlorine, bromine, and iodine. In one embodiment, R 8 is fluorine. In an embodiment, R 8 is chlorine. In another embodiment, R 8 is bromine. In an embodiment, R 8 is iodine. In one embodiment, —NHR 9 is -NH2. In the embodiment, -NHR 9 are -NHMe, -NHEt, -NHCH2CH2CH3, -NHCH2CH2CH2CH3, and -NHCH2 In one embodiment, -NHR 9 is -NHMe. , -NHR 9 is -NHEt. In one embodiment, -NHR 9 is -NHCH2CH2CH3. In embodiments, -NHR 9 is -NHCH2CH2CH2CH3. In one embodiment, -NHR 9 is -NHCH 2CH2CH2CH2CH3. In one embodiment, -NHR 9-NHC(O)Me, -NHC(O)Et, -NHC(O)C In one embodiment, the alkyl groups include -H2CH2CH3, -NHC(O)CH2CH2CH2CH3, and -NHC(O)CH2CH2CH2CH2CH3. -NHR 9 is -NHC(O)Me. In one embodiment, -NHR 9 is -NHC(O)Et. In one embodiment, -NHR 9 is -NHC(O)CH2CH2CH3. In one embodiment, -NHR 9 teeth, In one embodiment, -NHC(O)CH2CH2CH2CH3. 9 is -NHC(O)CH2CH2CH2CH2CH3 In one embodiment, m is 1. In one embodiment, m is 2.

[0087] In certain embodiments, described herein is a compound having the structure of formula XX, or and pharmaceutically acceptable salts thereof: [ka] In some embodiments, R 2 , R 3 , R 4 , R 5 , R 7 , and R 60 As stated in the previous paragraph, In one embodiment of Formula VIII, R 3 is -C(O)Me and R 2 , R 4 , R 5 , R 7 , and R 60 is as described in the preceding paragraph. In one embodiment of Formula VIII, R3 is - C(O)N(H)C1-C 10 alkyl, and R 2 , R 4 , R5 , R 7 , and R 60 is mentioned in the previous paragraph. That's exactly what I did.

[0088] In some embodiments, described herein are compounds having R 3 But -C(O)N(H)C1-C 10 Alkyl and;R 4 is hydrogen or C1-C5 alkyl; R 5 is C1-C5 alkyl; R 7 But -OH Ri;katsu R 60 is as described in the context of formula XIII. or a pharmaceutically acceptable salt or prodrug thereof. , R 2 is as described above in formula XIII. In some embodiments of formula XIII above, Useful R 3 The groups include -C(O)N(H)Me, -C(O)N(H)Et, -C(O)N(H)propyl and their structural isomers. -C(O)N(H)butyl and its structural isomers, -C(O)N(H)pentyl and its structural isomers, -C(O )N(H)hexyl and its structural isomers, -C(O)N(H)heptyl and its structural isomers, -C(O)N(H) Octyl and its structural isomers, -C(O)N(H)nonyl and its structural isomers, -C(O)N(H)decyl and In one embodiment of formula XIII above, R 3 is -C(O)N(H)Me In one embodiment of formula XIII above, R 3 is —C(O)N(H)Et. In an embodiment, R 3 is —C(O)N(H)propyl and its structural isomers. In one embodiment, R3 is —C(O)N(H)butyl and its structural isomers. In one embodiment, R 3 is —C(O)N(H)pentyl and its structural isomers. In one embodiment, R 3 is —C(O)N(H)hexyl and its structural isomers. In one embodiment of I, R 3 is —C(O)N(H)heptyl and its structural isomers. In one embodiment of II, R 3 is —C(O)N(H) octyl and its structural isomers. In one embodiment of III, R 3 is -C(O)N(H)nonyl and its structural isomers. In one embodiment of II, R 3 is —C(O)N(H)decyl and its structural isomers. In the same way, R 4 is hydrogen. In one embodiment, R 4 is methyl. In the same way, R 4 is ethyl. In another embodiment, R 4 is propyl and its structure In another embodiment, R 4 is butyl and its structural isomers. In the embodiment, R 4 is pentyl and its structural isomers. In one embodiment, R 5 teeth , methyl. In another embodiment, R 5 is ethyl. In another embodiment, R 5 is propyl and its structural isomers. In another embodiment, R 5 butyl and its In another embodiment, R 5 is pentyl and its structural isomers In one embodiment, R 4 and R 5 is methyl.

[0089] In certain embodiments, described herein are compounds having the structure of Formula XXI. R: [ka] (In the formula, R 60 is an alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl alkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl). Suitable R 60 As alkyl groups, in the context of formula XIII, R 1 For example, Suitable R groups include methyl, ethyl, etc. 60 Alkenyl, alkynyl, aryl, and Heteroaryl is described elsewhere herein. 60 Cycloalkyl and hexamethyl Tetracycloalkyls include those to which they are attached, as described in the context of formula XIII. R with carbon 4 and R 5 In one embodiment, R 11 is C1-C 10 alkyl; or a pharmaceutically acceptable salt thereof. R 11 is methyl. In one embodiment, R 11 is ethyl. , R 11 is propyl and its structural isomers. In one embodiment, R 11 is butyl and In one embodiment, R 11 is pentyl and its structural isomers In one embodiment, R11 is hexyl and its structural isomers. R 11 is heptyl and its structural isomers. In one embodiment, R 11 Is, Och In one embodiment, R 11 is nonyl and its structural isomers In one embodiment, R 11 is decyl and its structural isomers.

[0090] In certain embodiments, described herein are compounds wherein Q is -O-; R 2 But C1-C 10 a R is alkynyl; 3 is —C(O)C1-C5 alkyl; and R 60 However, alkyl, alkenyl, Alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, substituted A compound having the structure of formula XIII, wherein X is aryl or substituted heteroaryl, or a pharmaceutical thereof. Suitable R 60 The alkyl group may be a group represented by the formula XII R in the context of I 1 Examples of the alkyl groups include those described for the above groups, such as methyl, ethyl, and the like. Suitable R 60 Alkenyl, alkynyl, aryl, and heteroaryl are defined elsewhere herein. This is explained in the appropriate place. 60 Cycloalkyl and heterocycloalkyl include those of formula XII R with the carbon to which they are attached, as described in the context of I 4 and R 5 Regarding In one embodiment, R 1 , R 4 , R 5 , R 7 , and R 8 is the above formula XIII. In one embodiment of Formula XIII, R 2 is -CH2CCH In one embodiment of Formula XIII, R 2 is —CH 2 CH 2 CCH. In one embodiment of Formula XIII , R 2 is —CH2CH2CH2CCH. In one embodiment of Formula XIII, R 2 is -CH2CH2CH2CH2CCH In one embodiment of Formula XIII, R 2 is -CH2CH2CH2CH2CH2CCH. In an embodiment, R 2 is —CH 2 CH 2 CH 2 CH 2 CH 2 CCH. In one embodiment of Formula XIII , R 2 is —CH2CH2CH2CH2CH2CH2CH2CCH. In one embodiment of Formula XIII, R 2 is -CH2C H2CH2CH2CH2CH2CH2CH2CCH. In one embodiment of Formula XIII, R 2 is -CH2CH2CH2CH2CH 2CH2CH2CH2CH2CCH. In one embodiment of Formula XIII, R 2 is -CH2CH2CH2CH2CH2CH2CH2 In one embodiment, R 3 is —C(O)Me. Te, R 3 is —C(O)Et. In another embodiment, R 3 -C(O)propyl and its structural variants In another embodiment, R 3 is -C(O)butyl and its structural isomers. In an embodiment of the present invention, R 3 is -C(O)pentyl and its structural isomers.

[0091] In certain embodiments, described herein are compounds having the structure of Formula XXII, or is a pharmaceutically acceptable salt thereof: [ka] In some embodiments, R 2 , R 3 , R 4 , R 5 , R 7 , and R 60 As stated in the previous paragraph, It is.

[0092] In certain embodiments, described herein are compounds wherein Q is -O-; R 2 But C1-C 10 a R is alkynyl; 3 But -C(O)N(H)C1-C 10 alkyl; and R 60 However, alkyl, alkenyl alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, a compound having the structure of formula XIII, wherein the compound is a substituted aryl or a substituted heteroaryl; A suitable R is a pharmaceutically acceptable salt or prodrug. 60 Examples of alkyl groups include: R in the context of Formula XIII 1 For example, methyl, ethyl, etc. Suitable R 60 Alkenyl, alkynyl, aryl, and heteroaryl are defined herein. This is explained elsewhere. 60 Cycloalkyl and heterocycloalkyl include: R along with the carbon to which they are attached as described in the context of Formula XIII 4 and R 5 whereas In one embodiment, R 1 , R 4, R 5 , R 7 , and R 8 is above As depicted in Formula XIII. In one embodiment of Formula XIII, R 2 is -CH2CCH In one embodiment of Formula XIII, R 2 is —CH2CH2CCH. In one embodiment of Formula XIII, R 2 is —CH2CH2CH2CCH. In one embodiment of Formula XIII, R 2 is -CH2CH2CH2CH2 CCH. In one embodiment of Formula XIII, R 2 is -CH2CH2CH2CH2CH2CCH. In one embodiment, R 2 is -CH2CH2CH2CH2CH2CH2CCH. In one embodiment of Formula XIII Te, R 2 is —CH2CH2CH2CH2CH2CH2CH2CCH. In one embodiment of Formula XIII, R 2 is -CH In one embodiment of Formula XIII, R 2 is -CH2CH2CH2CH2 In one embodiment of Formula XIII, R 2 is -CH2CH2CH2CH2CH2CH2CH2C H2CH2CH2CH2CCH. In one embodiment of formula XIII above, R 3 is -C(O)N(H)Me. In one embodiment of formula XIII above, R 3 is -C(O)N(H)Et. One embodiment of formula XIII above In R 3 is —C(O)N(H)propyl and its structural isomers. In the same way, R 3is —C(O)N(H)butyl and its structural isomers. In the same way, R 3 is —C(O)N(H)pentyl and its structural isomers. In an embodiment, R 3 is -C(O)N(H)hexyl and its structural isomers. In the embodiment, R 3 is —C(O)N(H)heptyl and its structural isomers. In an embodiment, R 3 is —C(O)N(H) octyl and its structural isomers. In one embodiment, R 3 is -C(O)N(H)nonyl and its structural isomers. In one embodiment, R 3 is -C(O)N(H)decyl and its structural isomers.

[0093] In certain embodiments, described herein are compounds having the structure of Formula XXIII: or a pharmaceutically acceptable salt thereof: [ka] In some embodiments, R 2 , R 4 , R 5 , R 8 , and R 60 As stated in the previous paragraph, be.

[0094] In certain embodiments, described herein are compounds wherein Q is -O-; R 2 But C1-C3 Al Kiren-Q 1 -(CH2) n aryl; or C1-C3 hydroxyalkyl; R 3 But -C(O)C1-C5 ar Kill;R 4is hydrogen or C1-C5 alkyl; R 5 is C1-C5 alkyl; R 7 But -OH and R 60 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclo alkyl, aryl, heteroaryl, substituted aryl, or substituted heteroaryl; A compound having the structure of Formula XIII, or a pharmaceutically acceptable salt or prodrug thereof. There is a suitable R 60 As alkyl groups, in the context of formula XIII, R 1 What is stated for Examples include methyl and ethyl. 60 Alkenyl, alkynyl, aryl Aryl, and heteroaryl are described elsewhere herein. 60 Cycloalkane The alkyl and heterocycloalkyl include those described in the context of formula XIII. R with the carbon attached 4 and R 5 In one embodiment, Hey, R 1 and R 8 is as described above in formula XIII. R 2 is C1-C3 alkylene-Q 1 -(CH2) n aryl, and Q 1 is -CH2-. In an embodiment, R 2 is -CH2CH2(CH2) n aryl, wherein the aryl is unsubstituted; or substituted with nitro or amino, and n is an integer from 1 to 5. In the same way, R 2 is -CH2CH2(CH2) nphenyl, and n is 1, 2, 3, 4, or 5 In one embodiment, R 2 is -CH2CH2(CH2) n p-nitrophenyl, and n is 1, 2, 3, 4, or 5. In one embodiment, R 2 is -CH2CH2(CH2) n p-aminophenyl and n is 1, 2, 3, 4, or 5. In one embodiment, R 2 is -CH2CH2CH2(CH2) n a aryl, wherein aryl is unsubstituted or substituted with nitro or amino; and n is an integer from 1 to 5. In one embodiment, R 2 is -CH2CH2CH2(CH2) n Fe nyl, and n is 1, 2, 3, 4, or 5. In one embodiment, R 2 is -CH2CH2C H2(CH2) n p-nitrophenyl, and n is 1, 2, 3, 4, or 5. R 2 is -CH2CH2CH2(CH2) n p-aminophenyl, and n is 1, 2, 3, 4, or 5. In one embodiment, R 2 is -CH2CH2CH2CH2(CH2) n aryl (wherein, is unsubstituted or substituted with nitro or amino, and n is an integer from 1 to 5. In one embodiment, R 2 is -CH2CH2CH2CH2(CH2) n phenyl, and n is 1, 2 , 3, 4, or 5. In one embodiment, R 2 is -CH2CH2CH2CH2(CH2) n p-nitrophenyl and n is 1, 2, 3, 4, or 5. In one embodiment, R 2 is -CH2CH2CH2 CH2(CH2) n p-aminophenyl, and n is 1, 2, 3, 4, or 5. In R 2 is C1-C3 alkylene-Q 1 -(CH2) n aryl, and Q 1 is -O-. In one embodiment, R 2 is -CH2O-(CH2) n aryl, wherein aryl is non- substituted with nitro or amino, and n is an integer from 1 to 5). In one embodiment, R 2 is -CH2O-(CH2) n phenyl, and n is 1, 2, 3, 4, or 5 In one embodiment, R 2 is -CH2O-(CH2) n p-nitrophenyl and n is 1 , 2, 3, 4, or 5. In one embodiment, R 2 is -CH2O-(CH2) n p-aminophenyl and n is 1, 2, 3, 4, or 5. In one embodiment, R 2 is -CH2CH2O-(CH2) n aryl, wherein the aryl is unsubstituted or substituted with nitro or amino; and n is an integer from 1 to 5. In one embodiment, R 2 is -CH2CH2O-(CH2) n centre and n is 1, 2, 3, 4, or 5. In one embodiment, R 2 is -CHCH 2O-(CH2) np-nitrophenyl, and n is 1, 2, 3, 4, or 5. In one embodiment, Hey, R 2 is -CH2CH2O-(CH2) n p-aminophenyl, and n is 1, 2, 3, 4, or 5 In one embodiment, R 2 is -CH2CH2CH2O-(CH2) n aryl (wherein n is an integer from 1 to 5; In one embodiment, R 2 is -CH2CH2CH2O-(CH2) n phenyl and n is 1 , 2, 3, 4, or 5. In one embodiment, R 2 is -CH2CH2CH2O-(CH2) n p-Nitrophen nyl, and n is 1, 2, 3, 4, or 5. In one embodiment, R 2 is -CH2CH2C H2O-(CH2) n p-aminophenyl, and n is 1, 2, 3, 4, or 5. Hey, R 2 is —CHOH. In one embodiment, R 2 is —CH2CH2OH. In the same way, R 2 In certain embodiments of formula XIII above, useful R 3 Groups include -C(O)Me, -C(O)Et, -C(O)propyl, -C(O)butyl, and -C(O)pentyl, as well as In one embodiment, R 3 is -C(O)Me. In an embodiment of the present invention, R 3 is —C(O)Et. In another embodiment, R 3 is -C(O)propanol In another embodiment, R 3 is -C(O)butyl and its structure In another embodiment, R 3 is -C(O)pentyl and its structural isomers In one embodiment, R 4 is hydrogen. In certain embodiments of formula I above, useful R 4 The groups include methyl, ethyl, propyl, butyl, and pentyl, as well as their structural variants. In one embodiment, R 4 is methyl. In another embodiment, R 4 is ethyl. In another embodiment, R 4 is propyl and its structural isomers In another embodiment, R 4 is butyl and its structural isomers. Te, R 4 is pentyl and its structural isomers. In certain embodiments of formula I above, useful NaR 5 The groups include methyl, ethyl, propyl, butyl, and pentyl, and their structures. In one embodiment, R 5 is methyl. Te, R 5 is ethyl. In another embodiment, R 5 is propyl and its structural isomers In another embodiment, R 5 is butyl and its structural isomers. Hey, R 5 is pentyl and its structural isomers. In one embodiment, R 4 and R 5 teeth, It is methyl.

[0095] In certain embodiments, described herein are compounds having the structure of Formula XXIV, or is a pharmaceutically acceptable salt thereof: [ka] In some embodiments, R 2 , R 3 , and R 60 is as described in the previous paragraph. In one embodiment of XIV, R 2 As mentioned in the paragraph above, Xylene-O-(CH2) n In one embodiment of Formula XXIV, R 2 The above paragraph As described in [2], it is C1-C3 hydroxyalkyl.

[0096] In any of the foregoing embodiments of this section, R 7 is -NR 7a R 7b (wherein R 7a Reach BiR 7b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl aryl, heteroaryl, acyl, and amino acid residues, Alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally In some embodiments, R 7a is hydrogen and R 7b is Amino It is an acid residue.

[0097] (binder) Suitable binding agents for any of the conjugates provided in this disclosure include antibodies, lymphocytes, and the like. kinases (e.g., IL-2 or IL-3), hormones (e.g., insulin and glucocorticoids) growth factors (e.g., EGF, transferrin, and type III fibronectin), viral receptors, receptors, interleukins, or any other cell- or peptide-binding molecules, Binding agents include, but are not limited to, ankyrin repeat-binding proteins. Also included are, but are not limited to, proteins and interferons.

[0098] In some embodiments, the binding agent is an antibody or an antigen-binding fragment thereof. It can be in any form known to those skilled in the art. The term refers to at least one molecule that specifically binds to or interacts with a particular antigen. "Antibody" refers to any antigen-binding molecule or molecular complex containing the complementarity-determining region (CDR) of The term refers to two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Immunoglobulin molecules, including those containing four polypeptide chains, and their multimers (e.g., IgM) Each heavy chain comprises a heavy chain variable region (HCVR or V H and a heavy chain constant region. The heavy chain constant region consists of three domains: C H 1. C H 2, and C H 3. Each light chain comprises a light chain variable region ( As used herein, LCVR or V L The light chain constant region contains one domain, N (C L 1) V H and V L The more highly conserved regions are called framework regions (FR). These regions are further subdivided into hypervariable regions called complementarity-determining regions (CDRs) interspersed with chromatid-modified regions. Each V H and V L It consists of three CDRs and four FRs, and The CDRs are arranged towards the hydroxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In various embodiments disclosed herein, antibodies (or antibodies) suitable for the compounds herein may be used. The FRs of the nucleotide sequences (or the antigen-binding portion thereof) may be identical to the human germline sequences or may be naturally occurring. The amino acid consensus sequence may be a sequence of two or more CDRs. The term "antibody" as used herein can be defined based on a specific antibody. As used herein, an "antigen-binding portion" of an antibody also includes an antigen-binding fragment of an entire antibody molecule. The term "antigen-binding fragment" of an antibody and the like refers to any fragment that specifically binds to an antigen to form a complex. Naturally occurring, enzymatically obtained, synthetic, or genetically modified polypeptides of Antigen-binding fragments of antibodies can be isolated using any suitable standard technique, e.g., by tagging. Enzyme-degrading or manipulating the DNA encoding the antibody variable domains and optionally the constant domains. It can be derived from whole antibody molecules using recombinant genetic engineering techniques involving the synthesis and expression of the antibody. Such DNA is known and / or can be obtained, for example, from commercial sources, DNA libraries (e.g. are readily available from libraries (including phage-antibody libraries) or can be synthesized. By sequencing the DNA and using chemical or molecular biology techniques Manipulating, e.g., arranging one or more variable and / or constant domains in a suitable configuration or codons are introduced to generate cysteine ​​residues, modify, add, or Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) (iii) F(ab')2 fragments; (iv) Fd fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) antibodies. A minimal recognition unit consisting of amino acid residues that mimic the hypervariable region of a peptide (e.g., CDR3 peptide) isolated CDRs of the FR3-CDR3-FR4 peptides, or constrained FR3-CDR3-FR4 peptides. For example, domain-specific antibodies, single domain antibodies, domain deleted antibodies, chimeric antibodies, CDR grafts Antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g., Monovalent nanobodies, bivalent nanobodies, etc.), small modular immunotherapeutics (SMIPs), and serogroups Variant IgNAR domains are also encompassed by the expression "antigen-binding fragment" as used herein. An antigen-binding fragment of an antibody typically contains at least one variable domain. They may be of any size or amino acid composition and typically contain one or more framework amino acids. at least one CDR adjacent to or in-frame with the sequence .V H Domain is V L In the antigen-binding fragment associated with the domain, V H Domains and V L Domain The domains may be in any suitable configuration relative to each other. For example, the variable region may be a dimer. , and V H -V H , V H -V L , or V L -V L Alternatively, the antibody may contain a dimer. The fragment is a monomeric V H or V L In one embodiment, the antibody The antigen-binding fragment of the present invention comprises at least one constant domain covalently linked to at least one constant domain. The variable domains that can be found in the antigen-binding fragments of the antibodies of the present invention may include and non-limiting exemplary configurations of constant domains include: (i) V H -C H 1;(ii)V H -C H 2;(iii)V H -C H 3;(iv)V H -C H 1-C H 2;(v)V H -C H 1-C H 2-C H 3;(vi)V H -C H 2-C H 3;(vii)V H -C L ;(viii)V L -C H 1;(ix)V L -C H 2;(x)V L -C H 3;(xi)V L -C H 1-C H 2;(xii)V L -C H 1-C H 2-C H 3;(xiii)V L -C H 2-C H 3; and (xiv) V L -C L Any of the variable and constant domains comprising any of the exemplary configurations above may be used. In any configuration, the variable and constant domains may be directly linked to each other, or may be linked by a complete or partial hinge or linker region. The hinge region serves to separate adjacent variable and / or constant domains in a single polypeptide molecule. At least two (e.g., five, ten, fifteen) flexible or semi-flexible connections between the The antibody may consist of 20, 40, 60 or more amino acids. Like molecules, antigen-binding fragments may be monospecific or multispecific (e.g., bispecific). Multispecific antigen-binding fragments of antibodies typically contain at least two different variable domains. wherein each variable domain is directed to a separate antigen or to a different epitope on the same antigen. Exemplary bispecific antibody forms disclosed herein are capable of specifically binding to Any multispecific antibody format, including mats, can be used with routine techniques available in the art. can be adapted for use in connection with antigen-binding fragments of the antibodies of the present disclosure. In certain embodiments described herein, the antibodies described herein are human antibodies. As used herein, the term "human antibody" refers to a human germline immunoglobulin The present invention is intended to include antibodies having variable and constant regions derived from the sequence. The antibody may be coded with human germline immunoglobulin sequences in the CDRs, particularly CDR3, for example. Uncoded amino acid residues (e.g., random or site-directed in vitro) Mutations introduced by mutagenesis or by somatic mutation in vivo may be included. However, the term "human antibody" as used herein may refer to antibodies derived from other mammals, such as mice. Antibody molecules in which CDR sequences derived from the germline of a mammalian species are grafted onto human framework sequences. The term "human antibody" refers to a naturally occurring, unmodified organism. does not include naturally occurring molecules that normally occur in the The antibodies disclosed herein are, in some embodiments, recombinant human antibodies. As used herein, the term "recombinant human antibody" refers to an antibody produced by recombinant means. All human antibodies prepared, expressed, produced, or isolated, e.g., within host cells, Antibodies expressed using transfected recombinant expression vectors (described further below) ), antibodies isolated from recombinant combinatorial human antibody libraries (discussed further below). described below), animals transgenic for human immunoglobulin genes (e.g., Antibodies isolated from mice (e.g., Taylor et al., (1992) Nucl. Acids Res. 20:628 7-6295), or splicing of human immunoglobulin gene sequences to other DNA sequences. prepared, expressed, produced, or isolated by any other means involving Such recombinant human antibodies are intended to include antibodies that are derived from human germline immune groups. The variable and constant regions are derived from globulin sequences. Therefore, such recombinant human antibodies can be produced by in vitro mutagenesis (or transcription of human Ig sequences). When transgenic animals are used, they are subjected to in vivo somatic mutagenesis (SMM). The V of the recombinant antibody H and V L The amino acid sequence of the region is human germline V H and V L Originating from sequence and related thereto, but which naturally occur in vivo within the human antibody germline repertoire. Human antibodies exist in two forms related to hinge heterogeneity. In some forms, immunoglobulin molecules can be present in which the dimers are interchain heavy chain disulfides. The second form comprises a stable four-chain structure of approximately 150-160 kDa linked by peptide bonds. is a dimer not linked by interchain disulfide bonds but consisting of covalently linked light chains and A molecule of approximately 75-80 kDa is formed, consisting of heavy chains (half of the antibody). Even after affinity purification, the various intact IgG isotypes are extremely difficult to separate. The frequency of the second form in a group depends on, but is not limited to, the hinge region isotype of the antibody. This is due to the related structural differences. The amino acid substitutions suppressed the appearance of the second form to the level normally observed with the human IgG1 hinge. can be decreased arbitrarily (Angal et al. (1993) Molecular Immunology 30:105). The present disclosure provides a hinge region, C H 2nd area or C H 3 regions, e.g., suitable for manufacturing the desired antibody The present invention also encompasses antibodies with one or more mutations that may improve the yield of the desired form. The antibody may be an isolated antibody. As used herein, an "isolated antibody" refers to , identified and separated and / or recovered from at least one component of its natural environment. It refers to an antibody, e.g., a molecule derived from at least one component of an organism or a cell in which the antibody is naturally occurring. Antibodies isolated or removed from tissues or cells in which they are naturally produced are also contemplated by the present disclosure. An isolated antibody is an antibody that is produced in situ within a recombinant cell. An isolated antibody is an antibody that has been subjected to at least one purification or isolation step. In one embodiment, the isolated antibody is free of other cellular and / or chemical material. As used herein, an antibody may be substantially free of the antigens from which it is derived. The framework and amino acid sequences of the heavy and light chain variable domains were compared to the corresponding germline sequences. and / or may contain one or more amino acid substitutions, insertions, and / or deletions in the CDR regions. Such mutations can be made by modifying the amino acid sequences disclosed herein, for example, using public antibody sequence data. This can be easily confirmed by comparison with the germline sequence available from the The present disclosure also provides antibodies and their antigens derived from any of the amino acid sequences disclosed herein. and binding fragments, wherein one or more amino acids in one or more framework and / or CDR regions are present. or a nucleotide sequence corresponding to the corresponding residue(s) in the germline sequence from which the antibody is derived, or in another human germline sequence. Conserved amino acids to the corresponding residue(s) in the sequence or to the corresponding germline residue(s). substitutions (such sequence changes are referred to herein as "germline mutations"). Those skilled in the art can easily generate the heavy and light chain variable region sequences starting from those disclosed herein. , a number of antibodies and antigen-binding fragments comprising one or more individual germline mutations or combinations thereof. In one embodiment, V H and / or V L Within the domain All framework and / or CDR residues are mutated to mimic the original germline sequence from which the antibody was derived. In another embodiment, only certain residues, e.g., The first 8 amino acids or the last 8 amino acids of FR4 Only mutated residues found in the amino acid sequence of Only residues are mutated to revert to the original germline sequence. One or more of the CDR and / or CDR residues may be altered to a different germline sequence (i.e., the sequence from which the antibody is originally derived). The resulting germline sequence is then mutated to the corresponding residue in the corresponding germline sequence (which differs from the germline sequence in which the gene was derived). The antibodies shown may have, for example, specific individual residues within the framework and / or CDR regions. While mutated to the corresponding residue in the germline sequence, it differs from the original germline sequence. Certain other residues are either maintained or mutated to the corresponding residues in different germline sequences. A person may contain any combination of two or more germline mutations that have been identified. Antibodies and antigen-binding fragments containing one or more germline mutations, e.g., those with improved binding, specificity, increased binding affinity, improved or enhanced antagonistic or agonistic biological properties (as the case may be) can be easily tested for one or more desired properties, such as reduced immunogenicity Antibodies and antigen-binding fragments obtained by this general method are included within the scope of the present disclosure. Antibodies useful in the compounds of the present invention also include those having one or more conservative substitutions. and variants of any of the HCVR, LCVR, and / or CDR amino acid sequences disclosed herein. Antibodies are also included. The term "epitope" refers to the portion of an antibody molecule known as a paratope. The antigenic determinant interacts with the specific antigen-binding site in the variable region. An antigen may have more than one epitope. Thus, different antibodies bind to different parts of the antigen. Epitopes can be either conformational or linear and can have different biological effects. Conformational epitopes can be spatially distinct from different segments of a linear polypeptide chain. A linear epitope is formed by adjacent amino acids in a polypeptide chain. In some situations, an epitope is a polypeptide on an antigen. It may contain a chloride, phosphoryl, or sulfonyl moiety.

[0099] In certain embodiments, the antibody comprises a light chain. In certain embodiments, the light chain is a kappa In some embodiments, the light chain is a lambda light chain. In some embodiments, the antibody comprises a heavy chain. In some embodiments, the heavy chain is IgA. In some embodiments, the heavy chain is IgD. In some embodiments, the heavy chain is IgE. In some embodiments, the heavy chain is IgG. The heavy chain is IgM. In some embodiments, the heavy chain is IgG1. In some embodiments, the heavy chain is IgG2. In some embodiments, the heavy chain is IgG3. In some embodiments, the heavy chain is IgG4. The heavy chain is IgA1. In some embodiments, the heavy chain is IgA2.

[0100] In some embodiments, the antibody is an antibody fragment. In some embodiments, the antibody fragment is an Fv fragment. In some embodiments, the antibody fragment is a Fab fragment. In some embodiments, the antibody fragment is a F(ab')2 fragment. In some embodiments, the antibody fragment is a Fab′ fragment. , scFv (sFv) fragment. In some embodiments, the antibody fragment is an scFv-Fc fragment. .

[0101] In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a polyclonal antibody. , a first antigen-binding domain (also referred to herein as "D1"), and a second antigen-binding domain The antibody is a bispecific antibody comprising a domain (also referred to herein as "D2").

[0102] As used herein, the term "antigen-binding domain" refers to a domain that binds to a particular antigen of interest. Any peptide, polypeptide that can specifically bind to a target protein (e.g., PRLR or STEAP2) a nucleic acid molecule, a scaffold-type molecule, a peptide display molecule, or a polypeptide-containing molecule As used herein, the term "specifically binds" and the like refers to an antibody or construct. The original binding domain has a dissociation constant (K D ) that form complexes with specific antigens and does not bind to other unrelated antigens under normal test conditions. "Antigens" are proteins, peptides, or polypeptides that share less than 95% amino acid identity with each other. It's Chido.

[0103] Exemplary categories of antigen-binding domains that can be used in the context of the present disclosure include: is an antibody that specifically interacts with a particular antigen (e.g., a peptibody), the antigen-binding portion of an antibody molecules, peptides, receptor molecules that specifically interact with specific antigens, proteins containing the ligand-binding portion of the receptor to which they bind, antigen-binding scaffolds (e.g., For example, DARPins, HEAT repeat proteins, ARM repeat proteins, tetratricopeptides Repetitive sequence proteins and other scaffolds based on naturally occurring repeat proteins, etc. For example, Boersma and Pluckthun, 2011, Curr. Opin. Biotechnol. 22:8 49-857 and references cited therein]), and aptamers or their Parts include:

[0104] Methods for determining whether two molecules specifically bind to one another are well known in the art. These methods are well known in the art, and examples thereof include equilibrium dialysis and surface plasmon resonance. An antigen-binding domain, as used in the context of this disclosure, is a domain that binds to a specific antigen (e.g., a target molecule [T] or or an internalization effector protein [E]) or a portion thereof, and less than about 1 μM, less than about 500 nM, less than about 250 nM, less than about 125 nM, less than about 60 nM, less than about 30 nM when measured less than about 10 nM, less than about 5 nM, less than about 2 nM, less than about 1 nM, less than about 500 pM, less than about 400 pM, less than about 3 less than about 00 pM, less than about 200 pM, less than about 100 pM, less than about 90 pM, less than about 80 pM, less than about 70 pM, less than about 60 pM less than about 50 pM, less than about 40 pM, less than about 30 pM, less than about 20 pM, less than about 10 pM, less than about 5 pM, about 4 pM less than about 2 pM, less than about 1 pM, less than about 0.5 pM, less than about 0.2 pM, less than about 0.1 pM, or about 0.05 pM Less than K D The present invention includes polypeptides that bind at

[0105] In some embodiments, the antibody is a chimeric antibody. In some embodiments, the antibody is a humanized antibody. In some embodiments, the antibody is a human antibody. .

[0106] In some embodiments, the antibody is anti-PSMA, anti-PRLR, anti-MUC16, anti-HER2, or In some embodiments, the antibody is an anti-EGFRvIII or anti-STEAP2 antibody. is an anti-HER2 antibody. In some embodiments, the antibody, or antigen-binding fragment thereof, is an anti-HER2 antibody. In some embodiments, the antibody, or antigen-binding fragment thereof, is anti-PRLR. be.

[0107] The antibody may have a binding specificity for any antigen deemed suitable by one of skill in the art. In some embodiments, the antigen is a transmembrane molecule (e.g., a receptor). In some embodiments, the antigen is expressed on a tumor. The combination drug targets compounds that are common, overexpressed, or modified on specific tumor types. interacting with or containing tumor antigens, including antigens specific to the type of tumor or antigen present. In one embodiment, the antigen is expressed on a solid tumor. Exemplary Antigens These include lipoproteins; alpha-1-antitrypsin; and cytotoxic T-lymphocytes such as CTLA-4. CTLA (Cell-Like Lymphocyte-Related Antigen); Vascular Endothelial Growth Factor (VEGF); Hormone or Growth Factor Receptor; Protein A or D; fibroblast growth factor receptor 2 (FGFR2), EpCAM, GD3, FLT3, PSMA, PSCA, MUC1, MUC1 6, STEAP, STEAP2, CEA, TENB2, EphA receptor, EphB receptor, folate receptor, FOLRI, mesothelial cell membrane protein Phosphorin, Crypto, alphavbeta6, integrin, VEGF, VEGFR, EGFR, trans receptors, IRTA1, IRTA2, IRTA3, IRTA4, IRTA5; CD2, CD3, CD4, CD5, CD6, CD8, CD 11, CD14, CD19, CD20, CD21, CD22, CD25, CD26, CD28, CD30, CD33, CD36, CD37, CD38 , CD40, CD44, CD52, CD55, CD56, CD59, CD70, CD79, CD80, CD81, CD103, CD105, CD13 4. CD proteins such as CD137, CD138, and CD152, or each in its entirety, are incorporated by reference. One of the compounds disclosed in U.S. Publication No. 2008 / 0171040 or U.S. Publication No. 2008 / 0305044, which are incorporated herein by reference. Antibodies that bind to the above tumor-associated antigens or cell surface receptors; erythropoietin; osteoinductive factor ;Immunotoxin;Bone morphogenetic protein (BMP);T cell receptor;Surface membrane protein;CD11a, CD11b, CD11c integrins such as CD18, ICAM, VLA-4, and VCAM; AFP, ALK, B7H4, BAGE proteins; β-catenin, brc-abl, BRCA1, BORIS, CA9 (carbonic anhydrase IX), caspase-8, CD20, CD4 0, CD123, CDK4, CEA, CLEC12A, c-kit, cMET, CTLA4, cyclin-B1, CYP1B1, EGFR, EGFRv III, endoglin, EpCAM, EphA2, ErbB2 / Her2, ErbB3 / Her3, ErbB4 / Her4, ETV6-AML, F ra-1, FOLR1, GAGE ​​protein, GD2, GD3, GloboH, glypican-3, GM3, gp100, Her2, H LA / B-raf, HLA / EBNA1, HLA / k-ras, HLA / MAGE-A3, hTERT, IGF1R, LGR5, LMP2, MAGE tan Protein, MART-1, Mesothelin, ML-IAP, Muc1, Muc16, CA-125, MUM1, NA17, NGEP, NY-BR 1, NY-BR62, NY-BR85, NY-ESO1, OX40, p15, p53, PAP, PAX3, PAX5, PCTA-1, PDGFR-α , PDGFR-β, PDGF-A, PDGF-B, PDGF-C, PDGF-D, PLAC1, PRLR, PRAME, PSCA, PSGR, PSMA (FOLH1), RAGE protein, Ras, RGS5, Rho, SART-1, SART-3, Steap-1, Steap-2, STn, Survivin, TAG-72, TGF-β, TMPRSS2, Tn, TNFRSF17, TRP-1, TRP-2, tyrosinase, and uroplakin-3, and tumor-associated antigens, and any of the polypeptides listed above. Fragment; Cell surface expressed antigen; MUC16; c-MET; Class A scavenger including scavenger receptor A (SR-A) and molecules such as the sensitizer receptor, and the B7 family, including V-set and Ig domain-containing 4 (VSIG4). Lee-related members, colony-stimulating factor 1 receptor (CSF1R), asialoglycoprotein receptor (ASG Other membrane proteins include amyloid beta precursor-like protein 2 (APLP-2), and amyloid beta precursor-like protein 2 (APLP-3). In some embodiments, the antigen is PRLR or HER2. In some embodiments, the antigen is STEAP2. In some instances, the antigen is human STEAP2. In some instances, the MAGE protein is MAGE-1, In some examples, the GAGE ​​protein is selected from G It is selected from AGE-1 and GAGE-2.

[0108] Exemplary antigens also include, but are not limited to, BCMA, SLAMF7, GPNMB, and UPK3A. Exemplary antigens also include, but are not limited to, MUC16, STEAP2, and HER2. Not limited to.

[0109] In some embodiments, the antigen comprises MUC16. The antigen comprises STEAP2. In some embodiments, the antigen comprises PSMA. In some embodiments, the antigen comprises HER2. In some embodiments, the target polypeptide is a prostate-specific membrane antigen (PSMA). In some embodiments, the antigen is MUC16. In some embodiments, the antigen comprises PSMA. In some embodiments, the antigen is HER2. In some embodiments, the antigen is STEA It's P2.

[0110] In certain embodiments, the antibody comprises one or more heavy chain positions numbered 295 in the EU numbering system. In the present disclosure, this position is glutamine 295, or Gln295, or is referred to as Q295. Those skilled in the art will recognize that this is a conserved position in the wild-type sequences of many antibodies. It will be appreciated that the amino acid sequence is a glutamine residue. The antibody can be engineered to contain a cysteine ​​residue. In one embodiment, the antibody Contains one or more N297Q mutations. Techniques for modifying antibody sequences to include glutamine residues. It is within the skill of one in the art (see, e.g., Ausubel et al., Current Protocols. Mol. Biology, 1999). ol.).

[0111] In some embodiments, the linker-payload or payload conjugate The antibody or antigen-binding fragment thereof may be an antibody that targets STEAP2. Suitable anti-STEAP2 antibodies or antigen-binding fragments thereof include, for example, those described in International Publication No. WO2018 / 058001A1 No. 6,299,499 (including those containing the amino acid sequence disclosed in Table 1 on page 75 thereof). In some embodiments, the anti-STEAP2 antibody is H1H7814N of WO2018 / 058001A1 ( In some embodiments, the anti-STEAP2 antibody is selected from the group consisting of SEQ ID NO: H1M7814N. Heavy chain complementarity determining region (HCDR)-1 comprising SEQ ID NO:2; HCDR2 comprising SEQ ID NO:3; HCDR3 comprising SEQ ID NO:4 light chain complementarity determining region (LCDR)-1 comprising SEQ ID NO:6; LCDR2 comprising SEQ ID NO:7; and SEQ ID NO:8 In some embodiments, the anti-STEAP2 antibody comprises an LCDR3 comprising SEQ ID NO: 1. The heavy chain variable region (HCVR) and the light chain variable region (LCVR) comprise SEQ ID NO: 5. In either case, the anti-STEAP2 antibody may have a glutamine residue that abolishes antibody function or binding. For example, the nucleotide sequence of the previous In any of the above-described embodiments, the anti-STEAP2 antibody comprises an Asn297Gln (N297Q) mutation. In addition, such antibodies having the N297Q mutation have transglutaminase in their variable regions. may be available to the enzyme and therefore may be used as a payload or linker-payload Contains one or more additional native glutamine residues that can be conjugated to the In some embodiments, the antibody or antigen-binding fragment thereof may have the sequence Number: Three heavy chain complementarity determining regions (HCDR1, HCDR2, HCDR3) in the heavy chain variable region (HCVR) amino acid sequence of 1 and HCDR3); and three light chain complementary regions within the light chain variable region (LCVR) amino acid sequence of SEQ ID NO: 5 In some embodiments, the antibody or its antibody fragments comprise a sex-determining region (LCDR1, LCDR2, and LCDR3). The original binding fragment comprises the HCVR amino acid sequence of SEQ ID NO:1; and the LCVR amino acid sequence of SEQ ID NO:5. International Publication No. WO2018 / 058001A1 is hereby incorporated by reference in its entirety. be absorbed.

[0112] In some embodiments, the linker-payload or payload conjugate The antibody, or antigen-binding fragment thereof, targets the human prolactin receptor (PRLR). Suitable anti-PRLR antibodies or antigen-binding fragments thereof include, for example, those listed in the International Publication The amino acid sequence disclosed in Table 1 on page 36 of WO2015 / 026907A1 is also disclosed. In some embodiments, the anti-PRLR antibody is a compound described in WO2015 / 0269 In some embodiments, the CDR is H1H6958N2 of the same publication. The anti-PRLR antibody comprises a heavy chain complementarity determining region (HCDR)-1 comprising SEQ ID NO: 10; a HCDR-2 comprising SEQ ID NO: 11; R2; HCDR3 comprising SEQ ID NO:12; light chain complementarity determining region (LCDR)-1 comprising SEQ ID NO:14; SEQ ID NO:1 and LCDR3 comprising SEQ ID NO: 16. In some embodiments, the anti-PRL The R antibody contains a heavy chain variable region (HCVR) comprising SEQ ID NO: 9 and a light chain variable region (LCV) comprising SEQ ID NO: 13. In any of the foregoing embodiments, the anti-PRLR antibody comprises a glutamine residue at the site of the anti-PRLR. Prepared by site-directed mutagenesis to insert into a position that does not abolish body function or binding For example, in any of the above embodiments, the anti-PRLR antibody may be Asn297Gln (N297Q) mutation. Such antibodies with N297Q mutation may also be used for their potential The variable region may be accessible to transglutaminase and therefore One or more additional linkers that can be conjugated to the payload Naturally occurring glutamine residues may also be included (Table A). In certain embodiments, the antibody or The antigen-binding fragment comprises three heavy chain complementary domains within the heavy chain variable region (HCVR) amino acid sequence of SEQ ID NO:9. a light chain variable region (LCVR) comprising the sex-determining region (HCDR1, HCDR2, and HCDR3); and a light chain variable region (LCVR) comprising the sequence of SEQ ID NO: 13. In one embodiment, the amino acid sequence of the light chain complementarity determining region (LCDR1, LCDR2, and LCDR3) is included. In such a case, the antibody or antigen-binding fragment thereof comprises the HCVR amino acid sequence of SEQ ID NO: 9; and No. 13, containing the LCVR amino acid sequence. International Publication No. WO2015 / 026907A1 is hereby incorporated by reference. No. 6,299,499, filed on Dec. 1, 2003, which is hereby incorporated in its entirety. Table A. Sequences of exemplary antibodies H1H7814N (anti-STEAP2) and H1H6958N2 (anti-PRLR) [Table 1]

[0113] The present disclosure provides an amino acid sequence selected from any of the HCVR amino acid sequences listed in Table A. or at least 90%, at least 95%, at least 98%, or HCVRs containing substantially similar sequences with at least 99% sequence identity, specific to STEAP2. Antibodies or antigen-binding fragments thereof that bind heterologously are provided.

[0114] The present disclosure also provides a method for the preparation of a LCVR comprising administering to a subject ... an amino acid sequence, or at least 90%, at least 95%, at least 98%, or or a STEA containing an LCVR containing a substantially similar sequence having at least 99% sequence identity. Antibodies or antigen-binding fragments thereof that specifically bind to P2 are also provided.

[0115] The present disclosure also provides a method for preparing a LCVR comprising the steps of: HCVR and LCVR amino acid sequence pairs (HCV Also provided are antibodies or antigen-binding fragments thereof that specifically bind to STEAP2, including those containing the R / LCVR. According to embodiments, the present disclosure provides a method for the treatment of STEAP2 comprising administering to a subject an antibody selected from the group consisting of: and (c) providing an antibody or an antigen-binding fragment thereof comprising the HCVR / LCVR amino acid sequence pair contained in In one embodiment, the HCVR / LCVR amino acid sequence pair is incorporated herein by reference in its entirety. 250 / 258; as described in International Publication No. WO2018 / 058001A1, which is incorporated herein by reference. is selected from.

[0116] The present disclosure also provides an amino acid sequence selected from any of the HCDR1 amino acid sequences listed in Table A. or at least 90%, at least 95%, at least 98%, or at least STE, including a heavy chain CDR1 (HCDR1) containing a sequence substantially similar thereto with 99% sequence identity. Antibodies or antigen-binding fragments thereof that specifically bind to AP2 are also provided.

[0117] The present disclosure also provides an amino acid sequence selected from any of the HCDR2 amino acid sequences listed in Table A. or at least 90%, at least 95%, at least 98%, or at least STE, including a heavy chain CDR2 (HCDR2) containing a sequence substantially similar thereto with 99% sequence identity. Antibodies or antigen-binding fragments thereof that specifically bind to AP2 are also provided.

[0118] The present disclosure also provides an amino acid sequence selected from any of the HCDR3 amino acid sequences listed in Table A. or at least 90%, at least 95%, at least 98%, or at least STE, comprising a heavy chain CDR3 (HCDR3) containing a sequence substantially similar thereto with 99% sequence identity. Antibodies or antigen-binding fragments thereof that specifically bind to AP2 are also provided.

[0119] The present disclosure also provides an LCDR1 amino acid sequence selected from any of the LCDR1 amino acid sequences listed in Table A. or at least 90%, at least 95%, at least 98%, or at least STE, including a light chain CDR1 (LCDR1) containing a sequence substantially similar thereto with 99% sequence identity. Antibodies or antigen-binding fragments thereof that specifically bind to AP2 are also provided.

[0120] The present disclosure also provides an LCDR2 amino acid sequence selected from any of the LCDR2 amino acid sequences listed in Table A. or at least 90%, at least 95%, at least 98%, or at least STE, including a light chain CDR2 (LCDR2) containing a sequence substantially similar thereto with 99% sequence identity. Antibodies or antigen-binding fragments thereof that specifically bind to AP2 are also provided.

[0121] The present disclosure also provides an LCDR3 amino acid sequence selected from any of the LCDR3 amino acid sequences listed in Table A. or at least 90%, at least 95%, at least 98%, or at least STE, including a light chain CDR3 (LCDR3) containing a sequence substantially similar thereto with 99% sequence identity. Antibodies or antigen-binding fragments thereof that specifically bind to AP2 are also provided.

[0122] The present disclosure also provides a method for producing a nucleotide sequence of a nucleotide analog ... HCDR3 and LCDR3 amino acid sequence pairs (HCDR3 / LCDR3) containing any of the listed HCDR3 amino acid sequences Also provided are antibodies or antigen-binding fragments thereof that specifically bind to STEAP2, including LCDR3. According to an embodiment, the present disclosure provides a method for the treatment of STEAP2 comprising administering to a subject an antibody selected from the group consisting of: and (c) providing an antibody or antigen-binding fragment thereof comprising the HCDR3 / LCDR3 amino acid sequence pair. In one embodiment, the HCDR3 / LCDR3 amino acid sequence pair is disclosed herein in its entirety by reference. 256 / 254; as described in International Publication No. WO2018 / 058001A1, the disclosure of which is incorporated herein by reference. are selected.

[0123] The present disclosure also provides a method for the treatment of STEAP2 comprising administering to a subject therapies ... STEAP2 contains six CDR sets (i.e., HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) that Also provided are antibodies or antigen-binding fragments thereof that specifically bind to HCDR The entire contents of the set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequences are incorporated herein by reference. Described in International Publication No. WO2018 / 058001A1, which is incorporated herein by reference: 252-254-256-260-262-26 4;

[0124] In related embodiments, the present disclosure provides any of the exemplary anti-STEAP2 antibodies listed in Table A. The six CDRs contained within the HCVR / LCVR amino acid sequence pair as defined by either HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) For example, the present disclosure is incorporated herein by reference in its entirety. as described in International Publication No. WO2018 / 058001A1:250 / 258; or HCDR1-HCDR2-HCDR3 contained within an HCVR / LCVR amino acid sequence pair selected from the group consisting of: -An antibody that specifically binds to STEAP2, comprising an LCDR1-LCDR2-LCDR3 amino acid sequence set, or and antigen-binding fragments. Methods and techniques for identifying CDRs within HCVR and LCVR amino acid sequences. are well known in the art and can be used to identify specific HCVRs disclosed herein. and / or CDRs within the LCVR amino acid sequence. Exemplary conventional methods that can be used include, for example, the Kabat definition, the Chothia definition, The Kabat definition is generally based on sequence variability, while the Chot The definition of hia is based on the location of the structural loop regions, and the definition of AbM is based on the Kabat approach and C For example, Kabat's paper, "Tan "Sequences of Proteins of Immunological Interest," National Institute of utes of Health, Bethesda, Md. (1991); Al-Lazikani et al., J. Mol. Biol. 273:927- 948 (1997); and Martin et al., Proc. Natl. Acad. Sci. USA 86:9268-9272 (1989). Public databases are also available to identify CDR sequences within antibodies.

[0125] The present disclosure provides an amino acid sequence selected from any of the HCVR amino acid sequences listed in Table A. or at least 90%, at least 95%, at least 98%, or Specific for PRLR, including HCVR containing substantially similar sequences with at least 99% sequence identity. The present invention provides an antibody or antigen-binding fragment thereof that specifically binds to the target protein.

[0126] The present disclosure also provides a method for the preparation of a LCVR comprising administering to a subject ... an amino acid sequence, or at least 90%, at least 95%, at least 98%, or or a PRLR containing an LCVR containing a substantially similar sequence having at least 99% sequence identity. Also provided is an antibody or antigen-binding fragment thereof that specifically binds to

[0127] The present disclosure also provides a method for preparing a LCVR comprising the steps of: HCVR and LCVR amino acid sequence pairs (HCV Also provided are antibodies or antigen-binding fragments thereof that specifically bind to PRLR, including PRLR / LCVR. According to an embodiment, the present disclosure provides a method for the treatment of PRLR comprising administering to a subject a therapeutic agent selected from the group consisting of: The present invention provides an antibody or antigen-binding fragment thereof comprising the HCVR / LCVR amino acid sequence pair. In certain embodiments, the HCVR / LCVR amino acid sequence pairs are those set forth in their entirety in the specification by reference. The present invention is described in International Publication No. WO2015 / 026907A1, which is incorporated herein by reference: 18 / 26; 66 / 74; 274 / 282; 290 / 298; and 370 / 378;

[0128] The present disclosure also provides an amino acid sequence selected from any of the HCDR1 amino acid sequences listed in Table A. or at least 90%, at least 95%, at least 98%, or at least PRL, including a heavy chain CDR1 (HCDR1) containing a sequence substantially similar thereto with 99% sequence identity. Antibodies or antigen-binding fragments thereof that specifically bind to R are also provided.

[0129] The present disclosure also provides an amino acid sequence selected from any of the HCDR2 amino acid sequences listed in Table A. or at least 90%, at least 95%, at least 98%, or at least PRL, including a heavy chain CDR2 (HCDR2) containing a sequence substantially similar thereto with 99% sequence identity. Antibodies or antigen-binding fragments thereof that specifically bind to R are also provided.

[0130] The present disclosure also provides an amino acid sequence selected from any of the HCDR3 amino acid sequences listed in Table A. or at least 90%, at least 95%, at least 98%, or at least PRL, including a heavy chain CDR3 (HCDR3) containing a sequence substantially similar thereto with 99% sequence identity. Antibodies or antigen-binding fragments thereof that specifically bind to R are also provided.

[0131] The present disclosure also provides an LCDR1 amino acid sequence selected from any of the LCDR1 amino acid sequences listed in Table A. or at least 90%, at least 95%, at least 98%, or at least PRL, including a light chain CDR1 (LCDR1) containing a sequence substantially similar thereto with 99% sequence identity. Antibodies or antigen-binding fragments thereof that specifically bind to R are also provided.

[0132] The present disclosure also provides an LCDR2 amino acid sequence selected from any of the LCDR2 amino acid sequences listed in Table A. or at least 90%, at least 95%, at least 98%, or at least PRL, including a light chain CDR2 (LCDR2) containing a sequence substantially similar thereto with 99% sequence identity. Antibodies or antigen-binding fragments thereof that specifically bind to R are also provided.

[0133] The present disclosure also provides an LCDR3 amino acid sequence selected from any of the LCDR3 amino acid sequences listed in Table A. or at least 90%, at least 95%, at least 98%, or at least PRL, including a light chain CDR3 (LCDR3) containing a sequence substantially similar thereto with 99% sequence identity. Antibodies or antigen-binding fragments thereof that specifically bind to R are also provided.

[0134] The present disclosure also provides a method for producing a nucleotide sequence of a nucleotide analog ... HCDR3 and LCDR3 amino acid sequence pairs (HCDR3 / LCDR3) containing any of the listed HCDR3 amino acid sequences Also provided are antibodies or antigen-binding fragments thereof that specifically bind to PRLR, including LCDR3. According to an embodiment, the present disclosure provides a method for the treatment of PRLR comprising administering to a subject a therapeutically effective amount of a compound comprising any of the exemplary anti-PRLR antibodies listed in Table A. The present invention provides an antibody or antigen-binding fragment thereof comprising the HCDR3 / LCDR3 amino acid sequence pair. In certain embodiments, the HCDR3 / LCDR3 amino acid sequence pair is incorporated herein by reference in its entirety.

[0010] As described in International Publication No. WO2015 / 026907A1, which is incorporated herein by reference: 24 / 32; 72 / 80; 280 / 28 8; 296 / 304; and 376 / 384;

[0135] The present disclosure also provides a method for the production of a 6-antibody comprising any of the exemplary anti-PRLR antibodies listed in Table A. PRLR-specific CDRs containing two sets of CDRs (i.e., HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3). Also provided are antibodies or antigen-binding fragments thereof that specifically bind to HCDR1-HCDR1. The 2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequence set is incorporated herein by reference in its entirety. No. WO2015 / 026907A1, incorporated herein by reference: 20-22-24-28-30-32; 68-7 0-72-76-78-80; 276-278-280-284-286-288; 292-294-296-300-302-304; and 372-374-376-38 0-382-384;

[0136] In related embodiments, the present disclosure provides any of the exemplary anti-PRLR antibodies listed in Table A. The six CDRs contained within the HCVR / LCVR amino acid sequence pair as defined by specifically binds to PRLR, including the set (i.e., HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) For example, the present disclosure is incorporated in its entirety by reference. No. WO 2015 / 026907 A1, incorporated herein by reference in its entirety: 18 / 26;66 HCVR / LCVR amino acid sequence pairs selected from the group consisting of: / 74; 274 / 282; 290 / 298; and 370 / 378; P, comprising a set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequences contained within The present invention includes antibodies or antigen-binding fragments thereof that specifically bind to RLR. Methods and techniques for identifying CDRs of a gene are well known in the art and are described herein. can be used to identify the CDRs within the particular HCVR and / or LCVR amino acid sequences shown. Exemplary routine methods that can be used to identify the boundaries of a CDR include, for example, Examples include the Kabat definition, the Chothia definition, and the AbM definition. The definition is based on sequence variability, the Chothia definition is based on the location of structural loop regions, and the AbM definition is based on the location of structural loop regions. The definition of is a compromise between Kabat's approach and Chothia's approach. For example, Kabat's The literature, "Sequences of Proteins of Immunological Interest" National Institutes of Health, Bethesda, Md. (1991); Al-Lazikani et al. J. Mol. Biol. 273:927-948 (1997); and Martin et al., Proc. Natl. Acad. S See, e.g., J. Med. USA 86:9268-9272 (1989). Public databases also provide CDR sequences within antibodies. can be used to identify

[0137] A binder linker is attached to a binder, e.g., an antibody or antigen-binding molecule, The conjugation can be achieved by attachment at specific amino acids within the functional molecule. Exemplary amino acid attachments that can be used in connection with the embodiments include, for example, lysine ( See, e.g., US5,208,020; US2010 / 0129314; Hollander et al., Bioconjugate Chem., 2008, 19:358-361; WO2005 / 089808; US 5,714,586; US 2013 / 0101546; and US 2012 / 0585592. cysteine ​​(e.g., US2007 / 0258987; WO2013 / 055993; WO2013 / 055990; WO2013 / 05 3873; WO2013 / 053872; WO2011 / 130598; US2013 / 0101546; and US 7,750,116). Selenocysteine ​​(e.g., WO2008 / 122039; and Hofer et al., Proc. Natl. Acad. Sci. , USA, 2008, 105:12451-12456), formylglycine (see, e.g., Carrico et al. Nat. Chem. Biol., 2007, 3:321-322; Agarwal et al., Proc. Natl. Acad. Sci ., USA, 2013, 110:46-51, and Rabuka et al., Nat. Protocols, 2012, 10:1052-1067 ), unnatural amino acids (see, e.g., WO2013 / 068874 and WO2012 / 166559 and acidic amino acids (see, for example, WO2012 / 05982). Anchoring can also be conjugated to antigen-binding proteins via carbohydrate attachment. (See, e.g., US2008 / 0305497, WO2014 / 065661, and Ryan et al., Food & Agriculture re Immunol., 2001, 13:127-130).

[0138] In some instances, the binding agent is an antibody or an antigen-binding molecule, and the antibody is In some embodiments, the antibody or antigen is attached to the linker via a nucleotide residue. The binding molecule is attached to the linker via a cysteine ​​residue.

[0139] Alternatively, the linker can be conjugated by transglutaminase-based chemoenzymatic conjugation. Alternatively, the conjugated nucleotides can be conjugated to one or more glutamine residues via a nucleotide sequence (e.g., Dennle (See, for example, the reference by R. et al., Bioconjugate Chem. 2014, 25, 569-578). In the presence of glutaminase, one or more glutamine residues of the antibody are converted to a primary amine compound. The primary amine compounds can be coupled to, for example, transglutaminase. and a PEG-1000 antibody-drug conjugate that directly provides antibody-drug conjugates via amine-mediated coupling. Primary amine compounds include those used in antibody drug conjugates. functionalized with reactive groups that can be subsequently reacted with additional compounds for the synthesis of carboxylates. Antibodies containing glutamine residues are also included. The antibody polypeptide may be modified to contain one or more glutamine residues. A technique for artificially creating glutamine residues in peptide chains (glutaminyl-modified antibodies or antigen-binding molecules) Methods are within the skill of those in the art. In certain embodiments, the antibody is aglycosylated. This was done.

[0140] In one embodiment, the antibody or glutaminyl-modified antibody or antigen-binding molecule , containing at least one glutamine residue in at least one polypeptide chain sequence. In embodiments, the antibody or glutaminyl-modified antibody or antigen-binding molecule, respectively, comprises In a further embodiment, the polypeptide comprises two heavy chains each having one Gln295 or Q295 residue. In this case, the antibody or glutaminyl-modified antibody or antigen-binding molecule is a The present invention relates to a method for the treatment of leukemia, including the treatment of leukemia, in which the heavy chain is treated with a leukemia inhibitor containing a N297Q mutation(s) at a site other than 295 of the heavy chain. Antibodies of this type are included herein.

[0141] (Primary amine compounds) In certain embodiments, transglutaminase of an antibody (or antigen-binding compound) containing glutamine is Primary amine compounds useful for amine-mediated coupling are those deemed useful by those skilled in the art. The primary amine compound can be any primary amine compound that can be prepared by the method of formula H2. It has the formula NR, where R can be any group that is compatible with the antibody and reaction conditions. In embodiments, R is alkyl, substituted alkyl, heteroalkyl, or substituted heteroaromatic alkyl. It's Rukiru.

[0142] In some embodiments, the primary amine compound has a reactive group or a protected reactive group. Useful reactive groups include azides, alkynes, cycloalkynes, thiols, alkane, cycloalkynes ... Cholesterol, ketone, aldehyde, carboxylic acid, ester, amide, hydrazide, aniline, In some embodiments, the reactive group is an azide, an alkyne, a sulfonyl group, or an amine. selected from the group consisting of hydryl, cycloalkyne, aldehyde, and carboxyl .

[0143] In certain embodiments, the primary amine compound is according to the formula HN-LL-X, where LL is a divalent spacer, and X is a reactive group or a protected reactive group. In one embodiment, LL is a divalent polyethylene glycol (PEG) group. In the above formula, X is selected from the group consisting of -SH, -N3, alkyne, aldehyde, and tetrazole. In certain embodiments, X is -N3.

[0144] In certain embodiments, the primary amine compound is according to one of the following formulas: H2N-(CH2) n -X; H2N-(CH2CH2O) n -(CH2) p -X; H2N-(CH2) n -N(H)C(O)-(CH2) m -X; H2N-(CH2CH2O) n -N(H)C(O)-(CH2CHO) m -(CH2) p -X; H2N-(CH2) n -C(O)N(H)-(CH2) m -X; H2N-(CH2CH2O) n -C(O)N(H)-(CH2CH2O) m -(CH2) p -X; H2N-(CH2) n -N(H)C(O)-(CH2CHO) m -(C H2) p -X; H2N-(CH2CH2O) n -N(H)C(O)-(CH2) m -X; H2N-(CH2) n -C(O)N(H)-(CH2CH2O) m -(CH2) p -X; and H2N-(CH2CH2O) n -C(O)N(H)-(CH2) m -X; (In the formula, n is an integer selected from 1 to 12; m is an integer selected from 0 to 12; p is an integer selected from 0 to 2; and X is -SH, -N3, -C≡CH, -C(O)H, tetrazole, and [ka] (selected from the group consisting of:

[0145] In the above, any alkyl or alkylene (i.e., -CH2-) group may be, for example, Ba, C 1-8 It can be optionally substituted with alkyl, methyl, formyl, or -SO3H. In embodiments, the alkyl group is unsubstituted.

[0146] In some embodiments, the primary amine compound is: [ka] is selected from the group consisting of:

[0147] In certain embodiments, the primary amine compound is [ka] is. Exemplary conditions for the above reactions are provided in the Examples below.

[0148] (Linker) In certain embodiments, the linker L portion of the conjugates described herein is A moiety that covalently links the combination to a payload compound described herein, e.g., For example, it is a bivalent moiety. In another example, the linker L couples the binder to a A trivalent or multivalent moiety that covalently links to a payload compound. Carr, for example, in Antibody-Drug Interactions, the contents of each of which are incorporated herein by reference in their entireties. Antibody-Drug Conjugates and Immunotoxins; Phillips, Edited by GL; Springer Verlag: New York, 2013; Antibody-Drug Conjugates Conjugates); edited by Ducry, L.; Humana Press, 2013; Antibody-Drug Conjugates ug Conjugates); Wang, J., Shen, W.-C., and Zaro, J.L. (eds.); Springer International Publishing, 2015. In some embodiments, the methods described herein The linker L portion of the linker-payload is covalently linked to the payload compounds described herein. A bond-linked moiety that connects a binding agent to a payload compound described herein. In another example, the present invention provides a method for the preparation of a hydroxyl group containing a hydroxyl group that is bivalent and capable of being linked by a covalent bond. The linker L portion of the linker-payload described herein may be any of the payloads described herein. a moiety covalently linked to the bond compound, and as a trivalent or multivalent moiety, can be covalently linked to a payload compound described herein. The payload compound is represented by the above formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VI II, Formula IX, Formula X, Formula XI, and Formula XII, which are linked to or incorporate a linker L. The residues following this are the linker-payload. The linker-payload can be further linked to an antibody or and binding to a binding agent, such as an antigen-binding fragment thereof, to form an antibody-drug conjugate. Those skilled in the art will appreciate that certain functional groups on the payload moiety may be linked to linkers and / or conjugates. It will be appreciated that it may be convenient to link the In one embodiment, the linker is absent and the payload is directly attached to the binding agent. In one embodiment, the payload comprises a linker comprising a terminal alkyne and an azide, wherein each azide The azides and azides participate in regioisomeric click chemistry to deliver the payload moiety. In another embodiment, the payload is a carboxylic acid and a linker. The present invention also includes a linking agent containing a lysine, wherein each carboxylic acid and the lysine are involved in amide bond formation. The payload moiety is directly attached to the binder moiety. amines (e.g., Formula C, Formula D, Formula LPc, and Formula LPd), quaternary ammonium ions (e.g., Formula A and Formula LPa), hydroxyl (e.g., Formula C, Formula D, Formula LPc, and Formula LPd), phosphate, carboxylic acids (e.g., in the form of an ester when linked to L, as in Formula B, Formula D, Formula LPb, and Formula LPd) form), hydrazides (e.g., of formula B and formula LPb), amides (e.g., from anilines of formula C and formula LPc Derived or amines of formula D and formula LPd), and sugars.

[0149] In some embodiments, the linker is stable under physiological conditions. The linker may be cleavable, for example, in the presence of an enzyme or at a particular pH range or value. At least the payload portion can be released. The car contains an enzymatically cleavable site. Exemplary enzymatically cleavable sites include peptide Examples of linkages include amide bonds, ester bonds, hydrazone bonds, β-glucuronide bonds, and disulfide bonds. In some embodiments, the linker is a catecholamine. In some embodiments, the linker comprises a β-glucan-cleavable linker. Glucose-cleavable (GUSB) linker (e.g., Creative Biolabs, creative-biolab s.com / adc / beta-glucuronide-linker.htm or ACS Med. Chem. Lett. 2010, 1: 277-280 See the GUSB linker in

[0150] In some embodiments, the linker comprises a non-cleavable site. In embodiments, the non-cleavable linker is [ka] or a residue thereof. In some embodiments, the non-cleavable linker-peptide The erode residue is [ka] or a positional isomer thereof. In some embodiments, the non-cleavable linker is [ka] or a residue thereof. In some embodiments, the non-cleavable linker-peptide The erode residue is [ka] or a positional isomer thereof. In one embodiment, the linker is maleimidocyclohexa carboxylate or 4-(N-maleimidomethyl)cyclohexanecarboxylic acid (MCC) In this structure, [ka] indicates attachment to a binding agent. In this structure, in some instances, [ka] For example, a coupling agent having an azide or alkyne functionality and a complementary alkyne or azide Click chemistry resulting from reaction of functionalized linker-payload In this structure, another example is [ka] For example, one or more linkers having maleimide functionality on one or more of the binding agents cysteines or a divalent stearate resulting from reaction with the linker-payload via a Michael addition reaction. In this structure, another example is [ka] As will be appreciated by those skilled in the art, the activity of, for example, one or more of the binding agents, lysine, one or more linkers having activated or non-activated carboxyl functionality or an amide bond resulting from reaction with the linker-payload. Leave, [ka] As will be appreciated by those skilled in the art, the present invention may be embodied in a variety of ways, for example, by combining one or more binding agents, lysine, and an active ingredient. one or more linkers or linker-payloads having a functionalized carboxyl functionality The resulting amide bond of the reaction is shown.

[0151] In some embodiments, suitable linkers include a single binding agent, e.g., an antibody. These include, but are not limited to, those chemically linked to two cysteine ​​residues in Such linkers do not bind to antibodies that are destroyed as a result of the conjugation process. The disulfide bonds in the hydroxylase may act to mimic the disulfide bonds in the hydroxylase.

[0152] In some embodiments, the linker comprises one or more amino acids. Acids include natural, unnatural, standard, non-standard, proteinogenic, and non-proteinogenic. and L- or D-α-amino acids. In some embodiments, the linker is Alanine, valine, glycine, leucine, isoleucine, methionine, tryptophan, Phenylalanine, proline, serine, threonine, cysteine, tyrosine, asparagus glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, or citrulline, its derivatives, or combinations thereof (e.g., dipeptides, tripeptides, In some embodiments, one or more of the amino acids is linked to a side chain group described below. is a peptide comprising or consisting of the amino acids valine and citrulline (e.g., In some embodiments, the linker is an amino A peptide containing or consisting of the amino acid alanine and alanine, or the divalent -AA-. In some embodiments, the linker comprises the amino acids glutamic acid and alanine or -EA-. In some embodiments, the linker is a peptide comprising or consisting of It is a peptide comprising or consisting of the amino acids glutamic acid and glycine, or -EG-. In some embodiments, the linker comprises the amino acids glycine and glycine, or -GG-. In some embodiments, the linker is a peptide comprising or consisting of containing the amino acids glutamine, valine, and citrulline, or -QV-Cit- or -QVCit- In some embodiments, the linker is a peptide consisting of the amino acid group containing or containing glutamic acid, valine, and citrulline, or -EV-Cit- or -EVCit- In some embodiments, the linker is a peptide consisting of the amino acids -GGGGS- In some embodiments, the linker is a peptide comprising or consisting of: A peptide comprising or consisting of the amino acids -GGGGGG-. In some cases, the linker is a peptide comprising or consisting of the amino acids -GGGGK-. In this embodiment, the linker is a peptide comprising or consisting of the amino acids -GFGG-. In some embodiments, the linker is selected from the amino acids lysine, valine, and citric acid. In some embodiments, the peptide comprises or consists of -KVCit-, -KVCit-, or -KVCit-. In some cases, the linker is a peptide comprising or consisting of the amino acid -KVA-. In this embodiment, the linker is a peptide comprising or consisting of the amino acid -VA-. In any of the embodiments in this paragraph, and throughout this disclosure: Standard three-letter or one-letter amino acid names are used as will be recognized by those skilled in the art. Exemplary single-letter amino acid names include G for glycine, K for lysine, These include S for serine, V for valine, A for alanine, and F for phenylalanine.

[0153] In some embodiments, the linker comprises a self-immolative group. In certain embodiments, the self-immolative group is a p-amino group. Useful derivatives include p-aminobenzyloxybenzoates (PAB) and their derivatives. Those skilled in the art will appreciate that the self-immolative group can separate the remainder of the linker from the payload. You will be aware that chemical reactions can be carried out that release atoms.

[0154] In some embodiments, the linker is: [ka] is (In the formula: SP 1 is a spacer; SP 2 is a spacer; [ka] is one or more bonds to the binding agent; [ka] is one or more bindings to the payload; each AA is an amino acid residue; and and n is an integer from 1 to 10.

[0155] SP 1 The spacer is (AA) n The site or residue is attached to the binding agent (BA) or to a reactive group attached to the BA. The site of attachment to the residue. 1 The spacer may be an alkylene or poly The spacer may include, but is not limited to, those containing an ether, or both. The terminus, for example, the portion attached to BA or AA of the spacer, is used for the chemical synthesis of the conjugate. A reactive site is provided between the spacer and the antibody or AA. In certain embodiments, n is 1, 2, 3, or 4. In certain embodiments, n is 2. In certain embodiments, n is 3. and n is 4.

[0156] In some embodiments, SP 1 The spacer comprises an alkylene. In an embodiment, SP 1 The spacer is C 5-7 In some embodiments, the alkylene , SP 1 The spacer comprises a polyether. In some embodiments, SP 1 Spacer includes polymers of ethylene oxide such as polyethylene glycol.

[0157] In some embodiments, SP 1 Spacers are: [ka] is (In the formula: RG′ is the reactive group residue resulting from reaction of the reactive group RG with the binder; [ka] is the bond to the binding agent; [ka] is (AA) n wherein n is an integer from 1 to 10; and and b is an integer from 2 to 8.

[0158] It will be appreciated by those skilled in the art that the reactive group RG is capable of forming one or more bonds to a binding agent. The reactive group RG can be any known reactive group. The reactive group RG has a structure that allows it to bond with the binder. reacting (e.g., with an antibody at its cysteine ​​or lysine residues, or at an azide site, e.g., For example, a PEG-N3 functionalized antibody is reacted with one or more glutamine residues to form a compound of formula A, formula A', formula B, or formula B'. , a moiety that can form a compound of Formula C, Formula C', Formula D, or Formula D'. After conjugation to a binding agent, the reactive group becomes a reactive group residue (RG′). Reactive groups include haloacetyl, isothiocyanate, and the like, which can react with the binder. Examples include those containing succinimide, N-hydroxysuccinimide, or maleimide moieties. Examples include, but are not limited to:

[0159] In some embodiments, reactive groups include, but are not limited to, alkynes. In certain embodiments, the alkyne can be substituted in the absence of a copper catalyst, such as a strained alkyne. Strained alkynes are alkynes that can undergo 1,3-cycloaddition with diazides. Suitable for cycloalkyne-azide cycloaddition (SPAAC) to cycloalkynes, e.g., cyclooctadecyl azide Suitable alkynes include dibenzoazacycloalkynes, dibenzoazacycloalkynes, and aromatic alkynes. Octine or [ka] Dibenzocyclooctyne or [ka] Biarylazacyclooctynone or [ka] Difluorinated cyclooctyne or [ka] Substituted, e.g., fluorinated alkynes, aza-cycloalkynes, bicycles [6.1. bicycle[6.1.0]nonyne or [ka] and derivatives thereof. Particularly useful alkynes include, but are not limited to, teeth, [ka] Examples include:

[0160] In some embodiments, the binding agent is directly bound to RG'. The binding agent may be a spacer, e.g., [ka] SP located between and RG′ 4 In certain embodiments, the bond is The combination drug is SP 4 , for example, indirectly linked to RG′ via a PEG spacer. As discussed above, in certain embodiments, the linking agent may be functionalized with one or more azide groups. Each azide group can react with RG to form RG′. In one embodiment, the binding agent is derivatized with -PEG-N3 linked to a glutamine residue. Exemplary -N3 derivatized binders, methods for their preparation, and their reactivity with RG are described. Methods for their use in the treatment of rhesus malabsorption are provided herein. In certain embodiments, RG is , is an alkyne suitable for participating in a 1,3-cycloaddition, and RG′ is an azide-functionalized linking agent of RG. The regioisomeric 1,2,3-triazolyl moieties formed in the reaction are: In an embodiment, RG′ is [ka] or a mixture of each positional isomer. Each R and R' is linked to a linking agent as shown in the As described or illustrated in the document.

[0161] SP 2 The spacer, when present, is (AA) n This is the part that connects the part to the payload. Suitable spacers include SP 1 The spacers mentioned above are The present invention is not limited to the above. 2 The spacer may be an alkylene or a polyether. SP 2 End of spacer The end, e.g., the portion of the spacer directly attached to the payload or AA of the conjugate During chemical synthesis, the payload or AA is added to the SP. 2 Used for coupling to a spacer In some instances, the SP 2 Spacer end For example, the SP 2 The portion of the spacer directly attached to the payload or AA is the conjugate used to couple the payload or AA to the spacer during chemical synthesis of The residue may be a reactive site residue.

[0162] In some embodiments, SP 2 The spacer, when present, is -NH-(p-CH)-CH 2-, -NH-(p-C6H4)-CH2OC(O)-, amino acids, dipeptides, tripeptides, oligopeptides, -O-, -N(H)-, [ka] and any combination thereof. In some embodiments, each [ka] is a binding to the payload, and each [ka] is (AA) n is a bond to

[0163] In the above formula, each (AA) n is an amino acid or, optionally, p-aminobenzyl oxycarbonyl residue (PABC), [ka] If a PABC is present, preferably only one PABC is present. , PABC residues, if present, are closer to the payload (AA) n Binds to the terminal AA in the group are. [ka] But if it exists, [ka] Preferably, only [ka] The residue, if present, is attached to the payload via a benzyloxycarbonyl moiety. The amino acids suitable for each AA are natural, unnatural, and standard. These include non-standard, proteinogenic, non-proteinogenic, and L- or D-α-amino acids. In some embodiments, AA is alanine, valine, leucine, isoleucine, or threonine, methionine, tryptophan, phenylalanine, proline, serine, threonine, Cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, arginine, histidine, or citrulline, or a derivative thereof, or any of them Combinations (e.g., dipeptides, tripeptides, and oligopeptides, etc.) are included. In embodiments, one or more side chains of the amino acid are linked to a side chain group as described below. In some embodiments, n is 2. In some embodiments, (AA) n Is, Balin-Sito In some embodiments, (AA) n is citrulline-valine. In some embodiments, (AA) n is valine-alanine. (AA) n is alanine-valine. In some embodiments, (AA) n Ha, ballin- In some embodiments, (AA) is glycine. n is glycine-valine. In some embodiments, n is 3. In some embodiments, (AA) n Is Bali In some embodiments, (AA) n Citrulline-Valine In some embodiments, (AA) n Glutamic acid-valine-citrulline In some embodiments, (AA) n is glutamine-valine-citrulline In some embodiments, (AA) nis lysine-valine-alanine. In an embodiment, (AA) n is lysine-valine-citrulline. In some embodiments, n is 4. n is glutamic acid-valine- Citrulline-PAB. In some embodiments, (AA) n is glutamine-valine-sulfate Those skilled in the art will recognize PABC as having the following structure: [ka] The PABC residue is a p-aminobenzyloxycarbonyl residue. , which have been shown to promote cleavage of certain linkers in vitro and in vivo. Those skilled in the art will recognize PAB as the divalent residue of p-aminobenzyl, i.e., -NH-(p-C6H4)-CH2-. It will be.

[0164] In some embodiments, the linker is: [ka] TIFF2024167209000142.tif231170TIFF2024167209000143.tif59170 (In the formula, each [ka] is the binding to the binding agent; each [ka] is the binding to the payload; Each R 9 is —CH or —(CH)N(H)C(O)NH; and Each A is -O-, -NH-, [ka] where ZZ is hydrogen or the side chain of an amino acid described elsewhere herein. For example, in one embodiment, ZZ is C 1-6 Further examples include alkyl. In one embodiment, ZZ is C 1-6 Heteroalkyl. Specific embodiments of this paragraph wherein A may be derived from a primary amine compound or a residue thereof, and wherein X is As explained elsewhere in the specification, -N3. The riazole residue can be converted from the azide to the alkyl group of a compound or payload described herein. or terminal acetylenes, as described elsewhere herein. - is derived after participating in the reaction. Thus, in one non-limiting example, A is [ka] or a mixture thereof. Alternatively, in another embodiment, A is [ka] or a mixture thereof. In another embodiment, A is [ka] or a mixture thereof. In another embodiment, A is [ka] or a mixture thereof. As mentioned above, the binding to the binding agent can be direct or In some embodiments, the binding to the binding agent may be via a spacer. In this case, the binding is to a glutamine residue of the binding agent via a PEG spacer.

[0165] In some embodiments, the linker is: [ka] is (In the formula: each [ka] is the binding to the binding agent; each [ka] is the binding to the payload; Each R 9 is —CH or —(CH)N(H)C(O)NH; and Each A is -O-, -N(H)-, [ka] where ZZ is hydrogen or the side chain of an amino acid described elsewhere herein. For example, in one embodiment, ZZ is C 1-6 As a further example, in one embodiment In this case, ZZ is C 1-6 In certain embodiments of this paragraph, A may be derived from a primary amine compound or residue thereof, where X is any of the groups defined herein. In these embodiments, the 1,2,3-triazole is -N3 as described in The residue can be converted from the azide to an alkyne or terminal end of a compound or payload described herein. to a click chemistry reaction with acetylene as described elsewhere herein. Thus, in one non-limiting example, A is [ka] or a mixture thereof. Alternatively, in another embodiment, A is [ka] or a mixture thereof. In another embodiment, A is [ka] or a mixture thereof. In another embodiment, A is [ka] or a mixture thereof. As mentioned above, the binding to the binding agent can be direct or In some embodiments, the binding to the binding agent may be via a spacer. In this case, the binding is to a glutamine residue of the binding agent via a PEG spacer.

[0166] In any of the above embodiments, (AA) n The group can be modified with one or more reinforcing groups. Advantageously, the reinforcing group is (AA) n It can be linked to the side chain of any amino acid in the Amino acids useful for attaching strengthening groups include lysine, asparagine, and The link to the reinforcing group is an amino acid. The linkage can be a direct bond to the amino acid side chain, or the linkage can be mediated by a spacer and / or a reactive Useful spacer and reactive groups include: The reinforcing group may be any of those deemed useful by one of skill in the art. For example, the enhancing group can be a group that exhibits, but is not limited to, a biological effect, Biochemical, synthetic, solubilizing, imaging, detecting, and reactive functions The beneficial effects, including but not limited to, the compound, payload, linker-payload, or antibody conjugate, In some embodiments, the enhancing group is a hydrophilic group. In some embodiments, the reinforcing group is a cyclodextrin. In the formula (I), the reinforcing group is alkyl, heteroalkyl, alkylenyl, heteroalkylenyls. sulfonic acid, heteroalkylenyl taurine, heteroalkylenyl phosphate or phosphate a heteroalkylenyl amine (e.g., a quaternary amine), or a heteroalkylenyl sugar. In some embodiments, sugars include, but are not limited to, monosaccharides, Exemplary monosaccharides include disaccharides and polysaccharides. are glucose, ribose, deoxyribose, xylose, arabinose, and mannose. , galactose, fructose, etc. In some embodiments, the sugars and sugar acids such as glucuronic acid, as well as conjugated sugar acids such as glucuronides. Exemplary disaccharides include: Examples include maltose, sucrose, lactose, lactulose, and trehalose. Exemplary polysaccharides include amylose, amylopectin, glycogen, Examples of cyclodextrin include cyclodextrin, inulin, cellulose, etc. The cyclodextrin may be any cyclodextrin. The cyclodextrins are alpha cyclodextrin, beta cyclodextrin, or gamma cyclodextrin. In some embodiments, the cyclodextrin is a cyclodextrin, or a mixture thereof. is alpha cyclodextrin. In some embodiments, the cyclodextrin is In some embodiments, the cyclodextrin is a galactosidase inhibitor. In some embodiments, the enhancing group is a cyclodextrin. In some embodiments, alkyl, The heteroalkyl, alkylenyl, or heteroalkylenyl sulfonic acid may be substituted or unsubstituted. In some embodiments, alkyl, heteroalkyl, alkylenyl, or heteroaryl is substituted. Tetraalkylenylsulfonic acid is -(CH2) 1-5 SO3H, -(CH2) n -NH-(CH2) 1-5 SO3H, -(CH2) n -C( O)NH-(CH2) 1-5 SO3H, -(CH2CH2O) m -C(O)NH-(CH2) 1-5 SO3H, -(CH2) n -N((CH2) 1-5 C(O)NH(CH2 ) 1-5 SO3H)2, -(CH2) n -C(O)N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H)2, or -(CH2CH2O) m -C(O)N((C H2) 1-5 C(O)NH(CH2) 1-5 SO3H2 (wherein n is 1, 2, 3, 4, or 5 and m is 1, 2, 3, , 4, or 5). In one embodiment, alkyl or alkylenyl sulfonic acid is -(CH2) 1-5 In another embodiment, heteroalkyl or heteroalkylene Nilsulfonic acid is -(CH2) n -NH-(CH2) 1-5SO3H (wherein n is 1, 2, 3, 4, or 5) In another embodiment, alkyl, heteroalkyl, alkylenyl, or heteroaromatic groups are Alkylenylsulfonic acid is -(CH2) n -C(O)NH-(CH2) 1-5 SO3H (wherein n is 1, 2, 3, 4, or 5 In another embodiment, alkyl, heteroalkyl, alkylenyl, or Heteroalkylenyl sulfonic acid is -(CH2CH2O) m -C(O)NH-(CH2) 1-5 SO3H (where m is 1, In another embodiment, alkyl, heteroalkyl, aryl, arylsulfonyl ... Alkylenyl or heteroalkylenyl sulfonic acids are -(CH2) n -N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H2, where n is 1, 2, 3, 4, or 5. In another embodiment, alkyl , heteroalkyl, alkylenyl, or heteroalkylenyl sulfonic acids are —(CH2) n -C(O) N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H2 (where n is 1, 2, 3, 4, or 5). In some embodiments, alkyl, heteroalkyl, alkylenyl, or heteroalkylenyls may be used. Sulfonic acid is -(CH2CH2O) m -C(O)N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H2 (where m is 1, 2, 3, 4 or 5). In some embodiments, the linker is: [ka] is (In the formula: SP 1 is a spacer; SP 2 is a spacer; SP 3 is (AA) n a spacer linked to one AA of [ka] is one or more bonds to the binding agent; [ka] is one or more bindings to the payload; [ka] is one or more bonds to the strengthening group EG; each AA is an amino acid; and (n is an integer from 1 to 10). As mentioned above, the binding to the binding agent should be direct. In some embodiments, the binding agent may be attached to the hydroxyl group of the hydroxyl group or via a spacer. Conjugation is via a PEG spacer to a glutamine residue of the binding agent.

[0167] SP 1 The spacer group is as described above. SP 2 The spacer group is as described above. A) n The groups are as defined above.

[0168] SP 3 The spacer is (AA) n A moiety that connects the moiety to the reinforcing group (EG). 3 Spacer Examples of the alkylene include those containing alkylene or polyether, or both. Not limited to these. SP 3 The end of the spacer, i.e., the SP 3 Spacer reinforcement group or AA The moiety directly attached to SP is the one that attaches the reinforcing group or AA to the SP during chemical synthesis of the conjugate. 3 Space The moiety may be derived from a reactive site used for coupling to the hydroxyl group. In the example, SP 3 The end of the spacer, i.e., the reinforcing group or AA of the spacer, is directly bonded to the The conjugated moiety couples the reinforcing group or AA to the spacer during chemical synthesis of the conjugate. In one embodiment, SP 3 is (AA) n In one embodiment, the spacer is linked to only one AA of , SP 3 The spacer is (AA) n is linked to the side chain of a lysine residue of

[0169] In some embodiments, SP 3 Spacers are: [ka] is (In the formula: RG′ is the reactive group residue resulting from reaction of the reactive group RG with the toughening agent EG; [ka] is the bond to the reinforcer; [ka] is (AA) n is a bond to; a is an integer from 2 to 8; and and n is an integer from 1 to 4.

[0170] It will be appreciated by those skilled in the art that the reactive group RG is capable of forming one or more bonds to the toughening agent. The reactive group RG can be any reactive group known in the art. The reactive group RG reacts with the reinforcing group to form a compound of the formula LPa , Formula LPb, Formula LPc, Formula LPd, Formula LPa', Formula LPb', Formula LPc', Formula LPd', Formula A, Formula B, Formula C, Formula D, A moiety capable of forming a compound of formula A', formula B', formula C', formula D', or formula A'' is After conjugation to the reinforcing group, the reactive group is a reactive group residue. (RG′). The reactive group RG can be any of the reactive groups described above. Exemplary Reactions The functional groups include haloacetyl, isothiocyanate, succinate, etc., which can react with the binder. and those containing an N-hydroxysuccinimide, N-hydroxysuccinimide, or maleimide moiety. However, the present invention is not limited to these.

[0171] In certain embodiments, reactive groups include, but are not limited to, alkynes. In certain embodiments, the alkyne is an alkyne that can be substituted in the absence of a copper catalyst, such as a strained alkyne. Strained alkynes are alkynes that can undergo 1,3-cycloaddition with diazides. Suitable for cycloalkyne-azide cycloaddition (SPAAC) to cycloalkynes, e.g., cyclooctadecyl azide Suitable alkynes include dibenzoazacyclooctamethylbenzoates, dibenzoazacyclooctamethylbenzoates, and aromatic alkynes. Chin or [ka] Dibenzocyclooctyne or [ka] Biarylazacyclooctynone or [ka] Difluorinated cyclooctyne or [ka] Substituted, e.g., fluorinated alkynes, aza-cycloalkynes, bicycles [6.1. bicycle[6.1.0]nonyne or [ka] and derivatives thereof. Particularly useful alkynes include, but are not limited to, teeth, [ka] Examples include:

[0172] In some embodiments, the linker is: [ka] is (In the formula: RG′ is the reactive group residue resulting from reaction of the reactive group RG with the binder; PEG is -NH-PEG4-C(O)-; SP 2 is a spacer; SP 3 is (AA) n a spacer linked to one AA residue of [ka] is one or more bonds to the binding agent; [ka] is one or more bindings to the payload; [ka] is one or more bonds to the strengthening group EG; each AA is an amino acid residue; and and n is an integer from 1 to 10. As mentioned above, the attachment to the binding agent can be direct or via a spacer. In some embodiments, the attachment to the binding agent is via a PEG spacer. All of the binding agents are to glutamine residues.

[0173] In some embodiments, the linker is: [ka] or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, or or a mixture of the positional isomers (In the formula: each [ka] is the binding to the binding agent; each [ka] is the binding to the payload; each [ka] is the bond to the reinforcer; Each R 9 is —CH or —(CH)N(H)C(O)NH; and Each A is -O-, -N(H)-, [ka] where ZZ is hydrogen or the side chain of an amino acid described elsewhere herein. For example, in one embodiment, ZZ is C 1-6 As a further example, in one embodiment In this case, ZZ is C 1-6 In certain embodiments of this paragraph, A may be derived from a primary amine compound or residue thereof, where X is any of the groups defined herein. In these embodiments, the 1,2,3-triazole is -N3 as described in The residue can be converted from the azide to an alkyne or terminal end of a compound or payload described herein. to a click chemistry reaction with acetylene as described elsewhere herein. Thus, in one non-limiting example, A is [ka] or a mixture thereof. Alternatively, in another embodiment, A is [ka] or a mixture thereof. In another embodiment, A is [ka] or a mixture thereof. In another embodiment, A is [ka] or a mixture thereof. In some embodiments, the 1,3-cycloaddition or SPAAC positions A mixture of isomers or positional isomers can be prepared from PEG-N3 derivatized antibodies treated with the appropriate alkyne. For example, in one embodiment, the linker is derivatized as: [ka] or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, or a positional isomer thereof As a further example, in one embodiment, The linker: [ka] or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, or a positional isomer thereof As a further example, the linker may be: [ka] or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, or a positional isomer thereof As a further example, in one embodiment, The linker: [ka] or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, or a positional isomer thereof As mentioned above, the binding to the binding agent can be performed by direct In some embodiments, the hydroxyl group may be a hydroxyl group or a spacer. The binding to the binder is via a PEG spacer to the glutamine residue of the binder. In some embodiments, the strengthening agent is a hydrophilic group. In some embodiments, the enhancing group is alkyl, hetero Alkyl, alkylenyl, heteroalkylenyl sulfonic acids, heteroalkylenyl taurines , heteroalkylenyl phosphoric acid or phosphate, heteroalkylenyl amine (e.g. , quaternary amine), or heteroalkylenyl sugar. These include, but are not limited to, monosaccharides, disaccharides, and polysaccharides. Exemplary monosaccharides include glucose, ribose, deoxyribonucleotides, and the like. Ribose, xylose, arabinose, mannose, galactose, fructose, etc. In some embodiments, the sugars include sugar acids such as glucuronic acid. , and conjugated forms such as glucuronides (i.e., glucuronidation) Exemplary disaccharides include maltose, sucrose, Examples of polysaccharides include lactose, lactulose, trehalose, etc. Examples include amylose, amylopectin, glycogen, inulin, and cellulose. The cyclodextrin may be any cyclodextrin known to those skilled in the art. In some embodiments, the cyclodextrin is alpha cyclodextrin. , beta cyclodextrin, or gamma cyclodextrin, or mixtures thereof In some embodiments, the cyclodextrin is alpha cyclodextrin. In some embodiments, the cyclodextrin is a beta cyclodextrin. In some embodiments, the cyclodextrin is gamma cyclodextrin. In certain embodiments, alkyl, heteroalkyl, alkylenyl, or heteroalkyleny Sulfonic acid is -(CH2) 1-5 SO3H, -(CH2) n -NH-(CH2) 1-5 SO3H, -(CH2) n -C(O)NH-(CH2) 1-5 S OH, -(CHCHO) m -C(O)NH-(CH2) 1-5 SO3H, -(CH2) n -N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H)2, -( CH2) n -C(O)N((CH2) 1-5 C(O)NH(CH2) 1-5SO3H)2, or -(CH2CH2O) m -C(O)N((CH2) 1-5 C(O)NH(C H2) 1-5 SO3H2 (where n is 1, 2, 3, 4, or 5 and m is 1, 2, 3, 4, or 5) In one embodiment, the alkyl or alkylenyl sulfonic acid is —(CH) 1-5 SO 3H. In another embodiment, the heteroalkyl or heteroalkylenyl sulfonic acid is , -(CH2) n -NH-(CH2) 1-5 SO3H, where n is 1, 2, 3, 4, or 5. In the above, alkyl, heteroalkyl, alkylenyl, or heteroalkylenyl sulfo Phosphoric acid is -(CH2) n -C(O)NH-(CH2) 1-5 SO3H (where n is 1, 2, 3, 4, or 5). In another embodiment, alkyl, heteroalkyl, alkylenyl, or heteroalkylene Nilsulfonic acid is -(CH2CH2O) m -C(O)NH-(CH2) 1-5 SO3H (where m is 1, 2, 3, 4, or 5) In another embodiment, alkyl, heteroalkyl, alkylenyl, or Heteroalkylenyl sulfonic acids are -(CH2) n -N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H2 (where n is , 1, 2, 3, 4, or 5). In another embodiment, alkyl, heteroalkyl , alkylenyl, or heteroalkylenyl sulfonic acids are —(CH2) n -C(O)N((CH2) 1-5 C(O)NH (CH2) 1-5SO3H2, where n is 1, 2, 3, 4, or 5. In another embodiment, The alkyl, heteroalkyl, alkylenyl, or heteroalkylenyl sulfonic acid is —(CH 2CH2O) m -C(O)N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H2, where m is 1, 2, 3, 4, or 5. be.

[0174] In some embodiments, the linker is: [ka] or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, or or a mixture of positional isomers thereof (In the formula: each [ka] is the binding to the binding agent; each [ka] is the bond to the reinforcer; each [ka] is the binding to the payload; Each R 9 is —CH or —(CH)N(H)C(O)NH; and Each A is -O-, -N(H)-, [ka] where ZZ is hydrogen or the side chain of an amino acid described elsewhere herein. For example, in one embodiment, ZZ is C 1-6 As a further example, in one embodiment In this way, ZZ is C 1-6 In certain embodiments of this paragraph, , A may be derived from a primary amine compound or residue thereof, where X is as defined herein. and -N3, as described elsewhere. In these embodiments, 1,2,3-triazoline is The alkyl residue can be converted from the azide to the alkyne or terminal of a compound or payload described herein. to a click chemistry reaction as described elsewhere herein with a terminal acetylene Thus, in one non-limiting example, A is [ka] or a mixture thereof. Alternatively, in another embodiment, A is [ka] or a mixture thereof. In another embodiment, A is [ka] or a mixture thereof. In another embodiment, A is [ka] or a mixture thereof. As mentioned above, the binding to the binding agent can be direct or In some embodiments, the binding to the binding agent may be via a spacer. In some cases, the binding agent is attached to a glutamine residue via a PEG spacer. In some embodiments, the enhancer is a hydrophilic group. In some embodiments, the reinforcing group is an alkyl, heteroalkyl, alkylene, Heteroalkylenyl, heteroalkylenyl sulfonic acid, heteroalkylenyl taurine, heteroalkylenyl a heteroalkylenyl amine (e.g., a quaternary amine), or is a heteroalkylenyl sugar. In some embodiments, the sugars include, but are not limited to: Examples include, but are not limited to, monosaccharides, disaccharides, and polysaccharides. Typical monosaccharides include glucose, ribose, deoxyribose, and xylose. Examples of sugars include arabinose, mannose, galactose, and fructose. In an embodiment, the sugars include sugar acids such as glucuronic acid, and further, glucuronic acid Conjugated forms (i.e., by glucuronidation) such as thiazol-2-one and thiazol-2-one Exemplary disaccharides include maltose, sucrose, lactose, lactulose, and Exemplary polysaccharides include amylose, trehalose, and the like. , amylopectin, glycogen, inulin, cellulose, etc. The cyclodextrin can be any cyclodextrin known to those of skill in the art. In this regard, cyclodextrins include alpha cyclodextrin, beta cyclodextrin, cyclodextrin, or gamma cyclodextrin, or a mixture thereof. In one embodiment, the cyclodextrin is alpha cyclodextrin. In some embodiments, the cyclodextrin is a beta cyclodextrin. In one embodiment, the cyclodextrin is gamma cyclodextrin. The alkyl, heteroalkyl, alkylenyl, or heteroalkylenyl sulfonic acid is —(CH 2) 1-5 SO3H, -(CH2) n -NH-(CH2) 1-5 SO3H, -(CH2) n-C(O)NH-(CH2) 1-5 SO3H, -(CH2CH2O) m -C(O )NH-(CH2) 1-5 SO3H, -(CH2) n -N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H)2, -(CH2) n -C(O)N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H)2, or -(CH2CH2O) m -C(O)N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H)2(where n is 1, 2, 3, 4, or 5, and m is 1, 2, 3, 4, or 5. In the formula, the alkyl or alkylenyl sulfonic acid is —(CH2) 1-5 SO3H. In the above, the heteroalkyl or heteroalkylenyl sulfonic acid is —(CH) n -NH-(CH2) 1- 5SO3H, where n is 1, 2, 3, 4, or 5. In another embodiment, alkyl , heteroalkyl, alkylenyl, or heteroalkylenyl sulfonic acids are —(CH2) n -C(O) NH-(CH2) 1-5 SO3H, where n is 1, 2, 3, 4, or 5. In another embodiment , alkyl, heteroalkyl, alkylenyl, or heteroalkylenyl sulfonic acids are -( CH2CH2O) m -C(O)NH-(CH2) 1-5 SO3H (where m is 1, 2, 3, 4, or 5). In some embodiments, alkyl, heteroalkyl, alkylenyl, or heteroalkylenyls may be used. Sulfonic acid is -(CH2) n-N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H2 (wherein n is 1, 2, 3, 4, or 5) In another embodiment, alkyl, heteroalkyl, alkylenyl, or Heteroalkylenyl sulfonic acids are -(CH2) n -C(O)N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H)2(formula wherein n is 1, 2, 3, 4, or 5. In another embodiment, alkyl, hetero The alkyl, alkylenyl, or heteroalkylenyl sulfonic acid is —(CH2CH2O) m -C(O)N((C H2) 1-5 C(O)NH(CH2) 1-5 SO3H2, where m is 1, 2, 3, 4, or 5.

[0175] In some embodiments, the linker is: [ka] TIFF2024167209000199.tif124170, or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, or or a mixture of positional isomers thereof (In the formula: each [ka] is the binding to the binding agent; each [ka] is the binding to the payload; R 9 is —CH or —(CH)N(H)C(O)NH; and A is -O-, -N(H)-, [ka] where ZZ is hydrogen or the side chain of an amino acid described elsewhere herein. For example, in one embodiment, ZZ is C 1-6 As a further example, in one embodiment In this way, ZZ is C 1-6 In certain embodiments of this paragraph, , A may be derived from a primary amine compound or residue thereof, where X is as defined herein. and -N3, as described elsewhere. In these embodiments, 1,2,3-triazoline is The alkyl residue can be converted from the azide to the alkyne or terminal of a compound or payload described herein. to a click chemistry reaction as described elsewhere herein with a terminal acetylene Thus, in one non-limiting example, A is [ka] or a mixture thereof. Alternatively, in another embodiment, A is [ka] or a mixture thereof. In another embodiment, A is [ka] or a mixture thereof. In another embodiment, A is [ka] or a mixture thereof. As mentioned above, the binding to the binding agent can be direct or In some embodiments, the binding to the binding agent may be via a spacer. In this case, the binding is to a glutamine residue of the binding agent via a PEG spacer.

[0176] In some embodiments, the linker is: [ka] TIFF2024167209000208.tif205170, or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, or or a mixture of positional isomers thereof (In the formula: each [ka] is the binding to the binding agent; each [ka] is the binding to the payload; R 9 is —CH or —(CH)N(H)C(O)NH; and A is -O-, -N(H)-, [ka] where ZZ is hydrogen or the side chain of an amino acid described elsewhere herein. For example, in one embodiment, ZZ is C 1-6 As a further example, in one embodiment In this way, ZZ is C 1-6 In certain embodiments of this paragraph, , A may be derived from a primary amine compound or residue thereof, where X is as defined herein. and -N3, as described elsewhere. In these embodiments, 1,2,3-triazoline is The alkyl residue can be converted from the azide to the alkyne or terminal of a compound or payload described herein. to a click chemistry reaction as described elsewhere herein with a terminal acetylene Thus, in one non-limiting example, A is [ka] or a mixture thereof. Alternatively, in another embodiment, A is [ka] or a mixture thereof. In another embodiment, A is [ka] or a mixture thereof. In another embodiment, A is [ka] or a mixture thereof. As mentioned above, the binding to the binding agent can be direct or In some embodiments, the binding to the binding agent may be via a spacer. In this case, the binding is to a glutamine residue of the binding agent via a PEG spacer.

[0177] In some embodiments, the linker is: [ka] or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, or or a mixture of positional isomers thereof (In the formula: each [ka] is the binding to the binding agent; each [ka] is the binding to the payload; each [ka] is the bond to the reinforcing group; Each R 9 is —CH or —(CH)N(H)C(O)NH; and Each A is -O-, -N(H)-, [ka] where ZZ is hydrogen or the side chain of an amino acid described elsewhere herein. For example, in one embodiment, ZZ is C 1-6 As a further example, in one embodiment In this way, ZZ is C 1-6 In certain embodiments of this paragraph, , A may be derived from a primary amine compound or residue thereof, where X is as defined herein. and -N3, as described elsewhere. In these embodiments, 1,2,3-triazoline is The alkyl residue can be converted from the azide to the alkyne or terminal of a compound or payload described herein. to a click chemistry reaction as described elsewhere herein with a terminal acetylene Thus, in one non-limiting example, A is [ka] or a mixture thereof. Alternatively, in another embodiment, A is [ka] or a mixture thereof. In another embodiment, A is [ka] or a mixture thereof. In another embodiment, A is [ka] or a mixture thereof. As mentioned above, the binding to the binding agent can be direct or In some embodiments, the binding to the binding agent may be via a spacer. In some cases, the binding agent is attached to a glutamine residue via a PEG spacer. In some embodiments, the enhancer is a hydrophilic group. In some embodiments, the reinforcing group is an alkyl, heteroalkyl, alkylene, Heteroalkylenyl, heteroalkylenyl sulfonic acid, heteroalkylenyl taurine, heteroalkylenyl a heteroalkylenyl amine (e.g., a quaternary amine), or is a heteroalkylenyl sugar. In some embodiments, the sugars include, but are not limited to: Examples include, but are not limited to, monosaccharides, disaccharides, and polysaccharides. Typical monosaccharides include glucose, ribose, deoxyribose, and xylose. Examples of sugars include arabinose, mannose, galactose, and fructose. In an embodiment, the sugars include sugar acids such as glucuronic acid, and further, glucuronic acid Conjugated forms (i.e., by glucuronidation) such as thiazol-2-one and thiazol-2-one Exemplary disaccharides include maltose, sucrose, lactose, lactulose, and Exemplary polysaccharides include amylose, trehalose, and the like. , amylopectin, glycogen, inulin, cellulose, etc. The cyclodextrin can be any cyclodextrin known to those of skill in the art. In this regard, cyclodextrins include alpha cyclodextrin, beta cyclodextrin, cyclodextrin, or gamma cyclodextrin, or a mixture thereof. In one embodiment, the cyclodextrin is alpha cyclodextrin. In some embodiments, the cyclodextrin is a beta cyclodextrin. In one embodiment, the cyclodextrin is gamma cyclodextrin. The alkyl, heteroalkyl, alkylenyl, or heteroalkylenyl sulfonic acid is —(CH 2) 1-5 SO3H, -(CH2) n -NH-(CH2) 1-5 SO3H, -(CH2) n -C(O)NH-(CH2) 1-5 SO3H, -(CH2CH2O) m -C(O )NH-(CH2) 1-5 SO3H, -(CH2) n -N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H)2, -(CH2) n -C(O)N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H)2, or -(CH2CH2O) m -C(O)N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H)2(where n is 1, 2, 3, 4, or 5, and m is 1, 2, 3, 4, or 5. In the formula, the alkyl or alkylenyl sulfonic acid is —(CH2) 1-5 SO3H. In the above, the heteroalkyl or heteroalkylenyl sulfonic acid is —(CH) n -NH-(CH2) 1- 5SO3H, where n is 1, 2, 3, 4, or 5. In another embodiment, alkyl , heteroalkyl, alkylenyl, or heteroalkylenyl sulfonic acids are —(CH2) n -C(O) NH-(CH2) 1-5 SO3H, where n is 1, 2, 3, 4, or 5. In another embodiment , alkyl, heteroalkyl, alkylenyl, or heteroalkylenyl sulfonic acids are -( CH2CH2O) m -C(O)NH-(CH2) 1-5 SO3H (where m is 1, 2, 3, 4, or 5). In some embodiments, alkyl, heteroalkyl, alkylenyl, or heteroalkylenyls may be used. Sulfonic acid is -(CH2) n -N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H2 (wherein n is 1, 2, 3, 4, or 5) In another embodiment, alkyl, heteroalkyl, alkylenyl, or Heteroalkylenyl sulfonic acids are -(CH2) n -C(O)N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H)2(formula wherein n is 1, 2, 3, 4, or 5. In another embodiment, alkyl, hetero The alkyl, alkylenyl, or heteroalkylenyl sulfonic acid is —(CH2CH2O) m -C(O)N((C H2) 1-5 C(O)NH(CH2) 1-5 SO3H2, where m is 1, 2, 3, 4, or 5.

[0178] In some embodiments, the linker is: [ka] or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, or or a mixture of positional isomers thereof (In the formula: each [ka] is the binding to the binding agent; each [ka] is the binding to the payload; Each R 9 is —CH or —(CH)N(H)C(O)NH; and Each A is -O-, -N(H)-, [ka] where ZZ is hydrogen or the side chain of an amino acid described elsewhere herein. For example, in one embodiment, ZZ is C 1-6 As a further example, in one embodiment In this way, ZZ is C 1-6 In certain embodiments of this paragraph, , A may be derived from a primary amine compound or residue thereof, where X is as defined herein. and -N3, as described elsewhere. In these embodiments, 1,2,3-triazoline is The alkyl residue can be converted from the azide to the alkyne or terminal of a compound or payload described herein. to a click chemistry reaction as described elsewhere herein with a terminal acetylene Thus, in one non-limiting example, A is [ka] or a mixture thereof. Alternatively, in another embodiment, A is [ka] or a mixture thereof. In another embodiment, A is [ka] or a mixture thereof. In another embodiment, A is [ka] or a mixture thereof. As mentioned above, the binding to the binding agent can be direct or In some embodiments, the binding to the binding agent may be via a spacer. In some cases, the binding agent is attached to a glutamine residue via a PEG spacer. In some embodiments, the enhancer is a hydrophilic group. In some embodiments, the reinforcing group is an alkyl, heteroalkyl, alkylene, Heteroalkylenyl, heteroalkylenyl sulfonic acid, heteroalkylenyl taurine, heteroalkylenyl a heteroalkylenyl amine (e.g., a quaternary amine), or is a heteroalkylenyl sugar. In some embodiments, the sugars include, but are not limited to: Examples include, but are not limited to, monosaccharides, disaccharides, and polysaccharides. Typical monosaccharides include glucose, ribose, deoxyribose, and xylose. Examples of sugars include arabinose, mannose, galactose, and fructose. In an embodiment, the sugars include sugar acids such as glucuronic acid, and further, glucuronic acid Conjugated forms (i.e., by glucuronidation) such as thiazol-2-one and thiazol-2-one Exemplary disaccharides include maltose, sucrose, lactose, lactulose, and Exemplary polysaccharides include amylose, trehalose, and the like. , amylopectin, glycogen, inulin, cellulose, etc. The cyclodextrin can be any cyclodextrin known to those of skill in the art. In this regard, cyclodextrins include alpha cyclodextrin, beta cyclodextrin, cyclodextrin, or gamma cyclodextrin, or a mixture thereof. In one embodiment, the cyclodextrin is alpha cyclodextrin. In some embodiments, the cyclodextrin is a beta cyclodextrin. In one embodiment, the cyclodextrin is gamma cyclodextrin. The alkyl, heteroalkyl, alkylenyl, or heteroalkylenyl sulfonic acid is —(CH 2) 1-5 SO3H, -(CH2) n -NH-(CH2) 1-5 SO3H, -(CH2) n -C(O)NH-(CH2) 1-5 SO3H, -(CH2CH2O) m -C(O )NH-(CH2) 1-5 SO3H, -(CH2) n -N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H)2, -(CH2) n -C(O)N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H)2, or -(CH2CH2O) m -C(O)N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H)2(where n is 1, 2, 3, 4, or 5, and m is 1, 2, 3, 4, or 5. In the formula, the alkyl or alkylenyl sulfonic acid is —(CH2) 1-5 SO3H. In the above, the heteroalkyl or heteroalkylenyl sulfonic acid is —(CH) n -NH-(CH2)1- 5SO3H, where n is 1, 2, 3, 4, or 5. In another embodiment, alkyl , heteroalkyl, alkylenyl, or heteroalkylenyl sulfonic acids are —(CH2) n -C(O) NH-(CH2) 1-5 SO3H, where n is 1, 2, 3, 4, or 5. In another embodiment , alkyl, heteroalkyl, alkylenyl, or heteroalkylenyl sulfonic acids are -( CH2CH2O) m -C(O)NH-(CH2) 1-5 SO3H (where m is 1, 2, 3, 4, or 5). In some embodiments, alkyl, heteroalkyl, alkylenyl, or heteroalkylenyls may be used. Sulfonic acid is -(CH2) n -N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H2 (wherein n is 1, 2, 3, 4, or 5) In another embodiment, alkyl, heteroalkyl, alkylenyl, or Heteroalkylenyl sulfonic acids are -(CH2) n -C(O)N((CH2) 1-5 C(O)NH(CH2) 1-5 SO3H)2(formula wherein n is 1, 2, 3, 4, or 5. In another embodiment, alkyl, hetero The alkyl, alkylenyl, or heteroalkylenyl sulfonic acid is —(CH2CH2O) m -C(O)N((C H2) 1-5 C(O)NH(CH2) 1-5 SO3H2, where m is 1, 2, 3, 4, or 5.

[0179] In some embodiments, the linker is: [ka] or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, or or a mixture of positional isomers thereof (In the formula: each [ka] is the binding to the binding agent; each [ka] is the binding to the payload; R 9 is —CH or —(CH)N(H)C(O)NH; and A is -O-, -N(H)-, [ka] where ZZ is hydrogen or the side chain of an amino acid described elsewhere herein. For example, in one embodiment, ZZ is C 1-6 As a further example, in one embodiment In this case, ZZ is C 1-6 In certain embodiments of this paragraph, A may be derived from a primary amine compound or residue thereof, where X is any of the groups defined herein. In these embodiments, the 1,2,3-triazole is -N3 as described in The residue can be converted from the azide to an alkyne or terminal end of a compound or payload described herein. to a click chemistry reaction with acetylene as described elsewhere herein. Thus, in one non-limiting example, A is [ka] or a mixture thereof. Alternatively, in another embodiment, A is [ka] or a mixture thereof. In another embodiment, A is [ka] or a mixture thereof. In another embodiment, A is [ka] or a mixture thereof. As mentioned above, the binding to the binding agent can be direct or In some embodiments, the binding to the binding agent may be via a spacer. In this case, the binding is to a glutamine residue of the binding agent via a PEG spacer.

[0180] In some embodiments, the linker is: [ka] TIFF2024167209000242.tif94170, or a pharmaceutically acceptable salt, solvate, or stereoisomeric form thereof, or or a mixture of positional isomers thereof (In the formula: each [ka] is the binding to the binding agent; each [ka] is the binding to the payload; R 9 is —CH or —(CH)N(H)C(O)NH; and A is -O-, -N(H)-, [ka] where ZZ is hydrogen or the side chain of an amino acid described elsewhere herein. For example, in one embodiment, ZZ is C 1-6 As a further example, in one embodiment In this case, ZZ is C 1-6 In certain embodiments of this paragraph, A may be derived from a primary amine compound or residue thereof, where X is any of the groups defined herein. In these embodiments, the 1,2,3-triazole is -N3 as described in The residue can be converted from the azide to an alkyne or terminal end of a compound or payload described herein. to a click chemistry reaction with acetylene as described elsewhere herein. Thus, in one non-limiting example, A is [ka] or a mixture thereof. Alternatively, in another embodiment, A is [ka] or a mixture thereof. In another embodiment, A is [ka] or a mixture thereof. In another embodiment, A is [ka] or a mixture thereof. As mentioned above, the binding to the binding agent can be direct or In some embodiments, the binding to the binding agent may be via a spacer. In this case, the binding is to a glutamine residue of the binding agent via a PEG spacer.

[0181] In certain embodiments, the disclosed alkynes or compounds having terminal acetylenes or The payload is linked to a conjugate derivatized with PEG-N3 linked to a glutamine residue. Exemplary -N3 derivatized binding agents, methods for their preparation, and their uses In one embodiment, a method for the preparation of a PEG-N3-derivatized PEG-N3 derivative is provided herein. Alkyne-bearing compounds described herein suitable for participating in a 1,3-cycloaddition with the selected coupling agent The compound or payload may yield positional isomeric 1,2,3-triazolyl linkage moieties, e.g. In some embodiments, the compound or payload linked to the binding agent is [ka] or a mixture thereof. (In the formula, each [ka] is the binding to the binder).

[0182] (linker-payload) In some embodiments, the linker-payload is a compound of Formula I, Formula II, or the like attached to a linker. , any of formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, or formula XII Any specific compound encompassed by one or more of the compounds described herein. The linker may comprise a site reactive with an antibody or antigen-binding fragment thereof described herein. In certain embodiments, the linker comprises the above formula I, formula II, formula III, formula IV, formula V, any one or more piperidine derivatives of formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, or formula XII; piperdine nitrogen, R 2 , R6 , or R 7 In one embodiment, the linker- Erode has the structure of formula LPa′: [ka] (In the formula, SP 1 , (AA) p , SP 2 , R 1 , Q, Q 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 is used herein (as described in any of the disclosed embodiments). In one embodiment, the linker The payload has the structure of formula LPb': [ka] (In the formula, SP 1 , (AA) p , SP 2 , R 1 , Q, Q 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 is used herein (as described in any of the disclosed embodiments). In one embodiment, the linker The payload has the structure of formula LPc′: [ka] (In the formula, SP 1 , (AA) p , SP 2 , R 1 , Q, Q 1 , R 2 , R 3 , R 4 , R5 , R 6 , R 7 , and R 8 is used herein (as described in any of the disclosed embodiments). In one embodiment, the linker The payload has the structure of formula LPd′: [ka] (In the formula, SP 1 , (AA) p , SP 2 , R 1 , Q, Q 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 is used herein As described in any of the disclosed embodiments. In any of the above, the formula LPa', the formula LPb', the formula LPc', or the formula LPd' is a compound approved for use as a pharmaceutical. In any of the embodiments in this paragraph, p is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0183] In any of the foregoing embodiments, aryl includes phenyl, naphthyl, fluoro, heteroaryl, heteroaryl, heteroaza- ... The alkyl groups include furanyl, thiophenyl, pyrrolyl, oxazolyl, thiazolyl, and imino. Dazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridyl, pyrazinyl, pyridyl Rimidinyl, pyridazinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl , quinoxalinyl, phthalazinyl, pteridinyl, benzofuranyl, dibenzofuranyl, Benzothiophenyl, benzoxazolyl, benzthiazolyl, dibenzothiophenyl, Indolyl, indolinyl, benzimidazolyl, indazolyl, and benztriazolyl Acyl includes R 3c is alkyl, alkenyl, alkynyl, cycloalkane -C(O)R including alkyl, aryl, and heteroaryl 3c In one embodiment, In one embodiment, aryl is phenyl. In one embodiment, aryl is naphthyl. In one embodiment, aryl is fluorenyl. In one embodiment, aryl is anthryl. In one embodiment, the aryl is phenanthryl. In one embodiment, heteroaryl is furanyl. In one embodiment, heteroaryl is thiophenyl. In one embodiment, heteroaryl is oxazolyl. In one embodiment, the heteroaryl is thiazolyl. In one embodiment, heteroaryl is pyrazolyl. In one embodiment, heteroaryl is isoxazolyl. In one embodiment, the heteroaryl is isothiazolyl. In one embodiment, heteroaryl is pyridyl. In one embodiment, heteroaryl is pyrazinyl. In one embodiment, heteroaryl is pyrimidinyl. In one embodiment, heteroaryl is quinolinyl. In one embodiment, heteroaryl is isoquinolinyl. In one embodiment, the heteroaryl is cinnolinyl. In one embodiment, heteroaryl is quinazolinyl. In one embodiment, heteroaryl is phthalazinyl. In one embodiment, heteroaryl is: In one embodiment, heteroaryl is dibenzofuranyl. In one embodiment, heteroaryl is benzothiophenyl. In one embodiment, the heteroaryl is benzoxazolyl. In one embodiment, heteroaryl is dibenzothiazolyl. In one embodiment, heteroaryl is thiophenyl. In one embodiment, heteroaryl is indolyl. In an embodiment, heteroaryl is indolinyl. In one embodiment, the heteroaryl is benzoimidazolyl. In one embodiment, heteroaryl is benztriazolyl. In one embodiment, acyl is —C(O)R 3c and R 3c is alkyl. In embodiments, acyl is —C(O)R 3c and R 3c is alkenyl. In the formula, acyl is -C(O)R 3c and R 3c is alkynyl. Acyl is -C(O)R 3c and R 3c is cycloalkyl. Acyl is -C(O)R 3c and R 3c is aryl. In one embodiment, Acyl is -C(O)R 3c and R 3c is heteroaryl.

[0184] In any of the foregoing embodiments of this section, R 7 is -NR 7a R 7b (wherein R 7a Reach BiR 7b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl aryl, heteroaryl, acyl, and amino acid residues, Alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally In some embodiments, R 7a is hydrogen and R 7b is Amino It is an acid residue.

[0185] (Conjugates / Antibody Drug Conjugates (ADCs)) Provided herein is an antibody, or an antigen-binding fragment thereof, wherein the antibody is Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, Formula X , Formula XI, and / or Formula XII.

[0186] Provided herein is a conjugate of formula A, or a pharmaceutically acceptable salt thereof: , solvates, regioisomeric or stereoisomeric forms: [ka] (In the formula, R 1 , Q, Q 1 , R2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and m is as described above in the context of formula I. wherein BA is a binding agent, L is a linker, and k is 1, 2, 3, 4, 5, 6, , 7, 8, 9, or 10. In some embodiments, k is 1 to 2, 1 to 3, 2 to 3, 2 to 4, 3 to 4 In one embodiment, the -L-BA in Formula A is conjugated to The compounds represented by the above formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, and / or one or more compounds of formula XII, wherein BA is a binder; L is a linker and k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, k is in the range of 1 to 2, 1 to 3, 2 to 3, 2 to 4, 3 to 4, or 1 to 4. wherein BA is an antibody, or an antigen-binding fragment thereof, wherein the antibody is, as described above, In any embodiment of this paragraph, the BA is conjugated to a compound of formula I. or an antigen-binding fragment thereof, wherein the antibody is linked to a compound of Formula II, as described above. In any of the embodiments of this paragraph, the BA is an antibody, or an antigen thereof. a binding fragment, wherein the antibody is conjugated to a compound of formula III, as described above. In any embodiment of this paragraph, the BA is an antibody, or an antigen-binding fragment thereof. , wherein the antibody is conjugated to a compound of formula IV, as described above. In any of the embodiments, the BA is an antibody, or an antigen-binding fragment thereof, wherein the antibody is conjugated to a compound of formula V, as described above. wherein BA is an antibody, or an antigen-binding fragment thereof, wherein the antibody is as defined above. In any embodiment of this paragraph, BA is conjugated to a compound of formula VI. an antibody, or antigen-binding fragment thereof, wherein the antibody is a compound of formula VII, as described above; In any of the embodiments of this paragraph, the BA is conjugated to an antibody or an antigen-binding fragment, wherein the antibody is conjugated to a compound of formula VIII, as described above. In any embodiment of this paragraph, the BA is an antibody, or an antigen-binding fragment thereof. wherein the antibody is conjugated to a compound of formula IX, as described above. In any embodiment of the paragraph, the BA is an antibody, or an antigen-binding fragment thereof, wherein the The antibody is conjugated to a compound of formula X, as described above. In embodiments, the BA is an antibody, or an antigen-binding fragment thereof, wherein the antibody is as described above. In any embodiment of this paragraph, BA is an antibody, or antigen-binding fragment thereof, wherein the antibody is a compound of formula XII, as described above. In any of the embodiments in this paragraph, Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, any one or more compounds of formula IX, formula X, formula XI, and / or formula XII may be a compound of formula IX, formula X, formula XI, and / or formula XII, wherein the compound is a piperidine nitrogen It is conjugated via

[0187] Provided herein is a conjugate of formula B, or a pharmaceutically acceptable salt thereof: , solvates, regioisomeric or stereoisomeric forms: [ka] (In the formula, R 1 , Q, Q 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and m is as described above in the context of formula I. wherein BA is a binding agent, L is a linker, and k is 1, 2, 3, 4, 5, 6, In some embodiments, k is 1 to 2, 1 to 3, 2 to 3, 2 to 4, 3 to 5, 6 to 7, 7, 8, 9, or 10. 4, or in the range of 1 to 4. In one embodiment, the conjugate to -L-BA in Formula B The compounds represented by the above formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI and / or one or more compounds of formula XII, wherein BA is a binder; L is a linker and k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. , k ranges from 1 to 2, 1 to 3, 2 to 3, 2 to 4, 3 to 4, or 1 to 4. In the embodiment, the BA is an antibody, or an antigen-binding fragment thereof, wherein the antibody is as described above. is conjugated to a compound of formula I. In any embodiment of this paragraph, BA is , an antibody, or an antigen-binding fragment thereof, wherein the antibody is a compound of Formula II, as described above. In any of the embodiments of this paragraph, the BA is conjugated to an antibody or an antigen-binding fragment, wherein the antibody is conjugated to a compound of formula III, as described above. In any embodiment of this paragraph, the BA is an antibody, or an antigen-binding fragment thereof. wherein the antibody is conjugated to a compound of formula IV, as described above. In any embodiment of the paragraph, the BA is an antibody, or an antigen-binding fragment thereof, wherein the The antibody is conjugated to a compound of formula V, as described above. In embodiments, the BA is an antibody, or an antigen-binding fragment thereof, wherein the antibody is as described above. In any embodiment of this paragraph, BA is an antibody, or antigen-binding fragment thereof, wherein the antibody is a compound of Formula VII, as described above. In any embodiment of this paragraph, the BA is conjugated to an antibody, or and an antigen-binding fragment thereof, wherein the antibody is conjugated to a compound of Formula VIII, as described above. In any embodiment of this paragraph, the BA is an antibody, or an antigen-binding fragment thereof. wherein the antibody is conjugated to a compound of formula IX, as described above. In any of the embodiments of this paragraph, the BA is an antibody, or an antigen-binding fragment thereof, wherein wherein the antibody is conjugated to a compound of formula X, as described above. In an embodiment, the BA is an antibody, or an antigen-binding fragment thereof, wherein the antibody is an antibody as described above. In any embodiment of this paragraph, , BA is an antibody, or an antigen-binding fragment thereof, wherein the antibody has the structure of Formula XII, as described above. In any of the embodiments in this paragraph, Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII conjugated to -L-BA in Formula B , any one or more compounds of formula VIII, formula IX, formula X, formula XI, and / or formula XII may comprise a divalent R 6 of It is conjugated via

[0188] Provided herein is a conjugate of formula C, or a pharmaceutically acceptable salt thereof: , solvates, regioisomeric or stereoisomeric forms: [ka] (In the formula, R 1 , Q, Q 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and m is as described above in the context of formula I. wherein BA is a binding agent, L is a linker, and k is 1, 2, 3, 4, 5, 6, In some embodiments, k is 1 to 2, 1 to 3, 2 to 3, 2 to 4, 3 to 5, 6 to 7, 7, 8, 9, or 10. 4, or in the range of 1 to 4. In one embodiment, the -L-BA in Formula C is conjugated to The compounds represented by the above formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI and / or one or more compounds of formula XII, wherein BA is a binder; L is a linker and k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. , k ranges from 1 to 2, 1 to 3, 2 to 3, 2 to 4, 3 to 4, or 1 to 4. In the embodiment, the BA is an antibody, or an antigen-binding fragment thereof, wherein the antibody is as described above. is conjugated to a compound of formula I. In any embodiment of this paragraph, BA is , an antibody, or an antigen-binding fragment thereof, wherein the antibody is a compound of Formula II, as described above. In any of the embodiments of this paragraph, the BA is conjugated to an antibody or an antigen-binding fragment, wherein the antibody is conjugated to a compound of formula III, as described above. In any embodiment of this paragraph, the BA is an antibody, or an antigen-binding fragment thereof. wherein the antibody is conjugated to a compound of formula IV, as described above. In any embodiment of the paragraph, the BA is an antibody, or an antigen-binding fragment thereof, wherein the The antibody is conjugated to a compound of formula V, as described above. In embodiments, the BA is an antibody, or an antigen-binding fragment thereof, wherein the antibody is as described above. In any embodiment of this paragraph, BA is an antibody, or antigen-binding fragment thereof, wherein the antibody is a compound of Formula VII, as described above. In any embodiment of this paragraph, the BA is conjugated to an antibody, or and an antigen-binding fragment thereof, wherein the antibody is conjugated to a compound of Formula VIII, as described above. In any embodiment of this paragraph, the BA is an antibody, or an antigen-binding fragment thereof. wherein the antibody is conjugated to a compound of formula IX, as described above. In any of the embodiments of this paragraph, the BA is an antibody, or an antigen-binding fragment thereof, wherein wherein the antibody is conjugated to a compound of formula X, as described above. In an embodiment, the BA is an antibody, or an antigen-binding fragment thereof, wherein the antibody is an antibody as described above. In any embodiment of this paragraph, , BA is an antibody, or an antigen-binding fragment thereof, wherein the antibody has the structure of Formula XII, as described above. In any of the embodiments in this paragraph, Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII conjugated to -L-BA in Formula C , any one or more compounds of formula VIII, formula IX, formula X, formula XI, and / or formula XII may comprise a divalent R 7 of It is conjugated via

[0189] Provided herein are conjugates of formula D, or a pharmaceutically acceptable salt thereof: , solvates, regioisomeric or stereoisomeric forms: [ka] (In the formula, R 1 , Q, Q 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and m is as described above in the context of formula I. wherein BA is a binding agent, L is a linker, and k is 1, 2, 3, 4, 5, 6, In some embodiments, k is 1 to 2, 1 to 3, 2 to 3, 2 to 4, 3 to 5, 6 to 7, 7, 8, 9, or 10. 4, or in the range of 1 to 4. In some embodiments, in Formula D, -L-BA is conjugated to The compounds represented by the above formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI and / or one or more compounds of formula XII, wherein BA is a binder; L is a linker and k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. , k ranges from 1 to 2, 1 to 3, 2 to 3, 2 to 4, 3 to 4, or 1 to 4. In the embodiment, the BA is an antibody, or an antigen-binding fragment thereof, wherein the antibody is as described above. is conjugated to a compound of formula I. In any embodiment of this paragraph, BA is , an antibody, or an antigen-binding fragment thereof, wherein the antibody is a compound of Formula II, as described above. In any of the embodiments of this paragraph, the BA is conjugated to an antibody or an antigen-binding fragment, wherein the antibody is conjugated to a compound of formula III, as described above. In any embodiment of this paragraph, the BA is an antibody, or an antigen-binding fragment thereof. wherein the antibody is conjugated to a compound of formula IV, as described above. In any embodiment of the paragraph, the BA is an antibody, or an antigen-binding fragment thereof, wherein the The antibody is conjugated to a compound of formula V, as described above. In embodiments, the BA is an antibody, or an antigen-binding fragment thereof, wherein the antibody is as described above. In any embodiment of this paragraph, BA is an antibody, or antigen-binding fragment thereof, wherein the antibody is a compound of Formula VII, as described above. In any embodiment of this paragraph, the BA is conjugated to an antibody, or and an antigen-binding fragment thereof, wherein the antibody is conjugated to a compound of Formula VIII, as described above. In any embodiment of this paragraph, the BA is an antibody, or an antigen-binding fragment thereof. wherein the antibody is conjugated to a compound of formula IX, as described above. In any of the embodiments of this paragraph, the BA is an antibody, or an antigen-binding fragment thereof, wherein wherein the antibody is conjugated to a compound of formula X, as described above. In an embodiment, the BA is an antibody, or an antigen-binding fragment thereof, wherein the antibody is an antibody as described above. In any embodiment of this paragraph, , BA is an antibody, or an antigen-binding fragment thereof, wherein the antibody has the structure of Formula XII, as described above. In any of the embodiments in this paragraph, Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII conjugated to -L-BA in Formula D , any one or more compounds of formula VIII, formula IX, formula X, formula XI, and / or formula XII may comprise a divalent R 2 of It is conjugated via

[0190] In one embodiment of Formula B, BA is a binder; L is a linker; and Q is -CH2-. R 1 is C1-C 10 alkyl; R 2 is C5-C 10 alkyl; R 3 is -C(O)C1-C5 alkyl R 4 is hydrogen; R 5 is C1-C5 alkyl; R 6 is -NHNH-; R 7 Ha, ha Rogen;R 8 is hydrogen; m is 1; and k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment of Formula B, BA is a binder; L is a linker; and Q is -CH2-; R 1 are methyl, ethyl, propyl, butyl, pentyl, hexyl, and heptyl. R is methyl, octyl, nonyl, or decyl, and structural isomers thereof; 2is pentyl , hexyl, heptyl, octyl, nonyl, or decyl, and structural isomers thereof. ;R 3 is -C(O)CH3, -C(O)CH2CH3, -C(O)CH2CH2CH3, -C(O)CH2CH2CH2CH3, or -C(O)CH2CH2 CH2CH2CH3; R 4 is hydrogen; R 5 is methyl, ethyl, propyl, butyl, or phenyl butyl, and their structural isomers; R 6 is -NHNH-; R 7 are fluoro, chloro, Bromo or iodo; R 8 is hydrogen; m is 1; and k is 1, 2, 3, 4, 5, 6 , 7, 8, 9, or 10. In one embodiment, the conjugate of Formula B comprises Formula Bi: [ka] where BA is a binding agent; L is a linker; R 1 are methyl, ethyl, propyl, tyl, pentyl, hexyl, heptyl, octyl, nonyl, or decyl, and structures thereof It is an isomer; R 2 is pentyl, hexyl, heptyl, octyl, nonyl, or decyl and structural isomers thereof; R 3 are -C(O)CH3, -C(O)CH2CH3, -C(O)CH2CH2CH3, -C(O )CH2CH2CH2CH3, or —C(O)CH2CH2CH2CH2CH3; R 5 are methyl, ethyl, propyl, R is ethyl, or pentyl, and their structural isomers; 7 are fluoro, chloro, and bromo or iodo; and k is 1, 2, 3, or 4. In one embodiment of Formula Bi, BA is a binder; L is a linker; R 1 is methyl; R 2 is pentyl and its It is a structural isomer; R 3 is -C(O)CH3; R 5 is methyl; R 7 Fluoro, chloro , bromo, or iodo; and k is 1, 2, 3, or 4. In one embodiment, Conjugates of B include the following conjugates: [ka] (wherein BA is a binder; and k is 1, 2, 3, or 4). In any of the embodiments, the BA is an antibody or an antigen-binding fragment thereof. In any of the above embodiments, k is in the range of 1 to 2, 1 to 3, 2 to 3, 2 to 4, 3 to 4, or 1 to 4. In any of the embodiments in this paragraph, k is 1. In any of the embodiments in this paragraph, k is 2. In any of the embodiments in this paragraph, k is 3. and k is 4.

[0191] In one embodiment of Formula B, BA is a binder; L is a linker; and Q is -O-. ;R 1 is C1-C 10 alkyl; R 2 is C5-C 10 alkyl; R 3 is -C(O)C1-C5 alkyl and;R 4 is hydrogen; R 5 is C1-C5 alkyl; R 6 is -NHNH-; R 7 is -OH Yes;R 8 is hydrogen; m is 1; and k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment of Formula B, BA is a binder; L is a linker; and Q is -O-. Yes;R 1 is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl ethyl, nonyl, or decyl, and their structural isomers; R 2 is pentyl, hexyl , heptyl, octyl, nonyl, or decyl, and their structural isomers; R 3 is -C( O)CH3, -C(O)CH2CH3, -C(O)CH2CH2CH3, -C(O)CH2CH2CH2CH3, or -C(O)CH2CH2CH2CH2CH3 and;R 4 is hydrogen; R 5 is methyl, ethyl, propyl, butyl, or pentyl, and and their structural isomers; R 6 is -NHNH-; R 7 is -OH; R 8 is hydrogen; m is 1; and k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. , the conjugate of formula B comprises formula Bii: [ka] where BA is a binding agent; L is a linker; R 1 are methyl, ethyl, propyl, tyl, pentyl, hexyl, heptyl, octyl, nonyl, or decyl, and structures thereof It is an isomer; R 2 is pentyl, hexyl, heptyl, octyl, nonyl, or decyl and structural isomers thereof; R 3are -C(O)CH3, -C(O)CH2CH3, -C(O)CH2CH2CH3, -C(O )CH2CH2CH2CH3, or —C(O)CH2CH2CH2CH2CH3; R 5 are methyl, ethyl, propyl, R is ethyl, or pentyl, and their structural isomers; 7 is —OH; and k is 1, 2, 3, or 4). In one embodiment of Formula Bii, BA is a binder; L is a linker. R 1 is methyl; R 2 is pentyl and its structural isomers; R 3 is -C(O)CH3 Yes;R 5 is methyl; R 7 is —OH; and k is 1, 2, 3, or 4. In the embodiment, the conjugate of formula B is: [ka] wherein BA is a binder; and k is 1, 2, 3, or 4). In any of the embodiments in this paragraph, the BA is an antibody or In any of the embodiments in this paragraph, k is 1 to 2, 1 In any of the embodiments in this paragraph, In any of the embodiments in this paragraph, k is 1. In any of the embodiments in this paragraph, k is 3. In any of the embodiments in the graph, k is 4.

[0192] In one embodiment of Formula C, BA is a binder; L is a linker; and Q is -CH2-. R1 is C1-C 10 alkyl; R 2 is C5-C 10 alkynyl; R 3 is -C(O)C1-C5 ar Kill;R 4 and R 5 are independently C1-C5 alkyl; R 6 is -OH; R 7 is -NH- Yes;R 8 is hydrogen; m is 1; and k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment of Formula C, BA is a binder; L is a linker; and Q is -CH2- and;R 1 is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, or decyl, and their structural isomers; R 2 is pentynyl, hexyl cinyl, heptynyl, octynyl, nonynyl, or decynyl; R 3 is -C(O)CH3, -C( O)CH2CH3, -C(O)CH2CH2CH3, -C(O)CH2CH2CH2CH3, or -C(O)CH2CH2CH2CH2CH3; 4 Reach BiR 5 are independently methyl, ethyl, propyl, butyl, or pentyl, and their structures It is an isomer; R 6 is -OH; R 7 is -NH-; R 8 is hydrogen; m is 1; and k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment, the conjugate of Formula C is The gate contains the formula Ci: [ka] where BA is a binding agent; L is a linker; R1 are methyl, ethyl, propyl, tyl, pentyl, hexyl, heptyl, octyl, nonyl, or decyl, and structures thereof It is an isomer; R 2 is pentynyl, hexynyl, heptynyl, octynyl, nonynyl, or decynyl; R 3 is -C(O)CH3, -C(O)CH2CH3, -C(O)CH2CH2CH3, -C(O)CH2CH2CH2CH 3, or -C(O)CH2CH2CH2CH2CH3; R 4 and R 5 are independently methyl, ethyl, propyl, butyl, or pentyl, and their structural isomers; R 7 is -NH-; and k is 1, In one embodiment of Formula Ci, BA is a binder; L is a linker. Yes;R 1 is methyl; R 2 is pentynyl; R 3 is -C(O)CH3; R 4 and R 5 teeth, Methyl; R 7 is —NH—; and k is 1, 2, 3, or 4. , a conjugate of formula C is as follows: [ka] wherein BA is a binder; and k is 1, 2, 3, or 4). In any of the embodiments in this paragraph, the BA is an antibody or In any of the embodiments in this paragraph, k is 1 to 2, 1 In any of the embodiments in this paragraph, In any of the embodiments in this paragraph, k is 1. In any of the embodiments in this paragraph, k is 3. In any of the embodiments in the graph, k is 4.

[0193] In one embodiment of Formula C, BA is a binder; L is a linker; and Q is -O-. ;R 1 is C1-C 10 alkyl; R 2 is C5-C 10 alkynyl; R 3 is -C(O)C1-C5 alkyl R 4 and R 5 are independently C1-C5 alkyl; R 6 is -OH; R 7 is -NH- R 8 is hydrogen; m is 1; and k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment of Formula C, BA is a binder; L is a linker; and Q is -O-. R 1 is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl R is methyl, nonyl, or decyl, and their structural isomers; 2 is pentynyl, hexynyl R is aryl, heptynyl, octynyl, nonynyl, or decynyl; 3 is -C(O)CH3, -C(O)CH 2CH3, -C(O)CH2CH2CH3, -C(O)CH2CH2CH2CH2CH3, or -C(O)CH2CH2CH2CH2CH3; R 4 and R 5 are independently methyl, ethyl, propyl, butyl, or pentyl, and structural isomers thereof; Body;R 6 is -OH; R7 is -NH-; R 8 is hydrogen; m is 1; and k is , 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment, the conjugate of formula C is The compound includes formula Cii: [ka] where BA is a binding agent; L is a linker; R 1 are methyl, ethyl, propyl, tyl, pentyl, hexyl, heptyl, octyl, nonyl, or decyl, and structures thereof It is an isomer; R 2 is pentynyl, hexynyl, heptynyl, octynyl, nonynyl, or decynyl; R 3 is -C(O)CH3, -C(O)CH2CH3, -C(O)CH2CH2CH3, -C(O)CH2CH2CH2CH 3, or -C(O)CH2CH2CH2CH2CH3; R 4 and R 5 are independently methyl, ethyl, propyl, butyl, or pentyl, and their structural isomers; R 7 is -NH-; and k is 1, 2, 3, or 4. In one embodiment of Formula Cii, BA is a binder; L is a linker. Yes;R 1 is methyl; R 2 is pentynyl; R 3 is -C(O)CH3; R 4 and R 5 teeth, Methyl; R 7 is —NH—; and k is 1, 2, 3, or 4. In one embodiment , a conjugate of formula C is as follows: [ka] The compound includes a compound selected from the group consisting of wherein BA is a binding agent; and k is 1, 2, 3, or 4. In one embodiment, The conjugate of C is: [ka] wherein BA is a binder; and k is 1, 2, 3, or 4). In one embodiment, the conjugate of Formula C is: [ka] wherein BA is a binder; and k is 1, 2, 3, or 4). In one embodiment, the conjugate of Formula C is: [ka] wherein BA is a binder; and k is 1, 2, 3, or 4). In one embodiment, the conjugate of Formula C is: [ka] wherein BA is a binder; and k is 1, 2, 3, or 4). In one embodiment, the conjugate of Formula C is: [ka] wherein BA is a binder; and k is 1, 2, 3, or 4). In one embodiment, the conjugate of Formula C is: [ka] wherein BA is a binder; and k is 1, 2, 3, or 4). In one embodiment, the conjugate of Formula C is: [ka] wherein BA is a binder; and k is 1, 2, 3, or 4). In one embodiment, the conjugate of Formula C is: [ka] wherein BA is a binder; and k is 1, 2, 3, or 4). In one embodiment, the conjugate of Formula C is: [ka] wherein BA is a binder; and k is 1, 2, 3, or 4). In one embodiment, the conjugate of Formula C is: [ka] wherein BA is a binder; and k is 1, 2, 3, or 4). In one embodiment, the conjugate of Formula C is: [ka] wherein BA is a binder; and k is 1, 2, 3, or 4). In any of the embodiments in this paragraph, the BA is an antibody or In any of the embodiments in this paragraph, k is 1 to 2, 1 In any of the embodiments in this paragraph, In any of the embodiments in this paragraph, k is 1. In any of the embodiments in this paragraph, k is 3. In any of the embodiments in the graph, k is 4.

[0194] In one embodiment of Formula C, BA is a binder; L is a linker; and Q is -CH2-. R 1 is C1-C 10 alkyl; R 2 is C5-C 10 alkynyl; R 3 is -C(O)C1-C5 ar Kill;R 4 and R 5 are independently C1-C5 alkyl; R 6 is -OH; R 7 is -NH- Yes;R 8 is hydrogen; m is 1; and k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment of Formula C, BA is a binder; L is a linker; and Q is -CH2- and;R 1 is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, or decyl, and their structural isomers; R 2 is pentynyl, hexyl cinyl, heptynyl, octynyl, nonynyl, or decynyl; R 3 is -C(O)CH3, -C( O)CH2CH3, -C(O)CH2CH2CH3, -C(O)CH2CH2CH2CH3, or -C(O)CH2CH2CH2CH2CH3; 4 Reach BiR 5 are independently methyl, ethyl, propyl, butyl, or pentyl, and their structures It is an isomer; R 6 is -OH; R 7 is -NH-; R 8is hydrogen; m is 1; and k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment, the conjugate of Formula C is The gate contains the formula Ci: [ka] where BA is a binding agent; L is a linker; R 1 are methyl, ethyl, propyl, tyl, pentyl, hexyl, heptyl, octyl, nonyl, or decyl, and structures thereof It is an isomer; R 2 is pentynyl, hexynyl, heptynyl, octynyl, nonynyl, or decynyl; R 3 is -C(O)CH3, -C(O)CH2CH3, -C(O)CH2CH2CH3, -C(O)CH2CH2CH2CH 3, or -C(O)CH2CH2CH2CH2CH3; R 4 and R 5 are independently methyl, ethyl, propyl, butyl, or pentyl, and their structural isomers; R 7 is -NH-; and k is 1, In one embodiment of Formula Ci, BA is a binder; L is a linker. Yes;R 1 is methyl; R 2 is pentynyl; R 3 is -C(O)CH3; R 4 and R 5 teeth, Methyl; R 7 is —NH—; and k is 1, 2, 3, or 4. In one embodiment , a conjugate of formula C is as follows: [ka] wherein BA is a binder; and k is 1, 2, 3, or 4). In any of the embodiments in this paragraph, the BA is an antibody or In any of the embodiments in this paragraph, k is 1 to 2, 1 In any of the embodiments in this paragraph, In any of the embodiments in this paragraph, k is 1. In any of the embodiments in this paragraph, k is 3. In any of the embodiments in the graph, k is 4.

[0195] In one embodiment of Formula C, BA is a binder; L is a linker; and Q is -O-. ;R 1 is C1-C 10 alkyl; R 2 is C5-C 10 alkyl; R 3 is -C(O)C1-C5 alkyl and;R 4 and R 5 are independently C1-C5 alkyl; R 6 is -OH; R 7 is -NH-; R 8 is hydrogen; m is 1; and k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment of Formula C, BA is a binder; L is a linker; Q is —O—; and R 1 is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, or decyl, and their structural isomers; R 2 are pentyl, hexyl, heptyl R is methyl, octyl, nonyl, or decyl, and structural isomers thereof; 3 is -C(O)CH3 , -C(O)CH2CH3, -C(O)CH2CH2CH3, -C(O)CH2CH2CH2CH3, or -C(O)CH2CH2CH2CH2CH3 ;R 4 and R 5 are independently methyl, ethyl, propyl, butyl, or pentyl, and is a structural isomer of; R 6 is -OH; R 7 is -NH-; R 8 is hydrogen; m is 1 and k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment, The conjugates include those of formula Cii: [ka] where BA is a binding agent; L is a linker; R 1 are methyl, ethyl, propyl, tyl, pentyl, hexyl, heptyl, octyl, nonyl, or decyl, and structures thereof It is an isomer; R 2 is pentyl, hexyl, heptyl, octyl, nonyl, or decyl and structural isomers thereof; R 3 are -C(O)CH3, -C(O)CH2CH3, -C(O)CH2CH2CH3, -C(O )CH2CH2CH2CH3, or —C(O)CH2CH2CH2CH2CH3; R 4 and R 5 are independently methyl, ethyl , propyl, butyl, or pentyl, and their structural isomers; R 7 is -NH-; and k is 1, 2, 3, or 4. In one embodiment of Formula Cii, BA is a binder; is the linker; R 1 is methyl; R 2 is pentyl; R 3 is -C(O)CH3; R4 and R 5 is methyl; R 7 is -NH-; and k is 1, 2, 3, or 4. In embodiments, the conjugate of formula C is: [ka] wherein BA is a binder; and k is 1, 2, 3, or 4). In one embodiment, the conjugate of Formula C is: [ka] wherein BA is a binder; and k is 1, 2, 3, or 4). In one embodiment, the conjugate of Formula C is: [ka] wherein BA is a binder; and k is 1, 2, 3, or 4). In any of the embodiments in this paragraph, the BA is an antibody or In any of the embodiments in this paragraph, k is 1 to 2, 1 In any of the embodiments in this paragraph, In any of the embodiments in this paragraph, k is 1. In any of the embodiments in this paragraph, k is 3. In any of the embodiments in the graph, k is 4.

[0196] In one embodiment of Formula C, BA is a binder; L is a linker; and Q is -CH2-. R 1 is C1-C 10alkyl; R 2 is C5-C 10 alkynyl; R 3 is -C(O)C1-C5 ar Kill;R 4 and R 5 are independently C1-C5 alkyl; R 6 is -OH; R 7 is -NH- Yes;R 8 is hydrogen; m is 1; and k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment of Formula C, BA is a binder; L is a linker; and Q is -CH2- and;R 1 is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, or decyl, and their structural isomers; R 2 is pentynyl, hexyl cinyl, heptynyl, octynyl, nonynyl, or decynyl; R 3 is -C(O)CH3, -C( O)CH2CH3, -C(O)CH2CH2CH3, -C(O)CH2CH2CH2CH3, or -C(O)CH2CH2CH2CH2CH3; 4 Reach BiR 5 are independently methyl, ethyl, propyl, butyl, or pentyl, and their structures It is an isomer; R 6 is -OH; R 7 is -NH-; R 8 is hydrogen; m is 1; and k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment, the conjugate of Formula C is The gate contains the formula Ci: [ka] where BA is a binding agent; L is a linker; R 1 are methyl, ethyl, propyl, tyl, pentyl, hexyl, heptyl, octyl, nonyl, or decyl, and structures thereof It is an isomer; R 2 is pentynyl, hexynyl, heptynyl, octynyl, nonynyl, or decynyl; R 3 is -C(O)CH3, -C(O)CH2CH3, -C(O)CH2CH2CH3, -C(O)CH2CH2CH2CH 3, or -C(O)CH2CH2CH2CH2CH3; R 4 and R 5 are independently methyl, ethyl, propyl, butyl, or pentyl, and their structural isomers; R 7 is -NH-; and k is 1, 2, 3, or 4. In one embodiment of Formula Ci, BA is a binder; L is a linker. Yes;R 1 is methyl; R 2 is pentynyl; R 3 is -C(O)CH3; R 4 and R 5 teeth, Methyl; R 7 is —NH—; and k is 1, 2, 3, or 4. In one embodiment , a conjugate of formula C is as follows: [ka] wherein BA is a binder; and k is 1, 2, 3, or 4). In any of the embodiments in this paragraph, the BA is an antibody or In any of the embodiments in this paragraph, k is 1 to 2, 1 In any of the embodiments in this paragraph, In any of the embodiments in this paragraph, k is 1. In any of the embodiments in this paragraph, k is 3. In any of the embodiments in the graph, k is 4.

[0197] In one embodiment of Formula C, BA is a binder; L is a linker; and Q is -CH2-. R 1 is C1-C 10 alkyl; R 2 is C5-C 10 alkyl; R 3 is -C(O)C1-C5 alkyl R 4 and R 5 are independently C1-C5 alkyl; R 6 is -OH; R 7 is -NH- R 8 is halogen; m is 1; and k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment of Formula C, BA is a binder; L is a linker; and Q is -CH 2- and;R 1 is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, or decyl, and their structural isomers; R 2 is pentyl, hexyl cyclohexyl, heptyl, octyl, nonyl, or decyl; R 3 are -C(O)CH3, -C(O)CH2CH3, -C(O)CH2CH2CH3, -C(O)CH2CH2CH2CH3, or -C(O)CH2CH2CH2CH2CH3; R 4 and R 5 is German Specifically, methyl, ethyl, propyl, butyl, or pentyl, and their structural isomers. R 6 is -OH; R 7 is -NH-; R 8is a halogen; m is 1; and k is 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment, the conjugate of formula C contains the formula Ciii: [ka] where BA is a binding agent; L is a linker; R 1 are methyl, ethyl, propyl, tyl, pentyl, hexyl, heptyl, octyl, nonyl, or decyl, and structures thereof It is an isomer; R 2 is pentyl, hexyl, heptyl, octyl, nonyl, or decyl and;R 3 is -C(O)CH3, -C(O)CH2CH3, -C(O)CH2CH2CH3, -C(O)CH2CH2CH2CH3, or -C(O) CH2CH2CH2CH2CH3; R 4 and R 5 are independently methyl, ethyl, propyl, butyl, or pentyl and its structural isomers; R 7 is -NH-; R 8 is a halogen; m is , 1; and k is 1, 2, 3, or 4. In one embodiment of Formula Ciii, BA is a bond L is a linker; R 1 is methyl; R 2 is pentyl; R 3 is -C(O) CH3;R 4 and R 5 is methyl; R 7 is -NH-; R 8 is a halogen; m is 1 and k is 1, 2, 3, or 4. In one embodiment, the conjugate of Formula C is ,below: [ka] wherein BA is a binder; and k is 1, 2, 3, or 4). In one embodiment, the conjugate of Formula C comprises: [ka] (wherein BA is a binder; and k is 1, 2, 3, or 4). In any of the embodiments, the BA is an antibody or an antigen-binding fragment thereof. In any of the above embodiments, k is in the range of 1 to 2, 1 to 3, 2 to 3, 2 to 4, 3 to 4, or 1 to 4. In any of the embodiments in this paragraph, k is 1. In any of the embodiments in this paragraph, k is 2. In any of the embodiments in this paragraph, k is 3. and k is 4.

[0198] In one embodiment of Formula C, BA is a binder; L is a linker; and Q is -O-. ;R 1 is C1-C 10 alkyl; R 2 is C5-C 10 alkyl; R 3 is -C(O)N(H)C1-C 10 Al Kill;R 4 and R 5 are independently C1-C5 alkyl; R 6 is -OH; R 7 is -NH- Yes;R 8 is hydrogen; m is 1; and k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one embodiment of Formula C, BA is a binder; L is a linker; and Q is -O-. Yes;R 1 is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl ethyl, nonyl, or decyl, and their structural isomers; R 2 is pentyl, hexyl , heptyl, octyl, nonyl, or decyl, and their structural isomers; R 3 is -C( O)N(H)CH3, -C(O)N(H)CH2CH3, -C(O)N(H)CH2CH2CH3, -C(O)N(H)CH2CH2CH2CH3, or -C(O) N(H)CH2CH2CH2CH2CH3; R 4 and R 5 are independently methyl, ethyl, propyl, butyl, or pentyl, and their structural isomers; R 6 is -OH; R 7 is -NH-; R 8 teeth , hydrogen; m is 1; and k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In embodiments, the conjugate of Formula C comprises Formula Cii: [ka] where BA is a binding agent; L is a linker; R 1 are methyl, ethyl, propyl, tyl, pentyl, hexyl, heptyl, octyl, nonyl, or decyl, and structures thereof It is an isomer; R 2 is pentyl, hexyl, heptyl, octyl, nonyl, or decyl and structural isomers thereof; R 3 is -C(O)N(H)CH3, -C(O)N(H)CH2CH3, -C(O)N(H)CH2 CH2CH3, -C(O)N(H)CH2CH2CH2CH3, or -C(O)N(H)CH2CH2CH2CH2CH3; R 4 and R5 is German Specifically, methyl, ethyl, propyl, butyl, or pentyl, and their structural isomers. R 7 is —NH—; and k is 1, 2, 3, or 4. In one embodiment of Formula Cii, BA is a binder; L is a linker; R 1 is methyl; R 2 is pentyl; R 3 is -C(O)N(H)CH3; R 4 and R 5 is methyl; R 7 is -NH-; and k is 1, 2, 3, or 4. In one embodiment, the conjugate of Formula C is: [ka] wherein BA is a binder; and k is 1, 2, 3, or 4). In one embodiment, the conjugate of Formula C is: [ka] wherein BA is a binder; and k is 1, 2, 3, or 4). In any of the embodiments in this paragraph, the BA is an antibody or In any of the embodiments in this paragraph, k is 1 to 2, 1 In any of the embodiments in this paragraph, In any of the embodiments in this paragraph, k is 1. In any of the embodiments in this paragraph, k is 3. In any of the embodiments in the graph, k is 4.

[0199] In one embodiment of Formula C, BA is a binder; L is a linker; and Q is -CH2-. R 1 is C1-C 10 alkyl; R 2 is C5-C 10 alkyl; R 3 is -C(O)N(H)C1-C5 Rukill is;R 4 and R 5 are independently C1-C5 alkyl; R 6 is -OH; R 7 is -NH- and;R 8 is a halogen; m is 1; and k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or is 10. In one embodiment of Formula C, BA is a binder; L is a linker; and Q is , -CH2-; R 1 is methyl, ethyl, propyl, butyl, pentyl, hexyl, R is octyl, nonyl, or decyl, and their structural isomers; 2 is pentyl, hexyl, heptyl, octyl, nonyl, or decyl; R 3 is -C(O)N(H)CH3, -C(O) N(H)CH2CH3, -C(O)N(H)CH2CH2CH3, -C(O)N(H)CH2CH2CH2CH3, or -C(O)N(H)CH2CH2CH2CH2 CH3;R 4 and R 5 are independently methyl, ethyl, propyl, butyl, or pentyl, and and their structural isomers; R 6 is -OH; R 7 is -NH-; R 8 is a halogen m is 1; and k is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. Thus, the conjugate of formula C includes a conjugate of formula Ciii: [ka] where BA is a binding agent; L is a linker; R 1 are methyl, ethyl, propyl, tyl, pentyl, hexyl, heptyl, octyl, nonyl, or decyl, and structures thereof It is an isomer; R 2 is pentyl, hexyl, heptyl, octyl, nonyl, or decyl and;R 3 is -C(O)N(H)CH3, -C(O)N(H)CH2CH3, -C(O)N(H)CH2CH2CH3, -C(O)N(H)CH2CH2C H2CH3, or -C(O)N(H)CH2CH2CH2CH2CH3; R 4 and R 5 are independently methyl, ethyl, R is propyl, butyl, or pentyl, and their structural isomers; 7 is -NH-; R 8 teeth , halogen; m is 1; and k is 1, 2, 3, or 4. One embodiment of Formula Ciii wherein BA is a binder; L is a linker; R 1 is methyl; R 2 pliers R 3 is -C(O)N(H)CH3; R 4 and R 5 is methyl; R 7 is -NH-; R 8 teeth , halogen; m is 1; and k is 1, 2, 3, or 4. In one embodiment , a conjugate of formula C is as follows: [ka] wherein BA is a binder; and k is 1, 2, 3, or 4). In any of the embodiments in this paragraph, the BA is an antibody or In any of the embodiments in this paragraph, k is 1 to 2, 1 In any of the embodiments in this paragraph, In any of the embodiments in this paragraph, k is 1. In any of the embodiments in this paragraph, k is 3. In any of the embodiments in the graph, k is 4.

[0200] In certain embodiments, the antibody or antigen-binding fragment thereof is selected from the group consisting of Formula I, Formula I I, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, Formula X, Formula XI, and / or Formula XII In one embodiment, the antibody can be directly conjugated to any one or more of the following: The body-drug conjugates are [ka] TIFF2024167209000296.tif220170TIFF2024167209000297.tif214170TIFF2024167209000298.tif217170TIFF2024167209000299.tif221170TIFF2024167209000300.tif224170TIFF2024167209000301.tif181170, , Formula VII, Formula VIII, Formula IX, Formula X, Formula XI, and / or Formula XII. In one embodiment, the antibody-drug conjugate comprises a conjugated antibody or antigen-binding fragment thereof. Jugate is [ka] In one embodiment, the antibody or antigen-binding fragment thereof is conjugated to The drug conjugate is [ka] In one embodiment, the antibody or antigen-binding fragment thereof is conjugated to The drug conjugate is [ka] In one embodiment, the antibody or antigen-binding fragment thereof is conjugated to The drug conjugate is [ka] In one embodiment, the antibody or antigen-binding fragment thereof is conjugated to The drug conjugate is [ka] In one embodiment, the antibody or antigen-binding fragment thereof is conjugated to The drug conjugate is [ka] In one embodiment, the antibody or antigen-binding fragment thereof is conjugated to The drug conjugate is [ka] The antibody or antigen-binding fragment thereof is conjugated to

[0201] In any of the embodiments of the compounds or conjugates provided, the BA binds to the PRLR. The compound or conjugate is an antibody or antigen-binding fragment thereof that binds to the antibody. In any of the embodiments, the BA is an antibody, or antigen-binding fragment thereof, that binds to STEAP2. In any of the embodiments of the compounds or conjugates provided, the BA is an antibody or and the conjugation is via at least one Q295 residue. In any of the embodiments of the compounds or conjugates provided, BA is , an antibody or antigen-binding fragment thereof, and the conjugation is via two Q295 residues. In any of the embodiments of the compounds or conjugates provided, BA The compound or conjugate is an antibody N297Q or an antigen-binding fragment thereof. In any of the embodiments, the BA is the N297Q antibody or an antigen-binding fragment thereof, and The conjugation is via at least one Q295 and at least one Q297 residue. In any of the embodiments of the compounds or conjugates provided, the BA is an N297Q antibody. or an antigen-binding fragment thereof, and the conjugation is via two Q295 residues and two Q2 In certain embodiments, the numbering is according to the EU numbering system. be.

[0202] In any of the above embodiments, the BA is an anti-STEAP2 antibody. BA is the anti-STEAP2 antibody H1H7814N described in the Examples below. In this example, BA is the anti-STEAP2 antibody H1H7814N N297Q described in the Examples below. In an embodiment, the BA comprises an anti-STEAP2 antibody comprising an HCVR according to SEQ ID NO: 1 and an LCVR according to SEQ ID NO: 5. In one embodiment, the BA comprises an HCVR according to SEQ ID NO: 1 and an HCVR according to SEQ ID NO: 5. In one embodiment, the BA is an N297Q antibody comprising an LCVR. One or two of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 according to 4, 6, 7, and 8 In one embodiment, the BA is an anti-STEAP2 antibody comprising one, two, three, four, five, or six of the BAs. HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and and LCDR3, and one, two, three, four, five, or six of LCDR3. At least 297 residues have been mutated from asparagine (N) to glutamine (Q). Preferably, each residue 297 is mutated to Q. In a preferred embodiment, the numbering follows the EU numbering system In some embodiments of this paragraph, k is 1 to 4. In embodiments, k is 1, 2, 3, or 4. In certain embodiments, k is 4.

[0203] In any of the above embodiments, the BA is an anti-PRLR antibody. The BA is the anti-PRLR antibody H1H6958N2 described in the Examples below. In this case, BA is the anti-PRLR antibody H1H6958N2 N297Q described in the Examples below. In an embodiment, the BA comprises an anti-PRLR antibody comprising an HCVR according to SEQ ID NO:9 and an LCVR according to SEQ ID NO:13. In one embodiment, the BA comprises a HCVR according to SEQ ID NO: 9 and a LVR according to SEQ ID NO: 13. In one embodiment, the BA is an N297Q antibody comprising a CVR. , 12, 14, 15, and 16 of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 In one embodiment, the anti-PRLR antibody comprises one, two, three, four, five, or six BAs. are HCDR1, HCDR2, HCDR3, LCDR according to SEQ ID NOs: 10, 11, 12, 14, 15, and 16, respectively. and N297Q antibody, which comprises one, two, three, four, five, or six of LCDR1, LCDR2, and LCDR3. N297Q indicates that one or more residues 297 have been mutated from asparagine (N) to glutamine (Q). Preferably, each residue 297 is mutated to Q. In a preferred embodiment, the numbering is according to the EU numbering system. In certain embodiments of this paragraph, k is 1 to 4. In certain embodiments, k is 1, 2, 3, or 4. In certain embodiments, k is It is 4.

[0204] In any of the foregoing embodiments of this section, R 7 is -NR 7a R 7b (wherein R 7a Reach BiR 7b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl aryl, heteroaryl, acyl, and amino acid residues, Alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally In some embodiments, R 7a is hydrogen and R 7b is Amino It is an acid residue.

[0205] (Method of Preparing Compounds or Payloads and Linker-Payloads) The compounds provided herein may be prepared, isolated, or purified by any method apparent to one skilled in the art. Exemplary methods of preparation are described in detail in the Examples below. In certain embodiments, the compounds provided herein can be prepared generally according to Schemes A-D. It can be prepared as follows: Scheme A. Exemplary Preparation Scheme [ka] Scheme B. Exemplary Preparation Scheme [ka] Scheme C. Exemplary Preparation Scheme [ka] Scheme D. Exemplary Preparation Scheme [ka]

[0206] In the above exemplary preparation scheme, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 is a statement in formula I In Scheme A, amino acids are homologated and their The N-sulfonylcarboxamide was then gem-dimethylated at the α-carbon. As will be appreciated, under standard conditions H2NSO2R 60 It can be prepared using In Group B, the cysteine ​​is involved in cyclization en route to thiazole formation, followed by , followed by aldol condensation and Michael addition of Boc-protected N-alkoxyamine. The Boc-protected N-alkoxyamine was reduced to the Boc-protected amine derivative. In this case, the Boc-protected N-alkoxyamine was deprotected and acylated. The reaction was followed by amidation. Carbohydrate synthesis and acylation of the alcohol gave the penultimate intermediate. Activation of the carboxylic acid and subsequent amidation afforded compounds of Formula I. The reaction in the present invention is similar, in that the reductive amination is carried out early in the synthesis, followed by the analogous steps of Scheme C, which also gave compounds of Formula I. Typical preparation methods are described in detail in the Examples below.

[0207] The linker-payloads described herein generally follow Schemes EH, J, K, M, and N can be synthesized by a series of coupling steps as shown in: Scheme E. Exemplary Preparation Scheme [ka] TIFF2024167209000314.tif124170 (Scheme F. Exemplary preparation scheme) [ka] (Scheme G. Exemplary Preparation Scheme) [ka] (Scheme H. Exemplary Preparation Scheme) [ka] (Scheme J. Exemplary Preparation Scheme) [ka] TIFF2024167209000319.tif168170 (Scheme K. Exemplary preparation scheme) [ka] (Scheme M. Exemplary Preparation Scheme) [ka] TIFF2024167209000322.tif182170 (Scheme N. Exemplary preparation scheme) [ka]

[0208] In the above exemplary preparation scheme, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 is a statement in formula I In Scheme E, the payload is a benzyl halide. to generate the quaternary ammonium linker-payload. In N, the payload is treated with carbonate to generate the linker-payload. In Scheme H, the payload is treated with benzyl azide to give the triazolyl ribonucleotide. In Scheme K, the payload is generated by reacting a benzyl alcohol with a The linker is then esterified with hydroxypropyl methylcellulose to form the linker-payload.

[0209] In some embodiments, provided herein is a method for treating a psoriasis comprising administering to a subject a therapeutically effective amount of: [ka] TIFF2024167209000325.tif206170TIFF2024167209000326.tif225170TIFF2024167209000327.tif223170TIFF2024167209000328.tif208170TIFF2024167209000329.tif143170. In certain embodiments, all diastereomers are contemplated. For example, in one embodiment In [ka] The internal stereochemistry of is undefined or racemic. [ka] The internal stereochemistry of is (R)-. By way of further example, in one embodiment, [ka] The internal stereochemistry of is (S)-. By way of further example, in one embodiment, [ka] The internal stereochemistry of is in excess of (R)- over (S)-. Leave, [ka] The internal stereochemistry of is an excess of (S)- over (R)-.

[0210] The conjugates described herein may comprise a linker-payload as described herein. is coupled to a binding agent, e.g., an antibody, under standard conjugation conditions. and (e.g., the entire contents of which are incorporated herein by reference) (See Doronina et al., Nature Biotechnology 2003, 21, 778 for a review). When the agent is an antibody, the antibody is ligated via one or more cysteine ​​or lysine residues of the antibody. The linker-payload may be linked to a linker-payload via, for example, reducing the antibody. Disulfide bonds of the antibody are broken down by exposure to an agent such as dithiotheritol. The cleaved and reduced antibody is purified, for example, by gel filtration, and then the antibody is By treating the linker-payload with a suitable reactive moiety, e.g., a maleimide group, Suitable solvents include water, DMA, and DMF. and DMSO. Reactive groups, such as activated esters Alternatively, a linker-payload containing an acid halide group is linked to a lysine residue of the antibody. Suitable solvents include water, DMA, DMF, and DMSO. Conjugates can be purified by, for example, size exclusion chromatography, dialysis, and The protein can be purified using known protein techniques including ultrafiltration / diafiltration.

[0211] Conjugating a binding agent, e.g., an antibody, by a click chemistry reaction In some embodiments of the click chemistry reaction, a linker-pay Loading is a reactive group that can undergo regioisomeric 1,3-cycloaddition with azides, e.g. Suitable reactive groups include, for example, alkynes. Suitable reactive groups are described above. Such antibodies include, for example, azide-polyethylene glycol In some embodiments, such functionalized antibodies include antibodies functionalized with acetyl groups. The body, in the presence of the enzyme transglutaminase, converts at least one glutamine residue, e.g. For example, it is induced by treating an antibody having heavy chain Gln295 with a primary amine compound. In certain embodiments, such functionalized antibodies are synthesized in the presence of the enzyme transglutaminase. and cleaving an antibody having at least one glutamine residue, e.g., heavy chain Gln297, with a primary amine Such antibodies are induced by treatment with compounds such as Asn297Gln(N297Q). In some embodiments, such functionalized antibodies are capable of carrying out the enzyme transglutaminase (ETA)-dependent cleavage. In the presence of glutaminase, at least two glutamine residues, e.g., heavy chain Gln295 and heavy chain Gln305, are present. It is induced by treating an antibody having the chain Gln297 with a primary amine compound. Such antibodies include the Asn297Gln (N297Q) mutant. is a 2-mer as described in this paragraph for a total of two or a total of four glutamine residues. It has two heavy chains.

[0212] In certain embodiments, the antibody contains two glutamine residues, one in each heavy chain. In one embodiment, the antibody comprises a Q295 residue in each heavy chain. The body may contain one, two, three, four, five, six, seven, eight, or more glutamine residues. These glutamine residues can be present in the heavy chain, the light chain, or both the heavy and light chains. These glutamine residues can be wild-type residues or modified residues. The antibodies can be prepared by standard techniques.

[0213] Those skilled in the art will appreciate that antibodies often contain a glycosylated residue at residue N297, which is near residue Q295 in the heavy chain sequence. It will be recognized that the glycosylation at residue N297 is sylated at residue Q295. can interfere with transglutaminase (Dennler et al., supra). In a preferred embodiment, the antibody is aglycosylated. In certain embodiments, the antibody complex is deglycosylated or aglycosylated. The chain has an N297 mutation. In other words, the antibody no longer has an asparagine residue at position 297. In certain embodiments, the antibody heavy chain has a N297Q mutation. Such antibodies can be generated by site-directed mutagenesis to remove or disable glycosylation sequences. or sites other than glycosylation sites or any other interfering structures that interfere with glutamine residues Such antibodies can be prepared by site-directed mutagenesis, where the , can be isolated from natural or artificial sources.

[0214] The antibody, which does not interfere with glycosylation, is then reacted with or with a primary amine compound. In one embodiment, the aglycosylated antibody is treated with a primary amine compound. In one embodiment, the antibody is reacted or treated with glutaminyl-modified antibodies. The deglycosylated antibody is reacted or treated with a primary amine compound. to generate ...

Claims

1. A compound having the structure of Formula I, or a pharma- ceutically acceptable salt thereof: 【Chemistry 1】 (In the formula, R 1 is C 1 -C 10 is alkyl; R 3 is -C(O)C 1 -C 5 Alkyl, -C(O)N(H)C 1 -C 10 Alkyl, or -(C 1 -C 10 (alkylene)-NR 3 a R 3b and Here, R 3a and R 3b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl, where alkyl, aryl, heteroaryl, and acyl are Alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally has been replaced by intention; R 4 and R 5 is, independently in each occurrence, hydrogen or C 1 -C 5 is alkyl; R 6 is -OH or -NHNH 2 and; R 7 is, independently in each occurrence, hydrogen, -OH, halogen, or -NR 7a R 7b and Here, R 7a and R 7b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, acyl, and amino acid residues, , alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and and acyl are optionally substituted; R 8 is independently in each case hydrogen, deuterium, -NHR 9 or halogen, Here, R 9 is hydrogen, -C 1 -C 5 Alkyl, or -C(O)C 1 -C 5 is alkyl; and m is 1 or 2; Q is -CH 2 - or -O-, where When Q is -O-, R 2 is C 1 -C 10 Alkyl, C 1 -C 10 Alkynyl, -C 1 -C 10 Alki ren-(5-membered heteroaryl), -C 1 -C 3 Alkylene-Q 1 -(CH 2 ) n Aryl or C 1 -C 3 H or Q is -CH 2 - If R 2 is C 5 -C 10 Alkyl, C 1 -C 10 Alkynyl, -C 1 -C 10 Al Xylene-(5-membered heteroaryl), -C 1 -C 3 Alkylene-Q 1 -(CH 2 ) n Aryl or C 1 -C 3 is hydroxyalkyl; and Q 1 is -CH 2 - or -O-; The heteroaryl may be unsubstituted or may be substituted with an alkyl, aminoalkyl, hydroxyl, substituted with alkyl, carboxyalkyl, benzyl, or phenyl; the aryl is unsubstituted or substituted with nitro or amino; and and n is an integer from 1 to 5.

2. R 1 But, C 1 -C 10 is alkyl; R 3 But -C(O)C 1 -C 5 Alkyl, -C(O)N(H)C 1 -C 10 Alkyl, or -(C 1 -C 10 (alkylene)-NR 3 a R 3b and Here, R 3a and R 3b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl, where alkyl, aryl, heteroaryl, and acyl are Alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally has been replaced by intention; R 4 and R 5 is, independently in each occurrence, hydrogen or C 1 -C 5 is alkyl; R 6 is -OH or -NHNH 2 and; R 7 is, independently in each occurrence, hydrogen, —OH, halogen, or —NR 7a R 7b and Here, R 7a and R 7b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl, where alkyl, aryl, heteroaryl, and acyl are Alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally has been replaced by intention; R 8 is independently in each case hydrogen, deuterium, -NHR 9 or halogen, Here, R 9 But hydrogen, -C 1 -C 5 Alkyl, or -C(O)C 1 -C 5 is alkyl; and m is 1 or 2; Q is -CH 2 - or -O-, where When Q is -O-, R 2 But, C 1 -C 10 Alkyl, C 1 -C 10 Alkynyl, -C 1 -C 10 Alki ren-(5-membered heteroaryl), -C 1 -C 3 Alkylene-Q 1 -(CH 2 ) n Aryl or C 1 -C 3 H or Q is -CH 2 - If R 2 But, C 5 -C 10 Alkyl, C 1 -C 10 Alkynyl, -C 1 -C 10 Al Xylene-(5-membered heteroaryl), -C 1 -C 3 Alkylene-Q 1 -(CH 2 ) n Aryl or C 1 -C 3 is hydroxyalkyl; and Q 1 But -CH 2 - or -O-; The heteroaryl is unsubstituted or is selected from the group consisting of alkyl, aminoalkyl, hydroxyl, substituted with alkyl, carboxyalkyl, benzyl, or phenyl; the aryl is unsubstituted or substituted with nitro or amino; and n is an integer from 1 to 5; 2. The compound of claim 1.

3. Q is -CH 2 - and; R 2 But, C 5 -C 10 is alkyl; R 3 But -C(O)C 1 -C 5 is alkyl; R 4 is hydrogen; R 5 But, C 1 -C 5 is alkyl; and R 7 is a halogen, 2. The compound of claim 1.

4. 4. The compound of claim 3 according to the structure of Formula II, or a pharma- ceutically acceptable salt thereof: 【Chemistry 2】 。

5. below 【Chemistry 3】 5. The compound of claim 4, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

6. Q is -CH 2 - and; R 2 But, C 5 -C 10 is alkyl; R 3 But -C(O)C 1 -C 5 is alkyl; R 4 and R 5 is methyl; R 7 is -OH, halogen, or -NH 2 and; R 8 independently in each occurrence hydrogen, deuterium, -NHR 9 or halogen Here, R 9 is hydrogen or -C 1 -C 5 is alkyl; and m is 1 or 2; 2. The compound of claim 1.

7. 7. The compound of claim 6 according to the structure of Formula III, or a pharma- ceutically acceptable salt thereof: 【Chemistry 4】 。

8. below 【Chemistry 5】 【change】 【change】 8. The compound of claim 7, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

9. Q is -CH 2 - and; R 2 But, C 1 -C 10 alkynyl; and R 6 is -OH; 2. The compound of claim 1.

10. 10. The compound of claim 9 according to the structure of formula IV, or a pharma- ceutically acceptable salt thereof: 【Chemistry 6】 。

11. below 【Chemistry 7】 【change】 11. The compound of claim 10, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

12. Q is -CH 2 - and; R 2 However, the positional isomer -C 1 -C 10 alkylene-(5-membered heteroaryl), The heteroaryl is unsubstituted or is selected from the group consisting of alkyl, aminoalkyl, hydroxylalkyl, and aryl. substituted with aryl, carboxyalkyl, benzyl, or phenyl; R 3 But -C(O)C 1 -C 5 is alkyl; R 4 and R 5 But, C 1 -C 5 is alkyl; R 6 is -OH; and R 7 But -NH 2 That is, 2. The compound of claim 1.

13. 13. The compound of claim 12 according to the structure of Formula V, or a pharma- ceutically acceptable salt thereof: 【Chemistry 8】 。

14. According to the structure of formula VI or formula VII The compound of claim 13; or a pharma- ceutically acceptable salt thereof: 【Chemistry 9】 (In the formula, R 10 is hydrogen, methyl, -CH 2 CH 2 NH 2 , -CH 2 CH 2 OH, -CH 2 COOH, -CH 2 CH 2 CH 2 COOH, benzyl , or phenyl).

15. below 【Chemistry 10】 【change】 【change】 A compound according to claim 14 selected from the group consisting of: its positional isomer; or A pharma- ceutical acceptable salt thereof.

16. Q is -O-; R 2 But, C 1 -C 10 is alkyl; and R 7 is -OH or -NH 2 That is, 2. The compound of claim 1.

17. 17. The compound of claim 16 according to the structure of Formula VIII, or a pharma- ceutically acceptable salt thereof: 【Chemistry 11】 。

18. R 3 20. The compound of claim 17, wherein is -C(O)Me.

19. below 【Chemistry 12】 19. The compound of claim 18, selected from the group consisting of:

20. R 3 But -C(O)N(H)C 1 -C 10 is alkyl; R 4 is hydrogen; R 5 But, C 1 -C 5 is alkyl; and R 6 and R 7 is -OH; 18. The compound of claim 17.

21. 21. The compound of claim 20 having the structure of formula IX: or a pharma- ceutically acceptable salt thereof: 【Chemistry 13】 (In the formula, R 11 is C 1 -C 10 (alkyl).

22. below 【Chemistry 14】 22. The compound of claim 21, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

23. R 3 But -C(O)N(H)C 1 -C 10 20. The compound of claim 17, which is alkyl.

24. The following 【Chemistry 15】 24. The compound of claim 23, which is: or a pharma- ceutically acceptable salt thereof.

25. Q is -O-; R 2 But, C 1 -C 10 is alkynyl; R 3 But -C(O)C 1 -C 5 is alkyl; and R 6 is -OH; 2. The compound of claim 1.

26. 26. The compound of claim 25 according to the structure of formula X, or a pharma- ceutically acceptable salt thereof: 【Chemistry 16】 。

27. below 【Chemistry 17】 【change】 27. The compound of claim 26, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

28. Q is -O-; R 2 But, C 1 -C 10 is alkynyl; R 3 But -C(O)N(H)C 1 -C 10 is alkyl; and R 6 is -OH; 2. The compound of claim 1.

29. 29. The compound of claim 28 according to the structure of formula XI, or a pharma- ceutically acceptable salt thereof: 【Chemistry 18】 。

30. The following 【Chemistry 19】 30. The compound of claim 29, which is: or a pharma- ceutically acceptable salt thereof.

31. Q is -O-; R 2 But, C 1 -C 3 Alkylene-Q 1 -(CH 2 ) n Aryl; or C 1 -C 3 is hydroxyalkyl; R 3 But -C(O)C 1 -C 5 is alkyl; R 4 is hydrogen; R 5 But, C 1 -C 5 is alkyl; and R 6 and R 7 is -OH; 2. The compound of claim 1.

32. 32. The compound of claim 31 having the structure of Formula XII, or a pharma- ceutically acceptable salt thereof: 【Chemistry 20】 。

33. R 2 But, C 1 -C 3 Alkylene-O-(CH 2 ) n 33. The compound of claim 32, which is aryl.

34. below 【Chemistry 21】 34. The compound of claim 33, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

35. R 2 But, C 1 -C 3 33. The compound of claim 32, which is hydroxyalkyl.

36. The following 【Chemical 22】 36. The compound of claim 35, which is: or a pharma- ceutically acceptable salt thereof.

37. A compound of formula A, formula B, formula C, or formula D, or a pharma- ceutically acceptable salt thereof: 【Chemistry 23】 (In the formula, L is a linker; BA is a binder; k is an integer from 1 to 30; R 1 is C 1 -C 10 is alkyl; R 3 is -C(O)C 1 -C 5 Alkyl, -C(O)N(H)C 1 -C 10 Alkyl, or -(C 1 -C 10 (alkylene)-NR 3 a R 3b and Here, R 3a and R 3b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl, where alkyl, aryl, heteroaryl, and acyl are Alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally has been replaced by intention; R 4 and R 5 is, independently in each occurrence, hydrogen or C 1 -C 5 is alkyl; R 6 -OH, -O-, -NHNH 2 or -NHNH-; R 7 is, independently in each occurrence, hydrogen, -OH, -O-, halogen, or -NR 7a R 7b and Here, R 7a and R 7b is independently in each occurrence a bond, hydrogen, an alkyl, an alkenyl, an alkyl nyl, cycloalkyl, aryl, heteroaryl, acyl, and amino acid residues; Here, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl aryl, and acyl are optionally substituted; R 8 is independently in each case hydrogen, deuterium, -NHR 9 or halogen, Here, R 9 is hydrogen, -C 1 -C 5 Alkyl, or -C(O)C 1 -C 5 is alkyl; and m is 1 or 2; Q is -CH 2 - or -O-, where When Q is -O-, R 2 is C 1 -C 10 Alkyl, C 1 -C 10 Alkynyl, positional isomers of C 1 -C 10 Triazolylene, -C 1 -C 10 Alkylene-(5-membered heteroaryl), positional isomers of -C 1 -C 10 Alkylene-(5-membered heteroarylene), -C 1 -C 3 Alkylene-Q 1 -(CH 2 ) n Aryl, C 1 -C 3 H Hydroxyalkyl or C 1 -C 10 is an alkyl ether; or Q is -CH 2 - If R 2 is C 5 -C 10 Alkyl, C 1 -C 10 Alkynyl, positional isomers C 1 -C 10 Triazolylene, -C 1 -C 10 Alkylene-(5-membered heteroaryl), positional isomers of -C 1 -C 10 Alkylene-(5-membered heteroarylene), -C 1 -C 3 Alkylene-Q 1 -(CH 2 ) n Aryl, C 1 -C 3 Hydroxyalkyl or C 1 -C 10 is an alkyl ether; and Q 1 is -CH 2 - or -O-; The regioisomeric triazolylenes may be unsubstituted or may be substituted with an alkyl, alkenyl, aryl, substituted with quinyl, cycloalkyl, aryl, heteroaryl, and acyl; The heteroaryl or positional isomeric heteroarylene is unsubstituted or alkyl, aminoalkyl, -alkylene-NH-, hydroxylalkyl, -alkylene-O-, substituted with carboxyalkyl, -alkylene-COO-, benzyl, or phenyl; The aryl is unsubstituted or substituted with nitro, amino, or -NH-. ;and and n is an integer from 1 to 5.

38. L is a linker; BA is a binder; k is an integer from 1 to 30; R 1 But, C 1 -C 10 is alkyl; R 3 But -C(O)C 1 -C 5 Alkyl, -C(O)N(H)C 1 -C 10 Alkyl, or -(C 1 -C 10 (alkylene)-NR 3 a R 3b and Here, R 3a and R 3b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl, where alkyl, aryl, heteroaryl, and acyl are Alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally has been replaced by intention; R 4 and R 5 is, independently in each occurrence, hydrogen or C 1 -C 5 is alkyl; R 6 -OH, -O-, -NHNH 2 or -NHNH-; R 7 is, independently in each occurrence, hydrogen, -OH, -O-, halogen, or -NR 7a R 7b and Here, R 7a and R 7b is, independently in each occurrence, a bond, hydrogen, an alkyl, an alkenyl, an alkyl aryl, cycloalkyl, aryl, heteroaryl, and acyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl is optionally substituted; R 8 is independently in each case hydrogen, deuterium, -NHR 9 or halogen, Here, R 9 But hydrogen, -C 1 -C 5 Alkyl, or -C(O)C 1 -C 5 is alkyl; and m is 1 or 2; Q is -CH 2 - or -O-, where When Q is -O-, R 2 But, C 1 -C 10 Alkyl, C 1 -C 10 Alkynyl, positional isomers of C 1 -C 10 Triazolylene, -C 1 -C 10 Alkylene-(5-membered heteroaryl), positional isomers of -C 1 -C 10 Alkylene-(5-membered heteroarylene), -C 1 -C 3 Alkylene-Q 1 -(CH 2 ) n Aryl, C 1 -C 3 H Hydroxyalkyl or C 1 -C 10 is an alkyl ether; or Q is -CH 2 - If R 2 But, C 5 -C 10 Alkyl, C 1 -C 10 Alkynyl, positional isomers C 1 -C 10 Triazolylene, -C 1 -C 10 Alkylene-(5-membered heteroaryl), positional isomers of -C 1 -C 10 Alkylene-(5-membered heteroarylene), -C 1 -C 3 Alkylene-Q 1 -(CH 2 ) n Aryl, C 1 -C 3 Hydroxyalkyl or C 1 -C 10 is an alkyl ether; and Q 1 But -CH 2 - or -O-; The positional isomeric triazolylenes are unsubstituted or substituted with alkyl, alkenyl, aryl, substituted with quinyl, cycloalkyl, aryl, heteroaryl, and acyl; The heteroaryl or positional isomeric heteroarylene is unsubstituted or alkyl, aminoalkyl, -alkylene-NH-, hydroxylalkyl, -alkylene-O-, substituted with carboxyalkyl, -alkylene-COO-, benzyl, or phenyl; The aryl is unsubstituted or substituted with nitro, amino, or -NH-. ;and 38. The compound according to claim 37, or a pharma- ceutically acceptable salt thereof, wherein n is an integer from 1 to 5.

39. A compound according to any one of claims 1 to 38 and a pharma- ceutically acceptable excipient, carrier, or A pharmaceutical composition comprising a diluent.

40. A method for treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of any one of claims 1 to 39. The method comprises administering a compound or pharmaceutical composition according to any one of claims 1 to 5.

41. A method for treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of any one of claims 1 to 40. wherein the cancer is renal cell carcinoma. , pancreatic cancer, head and neck cancer, prostate cancer, castration-resistant prostate cancer, malignant glioma, osteosarcoma, colon Rectal cancer, stomach cancer, mesothelioma, malignant mesothelioma, multiple myeloma, ovarian cancer, lung cancer, small cell lung cancer Non-small cell lung cancer, synovial sarcoma, thyroid cancer, breast cancer, PRLR-positive (PRLR+) breast cancer, Breast cancer, acute myeloid leukemia, adult T-cell leukemia, astrocytoma, bladder cancer, cervical cancer, bile duct cancer Cell carcinoma, endometrial cancer, esophageal cancer, glioblastoma, Kaposi's sarcoma, kidney cancer, leiomyosarcoma, and liver Lymphoma, MFH / fibrosarcoma, nasopharyngeal cancer, rhabdomyosarcoma, colon cancer, gastric cancer, uterine cancer, The method further comprises treating the cancer, wherein the cancer is selected from the group consisting of residual cancer and Wilms' tumor.

42. A method for treating a tumor expressing an antigen selected from the group consisting of PRLR and STEAP2.

43. 39. The compound of claim 38, or a medicament thereof, which is of formula A', formula B', formula C', or formula D'. Acceptable salts or prodrugs of: 【Chemistry 24】 (In the formula, SP 1 and SP 2 is a spacer group, if present; each AA is an amino acid; and and p is an integer from 1 to 10.

44. The SP 2 Spacers, if present, 【Chemistry 25】 and; The above (AA) p but, 【Chemistry 26】 and; The SP 1 but, 【Chemical 27】 is (In the formula, RG′ is a reactive group residue resulting from reaction of the reactive group RG with a binder; 【Chemistry 28】 is directly or indirectly attached to the binding agent; and b is an integer from 1 to 4; 44. The compound of claim 43.

45. The binder is of formula H 2 N-LL-X (wherein LL is as follows) a divalent polyethylene glycol (PEG) group; -(CH 2 ) n -; -(CH 2 CH 2 O) n -(CH 2 ) p -; -(CH 2 ) n -N(H)C(O)-(CH 2 ) m -; -(CH 2 CH 2 O) n -N(H)C(O)-(CH 2 CH 2 O) m -(CH 2 ) p -; -(CH 2 ) n -C(O)N(H)-(CH 2 ) m -; -(CH 2 CH 2 O) n -C(O)N(H)-(CH 2 CH 2 O) m -(CH 2 ) p -; -(CH 2 ) n -N(H)C(O)-(CH 2 CH 2 O) m -(CH 2 ) p -; -(CH 2 CH 2 O) n -N(H)C(O)-(CH 2 ) m -; -(CH 2 ) n -C(O)N(H)-(CH 2 CH 2 O) m -(CH 2 ) p -; and -(CH 2 CH 2 O) n -C(O)N(H)-(CH 2 ) m - (In the formula, n is an integer selected from 1 to 12; m is an integer selected from 0 to 12; p is an integer selected from 0 to 2; ;and X is -SH, -N 3 , -C≡CH, -C(O)H, tetrazole, 【Chemical 29】 (selected from the group consisting of an antibody modified with a primary amine compound according to A compound according to any one of claims 38 to 44.

46. The binder has the following formula: 【Chemistry 30】 an antibody modified with a primary amine according to 46. ​​The compound of claim 45.

47. A linker-payload comprising a compound according to any one of claims 1 to 36 attached to a linker. wherein the linker comprises a site reactive with an antibody or an antigen-binding fragment thereof. Car - payload.

48. The linker is a piperidine nitrogen, R 2 , R 6 , or R 7 The linker-payload of claim 47, wherein the linker-payload is linked to

49. A linker-payload of formula LPa, formula LPb, formula LPc, or formula LPd, or a medicament thereof. Acceptable salts: 【Chemistry 31】 (In the formula, L is a linker; R 1 is C 1 -C 10 is alkyl; R 3 is -C(O)C 1 -C 5 Alkyl, -C(O)N(H)C 1 -C 10 Alkyl, or -(C 1 -C 10 (alkylene)-NR 3 a R 3b and Here, R 3a and R 3b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl, where alkyl, aryl, heteroaryl, and acyl are Alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally has been replaced by intention; R 4 and R 5 is, independently in each occurrence, hydrogen or C 1 -C 5 is alkyl; R 6 -OH, -O-, -NHNH 2 or -NHNH-; R 7 is, independently in each occurrence, hydrogen, -OH, -O-, halogen, or -NR 7a R 7b and Here, R 7a and R 7b is independently in each occurrence a bond, hydrogen, an alkyl, an alkenyl, an alkyl nyl, cycloalkyl, aryl, heteroaryl, acyl, and amino acid residues; Here, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl aryl, and acyl are optionally substituted; R 8 is independently in each case hydrogen, deuterium, -NHR 9 or halogen, Here, R 9 is hydrogen, -C 1 -C 5 Alkyl, or -C(O)C 1 -C 5 is alkyl; and m is 1 or 2; Q is -CH 2 - or -O-, where When Q is -O-, R 2 is C 1 -C 10 Alkyl, C 1 -C 10 Alkynyl, positional isomers of C 1 -C 10 Triazolylene, -C 1 -C 10 Alkylene-(5-membered heteroaryl), positional isomers of -C 1 -C 10 Alkylene-(5-membered heteroarylene), -C 1 -C 3 Alkylene-Q 1 -(CH 2 ) n Aryl, C 1 -C 3 H Hydroxyalkyl or C 1 -C 10 is an alkyl ether; or Q is -CH 2 - If R 2 is C 5 -C 10 Alkyl, C 1 -C 10 Alkynyl, positional isomers C 1 -C 10 Triazolylene, -C 1 -C 10 Alkylene-(5-membered heteroaryl), positional isomers of -C 1 -C 10 Alkylene-(5-membered heteroarylene), -C 1 -C 3 Alkylene-Q 1 -(CH 2 ) n Aryl, C 1 -C 3 Hydroxyalkyl or C 1 -C 10 is an alkyl ether; and Q 1 is -CH 2 - or -O-; The regioisomeric triazolylenes may be unsubstituted or may be substituted with an alkyl, alkenyl, aryl, substituted with quinyl, cycloalkyl, aryl, heteroaryl, and acyl; The heteroaryl or positional isomeric heteroarylene is unsubstituted or alkyl, aminoalkyl, -alkylene-NH-, hydroxylalkyl, -alkylene-O-, substituted with carboxyalkyl, -alkylene-COO-, benzyl, or phenyl; The aryl is unsubstituted or substituted with nitro, amino, or -NH-. ;and and n is an integer from 1 to 5.

50. L is a linker; R 1 But, C 1 -C 10 is alkyl; R 3 But -C(O)C 1 -C 5 Alkyl, -C(O)N(H)C 1 -C 10 Alkyl, or -(C 1 -C 10 (alkylene)-NR 3 a R 3b and Here, R 3a and R 3b is independently in each occurrence hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl, where alkyl, aryl, heteroaryl, and acyl are Alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl are optionally has been replaced by intention; R 4 and R 5 is, independently in each occurrence, hydrogen or C 1 -C 5 is alkyl; R 6 -OH, -O-, -NHNH 2 or -NHNH-; R 7 is, independently in each occurrence, hydrogen, -OH, -O-, halogen, or -NR 7a R 7b and Here, R 7a and R 7b is, independently in each occurrence, a bond, hydrogen, an alkyl, an alkenyl, an alkyl aryl, cycloalkyl, aryl, heteroaryl, and acyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, and acyl is optionally substituted; R 8 is independently in each case hydrogen, deuterium, -NHR 9 or halogen, Here, R 9 But hydrogen, -C 1 -C 5 Alkyl, or -C(O)C 1 -C 5 is alkyl; and m is 1 or 2; Q is -CH 2 - or -O-, where When Q is -O-, R 2 But, C 1 -C 10 Alkyl, C 1 -C 10 Alkynyl, positional isomers of C 1 -C 10 Triazolylene, -C 1 -C 10 Alkylene-(5-membered heteroaryl), positional isomers of -C 1 -C 10 Alkylene-(5-membered heteroarylene), -C 1 -C 3 Alkylene-Q 1 -(CH 2 ) n Aryl, C 1 -C 3 H Hydroxyalkyl or C 1 -C 10 is an alkyl ether; or Q is -CH 2 - If R 2 But, C 5 -C 10 Alkyl, C 1 -C 10 Alkynyl, positional isomers C 1 -C 10 Triazolylene, -C 1 -C 10 Alkylene-(5-membered heteroaryl), positional isomers of -C 1 -C 10 Alkylene-(5-membered heteroarylene), -C 1 -C 3 Alkylene-Q 1 -(CH 2 ) n Aryl, C 1 -C 3 Hydroxyalkyl or C 1 -C 10 is an alkyl ether; and Q 1 But -CH 2 - or -O-; The positional isomeric triazolylenes are unsubstituted or substituted with alkyl, alkenyl, aryl, substituted with quinyl, cycloalkyl, aryl, heteroaryl, and acyl; The heteroaryl or positional isomeric heteroarylene is unsubstituted or alkyl, aminoalkyl, -alkylene-NH-, hydroxylalkyl, -alkylene-O-, substituted with carboxyalkyl, -alkylene-COO-, benzyl, or phenyl; The aryl is unsubstituted or substituted with nitro, amino, or -NH-. ;and n is an integer from 1 to 5; 50. The linker-payload of claim 49, or a pharma- ceutically acceptable salt thereof.

51. 51. The linker payload of claim 50 having the formula LPa', the formula LPb', the formula LPc', or the formula LPd'. or a pharma- ceutical acceptable salt thereof: 【Chemistry 32】 (In the formula, SP 1 and SP 2 is a spacer group, if present; each AA is an amino acid; and and p is an integer from 1 to 10.

52. An antibody-drug conjugate comprising an antibody or an antigen-binding fragment thereof, The antibody-drug, wherein the antigen-binding fragment is conjugated to a compound according to claims 1 to 36. Conjugate.

53. Aryl is phenyl, naphthyl, fluorenyl, azulenyl, anthryl, phenanthyl, tolyl, and pyrenyl; heteroaryl includes pyridyl, pyrazinyl, pyrimidinyl , pyridazinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, quinoxa Linyl, phthalazinyl, pteridinyl, benzofuranyl, dibenzofuranyl, benzothio Phenyl, benzoxazolyl, benzthiazolyl, dibenzothiophenyl, indolyl , indolinyl, benzimidazolyl, indazolyl, and benztriazolyl; and Acyl is -C(O)R 3c (In the formula, R 3c is an alkyl, alkenyl, alkynyl, cycloalkyl aryl, aryl, and heteroaryl; A compound or linker-payload according to any one of claims 1 to 52.

54. below: 【Chemical 33】 【change】 【change】 【change】 【change】 【change】 【change】 The linker-payload of claim 51, selected from the group consisting of:

55. 54. An antibody-drug conjugate comprising contacting a binding agent with the linker-payload of claim 53. Methods for preparing jugates.

56. A compound selected from the group consisting of: 【Chemical Formula 34】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 【change】 where BA is a binding agent; and k is 1, 2, 3, or 4.

57. 57. The compound of claim 56, wherein the BA is an antibody or an antigen-binding fragment thereof.

58. The BA is a transfectant containing at least one glutamine residue that is used for conjugation.

58. The compound of claim 56 or 57, which is a sucrose-modified antibody or an antigen-binding fragment thereof.

59. The BA is a transfectant containing at least two glutamine residues that are used for conjugation.

58. The compound of claim 56 or 57, which is a sucrose-modified antibody or an antigen-binding fragment thereof.

60. The BA is a transfectant containing at least four glutamine residues that are used for conjugation.

58. The compound of claim 56 or 57, which is a sucrose-modified antibody or an antigen-binding fragment thereof.

61. BA is a transglutaminase-modified antibody or an antigen-binding fragment thereof, and the conjugate 61. The compound of claim 60, wherein the substitution is at two Q295 residues; and k is 2.

62. BA is a transglutaminase-modified antibody or an antigen-binding fragment thereof, and the conjugate and k is 4. The compound described.

63. below: 【Chemistry 35】 【change】 【change】 【change】 【change】 【change】 【change】 An antibody conjugated to the compound according to claim 1, or an antibody thereof Antibody-drug conjugates containing original binding fragments.

64. BA or the antibody or antigen-binding fragment thereof is anti-PRLR or anti-STEAP2.

63. The compound according to any one of claims 63.